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C h a p te r  1 
M a l a r ia
DISEASE, IMMUNITY AND VACCINE DEVELOPMENT 
A GENERAL INTRODUCTION
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M a l a r ia , c u r r e n t  s t a t u s , h is t o r y  a n d  s y m p t o m s
Malaria is thought to be the severest of all tropical diseases, widespread throughout the 
tropics, but also occurring in temperate regions. It is estimated that about 40% of the world 
population is carrier of the disease causing parasite. Of the total number of 300-500 million 
clinical cases every year, about 90% are in Africa, and the remaining 10% are primarily in 
India, Brazil, Sri Lanka, Vietnam, Colombia and the Solomon Islands (Butler et al., 
1997).The annual direct and indirect costs caused by malaria in Africa alone were expected 
to exceed US$ 1800 million by 1995 (WHO, 1995). Besides the economical effects malaria 
exacts a heavy toll of illness, and the disease malaria tropica may even be fatal with an 
estimated killing-rate between 1.5 and 2.7 million people every year (Butler et al., 1997). 
Although most casualties are aged 1 to 5 also pregnant women are at high risk. Malaria 
poses also a risk to business travellers, tourists and immigrants, and imported cases of 
malaria are increasingly seen in non-endemic areas such as Europe, North-America, Japan 
and Australia. Also the global climate change, foreseen for the coming century, might have 
a dramatic impact on the occurrence of malaria (Martens et al., 1995). Treatment and 
control have become more difficult with the spread of drug-resistant strains of the parasite 
and insecticide-resistant strains of the mosquito vectors.
But malaria is not a modern disease. Throughout history malaria has plagued travellers 
to the tropics. The first recordings date from the 5th century BC in ancient writings from Asia 
and China. In the ancient Greece of the first century BC Hippocrates described the clinical 
features, such as enlargement of the spleen, and related the intermittent fevers with the 
presence of marshes. The name 'malaria' was born in ancient Rome from mal'aria, meaning 
literally 'bad air'. It arose from the believe that malaria came from putrid air above stagnant 
water. The real cause, the parasites of the genus Plasmodium were not identified until 1880; 
Alphonse Laveran, a french doctor, discovered the tiny parasites in the red blood cells of 
malaria patients (Laveran, 1880). But it was 1897 when an English surgeon major to the 
Indian Army, Ronald Ross, made the vital discovery that mosquitoes of the genus 
Anopheles transmit malaria for which he gained the Nobel Prize for Medicine (McGregor et 
a., 1993).
These days, five malaria parasites are described as being infective to man: Plasmodium 
(P.) falciparum, P. vivax, P. ovale, and P. malariae, and a fifth species which is identified as 
P. vivax like (Qari et al., 1993). The illnesses caused by these parasites are more or less 
severe, but only infection with P. falciparum, causing malaria tropica, can be fatal. It is for
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this reason that most investigations concentrate on this species. In severe malaria tropica 
the infected erythrocytes can become attached to the endothelium of capillaries in the brain, 
causing a reduction in the oxygen supply and leading to confusion, coma and, finally, death; 
it is called cerebral malaria (White et al., 1992). Sequestration can also lead to possible fatal 
multi-organ failure (Arthachinta et al., 1974).
C o n q u e r in g  th e  d is ea s e
Despite huge successes in control-measures during the 1960s with the anti-malarial 
drug chloroquine, and DDT as an insecticidal, these days the resistance of the human 
malaria parasite to anti-malarial drugs and of its mosquito vector to insectides has led to an 
alarming situation (for a review on chloroquine resistance, see Slater, 1993). The global 
spending on malaria research, now estimated at just US$ 160 million annually (Butler et al.,
1997), has therefore to increase, and the organisation of all research efforts has to be 
improved. The United Nations Development Programme (UNDP)/ World Bank/ World Health 
Organisation (WHO) Special Programme for Research and Training in Tropical Diseases 
(TDR) will lead this organisation, and a new multi-agency 30-year programme for the control 
of malaria is planned to start around 2000 (Butler et al., 1997). The program will be an 
extension of the current UNDP/World Bank/WHO-TDR programs in which the development 
of vaccines is highly supported. Furthermore, research studies will be aimed at the 
development of new pesticides and prophylactic drugs (for a review on antimalarial drugs 
see: Nosten and van Vugt, 1996), to the use of pheromones in attracting and trapping 
mosquitoes, and to stimulation of preventive measures like the use of insecticide- 
impregnated bednets and draining of marshes to reduce open stretches of water where the 
mosquitoes can breed (WHO, 1995). In future, the development of transgenic mosquitoes 
may become feasible also. The genetically engineered strain may be used to replace field 
strains of mosquitoes, resulting in the establishment of a new mosquito population that is 
refractory to P. falciparum malaria. Whether this will be really possible remains, however, 
questionable (Collins et al., 1994; Curtis et al., 1994; Spielman et al., 1994; Carlson et al., 
1996; O'Brochta et al., 1997). For all control measures more basic studies to understand the 
circumstances in which severe and complicated malaria occurs are also extremely 
important. Until now, the precise interaction between malaria transmission-rates, acquired 
immunity (vide infra) and the clinical forms and incidence of disease are unknown.
From the mid-1970s the strategies to control malaria have been directed primarily to the
11
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development of effective vaccines. Vaccines may consist of (1) attenuated or killed parasite 
preparations, (2) synthetic peptides, (3) heterologously produced proteins, (4) live vectors 
expressing vaccine antigens, or (5) DNA containing the genes of vaccine antigens under 
control of a eukaryotic promoter. Ad (1); Although some successes with parasite-isolated 
proteins or attenuated and killed parasites have been described, for instance with irradiated 
sporozoites (Nussenzweig et al., 1984), and parasitised erythrocytes, purified merozoites 
and purified blood-stage proteins (Butcher et al., 1989; Pasloske et al., 1994), the 
production of attenuated, killed or subcomponenent vaccines is impractical with present 
technologies because P. falciparum malaria parasites can not be grown cost effectively in 
large enough quantities. In vitro culturing techniques are currently low scale, cumbersome, 
and expensive. The potential for contamination of human blood-derived parasites or 
parasite extracts with pathogenic human viruses presents another special problem. Growing 
the malaria parasites in monkeys is also expensive, and human vaccination with materials 
derived from monkeys might also pose a health risk due to the presence of simian viruses. 
Ad (2); A synthetic peptide vaccine would be a realistic option, since, theoretically, 
production can be well controlled and, provided the vaccine contains both B- and T-cell 
epitopes, an effective immune response may be obtained. An example of a synthetic 
peptide vaccine is that developed by the Colombian physician and chemist dr. Manuel 
Pattaroyo (vide infra). Ad (3); Advances in molecular biology have made the use of 
heterologously produced proteins, live vectors, and DNA vaccines, possible. Production of 
proteins in a heterologous system can be well-controlled and, depending on the expression 
system used, can be very safe. Many recombinant proteins produced in, for instance, yeast, 
E. coli and baculovirus expression systems have been shown to elicit protective immune 
responses in animals, and some of them are currently also in (planning for) phase I and II 
clinical trials in humans. Ad (4) and (5); The use of live vectors and DNA vaccines offer the 
newest methodology to induce (protective) responses which may also be accompanied with 
the induction of cytotoxic T cells which play an important role in the control of disease (Hviid 
et al., 1992). Currently tested live vaccines are for instance recombinant (attenuated) 
vaccinia viruses expressing proteins from all developmental stages (Tine et al., 1996; 
Ockenhouse et al., 1998), recombinant influenza viruses, and oral vaccinations with 
recombinant Salmonella bacteria (Somner et al., 1999; Gonzalez et al., 1994). DNA 
vaccines have been shown to elicit effective responses in mice against, for instance, the 
sporozoite antigen circumsporozoite protein (CSP) (Sedegah et al., 1994; Doolan et al.,
1998) and the sexual stage antigen Pfs25 (Lobo etal., 1999). The first clinical trials in
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humans with a DNA vaccine based on CSP and the development of a human multi-gene 
vaccine have been started (Hoffman et al., 1997).
The l i f e  c y c le  o f  p l a s m o d iu m
The parasite's life cycle comprises several stages which are morphologically, 
biochemically and antigenically distinct (Simonetti et al., 1996). A schematic representation 
of this complex life cycle is shown in Fig. 1. Infection of the vertebrate host starts when a
Fig. 1. Life cycle of Plasmodium falciparum, the parasite that causes malaria tropica. See text for detailed 
description. Life cycle starts when (1) an infected mosquito takes a blood-meal thereby injecting sporozoites 
into the venes. These are rapidly cleared from the bloodstream when they infect hepatocytes, in which they 
(2) divide to form thousands of merozoites. After release in the bloodstream these merozoites infect red blood 
cells in which they (3) multiply in a cyclic manner, causing all clinical symptoms associated with malaria. 
Certain merozoites may develop into sexual stage gametocytes which, when (4) taken up by a feeding 
mosquito, develop into gametes. After fertilisation in the mosquito midgut the zygote develops into a motile 
ookinete, which migrates through the midgut-wall and forms an oocyst. This oocyst forms sporozoites (5) 
which can migrate to the salivary gland, completing the life cycle
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female infected anopheline mosquito takes a blood-meal. This event is accompanied with 
the injection of the contents of the saliva, containing some (usually less than 50 (Beier et a/., 
1991a, 1991b, 1992; Ponnudurai et al., 1991)) infectious sporozoites. These sporozoites 
are within minutes efficiently cleared from the blood-stream when they reach the liver. 
Within the hepatocytes multiplication follows, a multi nucleated hepatic schizont is formed, 
and within as few as 6.5 days thousands of erythrocyte infective merozoites develop in this 
schizont (Murphy et al., 1989). In P. vivax and P. ovale, but not in P. falciparum and P. 
malariae, some of the liver-stage parasites may remain dormant. The activation of these 
dormant forms (called hypnozoites) can give rise to relapses weeks, months, or even years 
after the initial infection. When the merozoites are released from the hepatic schizont, they 
immediately invade erythrocytes (as reviewed in (Gratzer et al., 1993)). First the merozoite 
adheres randomly to the erythrocyte surface, then the merozoite reorientates and contacts 
its apical end, containing rhoptry and micronemes, to the erythrocyte surface. At the same 
time the contents of the micronemes and rhoptries are released into the red cell membrane 
(Hadley etal., 1986) which enables the merozoite to enter the erythrocyte. The parasite is 
now enclosed in an outer sheath, the parasitophorous vacuole membrane, and develops 
into erythrocytic multi nucleated schizonts via a ring-form (characterised by a vacuole in 
which haemoglobin is digested) and trophozoites. When these schizonts rupture 8-16 new 
merozoites are released, which invade more red blood cells to start a new generation in the 
blood. It is these cycles of asexual multiplication in erythrocytes which cause the periodic 
fevers of malaria (48 h for P. falciparum), as well as the clinical effects associated with 
sequestration of late trophozoites in capillaries in almost all organs. After several blood 
cycles a few percent of the billions of trophozoites develop in an alternative way, producing 
male and female gametocytes in a ratio of 1:4 (Read et al., 1992). Both male and female 
gametocytes can be produced by a haploid blood stage parasite, and the sex of the 
gametocyte therefore must be due to selective gene expression of which the mechanism is 
not yet understood. Differentiation of gametocytes has been divided into five stages (I to V) 
covering at least 7 days to reach maturity, each stage being distinguished by successive 
changes in the organisation of the cell (Hawking et al., 1971). Only the immature 
gametocytes sequestrate, especially in bone marrow and spleen (Smalley, 1976), which is 
at least partially mediated by modification of the erythrocyte band 3 protein (Rogers, 1996a; 
1996b). Mature stage V gametocytes become dormant, lose modified band 3, and circulate 
within the erythrocyte in the blood for prolonged periods. They are the sex-cells which can 
only develop further if they are taken up by a feeding mosquito. In the mosquito midgut the
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change in temperature, pH and carbon dioxide concentration, together with the presence of 
a mosquito exflaggelation factor (MEF) (Nijhout et al., 1979), possibly xanthurenic acid 
(Garcia et al., 1998) triggers the gametocytes within minutes to escape from the erythrocyte 
and to differentiate into gametes (Carter et al., 1988). The female gametocyte develops into 
one macrogamete, the male gametocyte develops into 8 exflaggelating microgametes 
consisting of nuclei associated with a flagellum. The lively microgametes, really 
spermatozoa, attach to the female gametes with which they fuse to form a zygote. 
Fertilisation is complete within 10 -30 minutes after ingestion of a blood meal (Carter et al., 
1988). After fertilisation the zygote differentiates over the next few hours into a mobile 
ookinete. The transitional stage between zygote and ookinete is called retort cell. Before the 
ookinete can leave the midgut, it has to leave the blood-bolus which is encapsulated by the 
peritrophic matrix. Enzymes, like chitinase, are involved in the penetration of this chitin rich 
peritrophic matrix (Shahabuddin et al., 1994). At the stomach wall the liberated ookinete 
penetrates through or between the epithelial cells to reach the basement membrane. At the 
basement membrane, the parasite rounds up and forms an oocyst. In about one week the 
oocyst enlarges and undergoes nuclear division, with differentiation of thousands of worm­
shaped sporozoites, which leave the oocyst after fourteen or more days after infection. The 
sporozoites move through the haemocoel and those that enter the mosquitoes salivary 
glands are the infective forms. When the mosquito feeds again, sporozoites in her saliva are 
injected into the blood of a new host, completing the life cycle.
Im m u n it y  to  M a l a r ia
The malaria parasites have evolved to maintain a well-balanced relationship with their 
human hosts. This implies that they can partially escape from protective effector 
mechanisms of their hosts, but also that hosts can develop partial immunity to the parasite. 
This immunity requires repeated infections, takes years to develop, and is usually short of 
duration, although protective immunity to clinical malaria rather than infection may be of 
long duration (Deloron and Chougnet, 1992). The natural acquired immunity is called 
premunition since a low parasitemia mostly persists in the presence of circulating antibodies 
to the various stages and in the absence of clinical disease. In children who do not have 
circulating antibodies to the parasite yet premunition is probably caused by 'antitoxic 
immunity' (vide infra) (Day and Marsh, 1991).
15
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The poor and slowly developing immune responses to malaria are partly due to immune 
evasion strategies of the parasite. Among these strategies antigenic polymorphism is very 
important; after infection an individual will acquire immunity only to that specific isolate, but 
not to heterologous parasites (Mendis et al., 1991; Mercereau-Puijalon et al., 1991; 
Conway, 1997). Among the many polymorphic antigens of P. falciparum the polymorphism 
in the erythrocyte membrane proteins of the EMP-1 family is very extensive and serves 
immune evasion tremendously. These EMPs are found in the knob structures which are 
involved in attachment of infected erythrocytes to vascular endothelium allowing the 
parasite to avoid splenic death (Baruch eta ., 1996). The EMP-1 proteins are encoded by a 
comprehensive set of genes, the so-called var (for variation) genes, of which already 150 
different genes scattered over the entire P. falciparum genome are known (Borst e ta ., 
1995; Baruch eta., 1995; Su et al, 1995; Smith eta/., 1995). In each infected red blood cell 
only one, or at the most a few var genes are expressed, and the rate of switching between 
the genes may be as high as 2.4% per generation (Smith etal., 1995). This enables the 
parasite to evade immune attack. Also many other antigens have a high antigenic diversity 
and may be the product of multiple copies of genes (Miller et al., 1994). Also shedding of 
(parts of) proteins may have immune evasion purposes. For instance the 310 kDa large 
sexual stage protein Pfs230 originates from a 360 kDa precursor (Williamson et al., 1995, 
1996). The 50 kDa protein that is shed contains very immunogenic amino acid repeats 
(Riley et al., 1995).The immune response is in a way diverted to this irrelevant epitope by a 
'smoke-screen' effect, suppressing the formation of high-affinity anti-Pfs230 antibodies. It is 
thought that the many cross-reactive epitopes of antigens of different developmental stages 
are also a heritage of the parasite's ability to divert the immune system (Moelans et a.,
1992). Very often these cross-reactive epitopes confer immunodominant amino acid 
repeats, which implicates that the formation of antibodies to important adjacent areas is 
suppressed (Moelans etal., 1992).
There is also evidence that prolonged exposure to endemic malaria lowers the immune 
responsiveness of populations to malarial antigens (Riley et a., 1989; Goonewardene et a., 
1990; Mshaba et al., 1990). This down-regulation, accompanied with an increased 
frequency of CD8+ cells, elevated levels of free CD8, and a decreased frequency of CD4+ T 
cells, may also be the result of a (cytokine-mediated) defective activation of helper T cells, 
activation of suppressor T cells and of lymphocyte reallocation, but the underlying 
mechanisms are not understood (Hviid et al., 1992). Finally, also a widespread restricted 
immunogenicity to defined antigens is being reported (Quakyi et al., 1989). This non­
16
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responsiveness may be partially due to genetic factors. It implicates that malaria vaccine 
strategies limited to one single antigen subunit approach will be inadequate.
M a l a r ia  v a c c in e s
A safe and effective malaria vaccine should preferentially contain antigens of more than 
one stage of the parasite's life cycle and, perhaps, some components relieving the clinical 
symptoms rather than acting on the parasite. The multi-component vaccine with various 
components and directed against several developmental stages would be expected to be 
more effective for two reasons; (1) There is very often antigenic diversity of particular 
antigens between and within parasite populations (vide supra; Mercereau-Puijalon et al., 
1991; Lockyer et al., 1990). (2) It is unlikely that the parasite when under immunological 
pressure is able to alter several antigens of subsequent developmental stages one after the 
other. Since the malaria life cycle comprises basically five different developmental and 
antigenically distinct stages, i.e. the asexual sporogenic, hepatic and erythrocytic stages, 
and the sexual erythrocytic and exo-erythrocytic stages (comprising the mosquito-stages), a 
multi-component vaccine should preferably contain some antigens from these stages (Table 
1 shows the most important target antigens that are currently under investigation).
The first multi-component vaccine was developed by Dr. Manuel Pattaroyo, designated 
the peptide-vaccine Spf66, consisting of three peptides derived from three blood-stage 
antigens combined with the repeat of the circumsporozoite protein CSP (vide infra). 
Although the vaccine was safe and immunogenic and seemed to protect against malaria in 
initial studies, it could not induce protection against malaria in well controlled clinical trials 
in the Gambia, Thailand, Brazil and Tanzania (Marshall et al., 1996; Urdaneta et al., 1998; 
Bojang et al., 1998; Acosta et al., 1999). In a couple of earlier studies already indications for 
poor efficacy's were raised, since in vitro inhibition of P. falciparum growth did not correlate 
to anti-Spf66 IgG titres (Salcedo et al., 1991; Rocha et al., 1992) nor to the incidence of 
malaria (Valero et al., 1993). A new formulation of Spf66 with QS21-containing adjuvant 
which has shown to be successful in inducing protection with recombinant circumsporozoite 
protein (CSP) (vide infra) (Stoute et al., 1997) is under phase I testing (WHO).
The second multi-stage malaria vaccine was developed by Virogenetics and Connaught, 
designated NYVAC-Pf7, being an attenuated vaccinia virus expressing 7 different antigens, 
i.e. CSP and sporozoite surface protein-2 (SSP-2), the liver stage antigen-1 (LSA-1), the 
merozoite surface protein-1 (MSP-1), serine rich antigen (SERA), apical membrane antigen-
17
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1 (AMA-1) and the sexual stage antigen Pfs25. Also this vaccine was safe and elicited a 
humoral immune response in monkeys (Tine et a/., 1996). Nevertheless, preliminary results 
of phase I and II clinical trials in humans suggested a disappointing effect in terms of 
immunogenicity and protection against malaria (Ockenhouse et al., 1998).
A third multi-stage vaccine was made by Hasnain and coworkers, and consisted of 12 B- 
cell, 6 T-cell proliferative, and 3 cytotoxic T lymphocyte epitopes derived from 9 stage- 
specific P. falciparum antigens CSP, SSP-2, LSA-1, MSP-1, MSP-2, AMA-1, Rhoptry 
associated protein-1 (RAP-1), erythrocyte-binding protein (EBA-175) and the 
gametocyte/gamete cytoplasmic antigen Pfg27. A synthetic gene encoding these epitopes 
was expressed in he baculovirus system, and a 41-kDa antigen, termed CDC/NIIMALVAC- 
1, was purified and used to immunise rabbits. The derived antisera strongly inhibited 
sporozoite invasion of hepatoma cells and growth of blood-stage parasites in the presence 
of monocytes (Shi et al., 1999).
The current status of development of anti-disease, asexual stage and sexual stage 
vaccines is described in the next four sections.
sequestration
antigens
sporozoite
antigens
hepatic
antigens
blood-stage
antigens
sexual and mosquito 
stage antigens
sequestrin CSP CSP MSA-1 / MSP-1 Pfs48/45
EMP-1 family SSP-2 / 
TRAP
LSA-1 RESA / Pf155 Pfs230
STARP MSA-1 SERA Pfs25
Pfexp-1 / an­
tigen 5.1 / 
QF116
RAP-1 Pfs28
RAP-2 chitinase
AMA-1 trypsin
EBA-175
TABLE 1. Major target antigens for malaria vaccine development and/or control (for references see text).
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A n ti- d is ea s e  v a c c in e s
The aim of the anti-disease vaccine is to relieve clinical symptoms and thus reduce the 
degree of mortality and morbidity associated with malaria. With a reduction of childhood 
mortality life might be extended until (limited) antiparasite immunity is developed at later 
age. Severe malaria symptoms have been correlated with the release of toxins when the 
infected erythrocytes rupture, and evidence is growing that immunity to malaria involves 
antibodies to these toxins (Playfair et al., 1990; Bate et al., 1994), as well to lymphokines 
induced by these toxins (Gerold et al., 1994; WHO, 1995). Also infection itself stimulates T- 
cells to secrete interferon^ (IFN-y) and TNF-a. Both may play roles in the suppression of 
the immune system by suppressing haematopoiesis in the bone marrow (i.e. 
dyseruthropoietic anaemia). TNF- itself, furthermore, up-regulates synthesis of 
intercellular adhesion molecule-1 (ICAM-1) in cerebral blood vessel endothelium (Aikawa et 
al., 1990), which is associated with cerebral malaria (Clark et al., 1991). The pathogenic role 
of TNF-a was illustrated by Kwiatkowski et al. who demonstrated that treatment of children 
infected with P. falciparum with an anti-TNF- monoclonal antibody (mAb) reduced their 
fever (Kwiatkowski et al., 1993). Antibodies that neutralise the ability to induce TNF-a 
production have been detected in both non-immune individuals with malaria and in long­
term residents of malaria endemic areas (Jakobsen et al., 1995). Another way to relieve 
disease might be the induction of antibodies directed against parasite-specific molecules 
involved in cyotadherence of trophozoites to endothelium, since sequestration is the cause 
for many serious clinical defects including cerebral malaria. Udeinya and coworkers have 
shown that immune sera from repeatedly infected Aotus monkeys can effectively inhibit 
cytoadherence (Udeinya et al., 1983). Target antigens for an anti-adherence vaccine are 
sequestrin (Ockenhouse et al., 1991) and those of the EMP-1 family (vide supra). Rather 
than vaccination, anti-adhesive therapies are most appropriate for the endothelial ligands of 
those parasite-specific antigens (Land et al., 1995). Candidate targets for such a therapy 
are the erythrocyte modified band-3 protein (Crandall et al., 1993), cluster of differentiation 
antigen-36 (CD36) (Asch et al., 1993; Barnwell et al., 1989; Chulay et al., 1990), 
intercellular adhesion molecule-1 (ICAM-1) (Berendt et al., 1992; Berendt et al., 1989; 
Chulay et al., 1990), endothelial leukocyte adhesion molecule-1 (ELAM-1) (Chulay eta/., 
1990; Ockenhouse et al., 1992), and chondroitin sulphate A (Rogerson et al., 1995), since 
they are at least in vitro involved in the binding of the infected erythrocyte to endothelial 
cells.
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P r e -e r y t h r o c y t ic  v a c c in e s , b a s e d  o n  s p o r o z o it e  a n d  l iv e r  s ta g e s
The ultimate aim of the sporozoite vaccine is to inhibit all subsequent parasitic 
developments within the vertebrate host. However, the speed in which sporozoites are 
cleared from the bloodstream, together with the fact that one single sporozoite may give rise 
to thousands of descendants, makes such a vaccine inherently difficult to be effective. To be 
effective, there steadily should be a high level of specific antibodies against the sporozoites. 
For this reason it may be more appropriate for persons spending relatively brief periods in 
malarious areas rather than for the permanent residents of endemic areas who most 
probably would need repeated vaccinations to sustain high antibody levels.
The ultimate aim of the hepatic vaccine is to prevent formation of the blood stadia, and 
thus preventing illness. Since the nine days long intracellular stay of parasites boosts and 
encourages induction of cytotoxic immune-responses, this stage is a much more attractive 
target for vaccine-induced protective immune-responses in people living in malarious areas.
Sporozoites attenuated by irradiation have long been known to give both in animals and 
in humans excellent protection against subsequent viable challenge (Nussenzweig et al., 
1984; Jones et al., 1994). However, because the irradiated sporozoites must be delivered 
with the bite of irradiated infected mosquitoes, this is clearly not a very practical method of 
immunisation. Since the circumsporozoite protein (CSP) is the most abundant protein on the 
surface of sporozoites, and is also present in the hepatic stages, many efforts were put into 
the induction of immunity by vaccination with synthetic and recombinant parts of this antigen 
(Wang et al., 1995; Brown et al., 1994; Jones et al., 1994). Also efforts were put into 
vaccination with recombinant forms of the thrombospondin-related adhesive protein (TRAP) 
(Robson etal., 1988; Müller et al., 1993; Scarselli et al., 1993) also known as sporozoite 
surface protein 2 (SSP2) (Hedstrom et al., 1990; Rogers et al., 1992), and with the 
sporozoite threonine and asparagine-rich protein (STARP) (Fidock etal., 1994a and b), and 
the 16 kDa sexual stage/sporozoite-specific antigen of P. falciparum (Moelans et al., 1995,
1991). (It should be mentioned here that, despite the presence of pfe16-specific mRNA in 
sporozoites, and anti-Pfs16 based in vitro invasion inhibition of hepatocytes (Moelans et al., 
1991; 1995), others have not been able to confirm the presence of Pfs16 on sporozoites 
(Sinnis etal., 1996)). Antisera against TRAP/SSP2, which like CSP seems to play a role in 
the binding of sporozoites to hepatocytes (via heparan sulphated proteoglycans) (Müller et 
al., 1993; Robson etal., 1995), were shown to inhibit hepatocyte invasion in vitro (Müller et 
al., 1993; Rogers et al., 1992a). Finally, preliminary data have indicated that immunisation
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with a sporozoite-specific antigen can lead to protection against malaria in humans. In this 
study protection was achieved in six out of seven human volunteers who were immunised 
with SBAS2, a fusion protein, comprising CSP and the hepatitus B surface antigen 
emulsified in monophosphoryl A and QS21-containing adjuvant (Stoute et al., 1997).
The often encountered absence of protection against malaria after immunisation with 
recombinant or synthetic sporozoite-specific proteins may be caused by the fact that CD8+ 
T cells are not induced when (recombinant) proteins are used for immunisation. It is known 
that CD8+ cytotoxic T cells play an important role in (circum)sporozoite based immunity 
which can be induced by 'live' vectors expressing CSP intracellularly (Kumar et al., 1988; 
Sadoff et al., 1988; Hoffman et al., 1989; Aggarwal et al., 1990; Malik et al., 1991; Good et 
al., 1993; Gonzalez etal., 1994; Rodrigues etal., 1994; Sedegah etal., 1994; Lanar etal., 
1996; Doolan et al., 1996). This CD8+ T cells activity is, of course, directed towards the 
hepatic intracellular stages. Other candidate antigens to which cytotoxic T cells and other 
cytotoxic leucocytes, like Kupfer cells and natural killer cells, may be directed, are the liver 
stage antigen 1 (LSA-1) (Guerin-Marchand et al., 1987; Zhu and Hollingdale, 1991), a 
specific heat-shock antigen (Renia etal., 1990; Kumar etal., 1993), and some antigens 
which are shared with sporozoites or merozoites, i.e. CSP and circumsporozoite related 
antigen (Coppel et al., 1985), merozoite surface antigen 1 (MSA-1) (Szarfman et al., 
1988a,b), and erythrocytic exported protein-1 Pfexp-1 (Sanchez etal., 1994) (also known as 
antigen 5.1 (Hope etal., 1984) and QF116 antigen (Kara etal., 1988)). In 1996, Doolan et 
al. reported a high protection of mice against infection with P. yoelii after immunisation with 
a DNA vaccine based on the P. yoelii 17 kDa hepatocyte erythrocyte protein (HEP17) - the 
P. yoelii homologue of Pfexp-1 (Doolan et al. 1996b), and a even higher protection when 
combined with a CSP based DNA vaccine (Doolan et al., 1996a). A Phase-I trial with a DNA 
CSP-based vaccine was shown to have good safety profile, but antibody responses were 
disappointing (WHO).
Other approaches to induce protective CD8+ T cells responses were described by Hill 
and colleagues. They reported a human leukocyte antigen class I (HLA-BW53) and class II 
haplotype associated with protection from severe malaria (Hill et al., 1991). Reverse 
immunogenetics (the elution and characterisation of peptides bound to the HLA antigen 
associated with protection) was used to search for epitopes reacting with the HLA BW53 
protein. One epitope within LSA-1 (Guerin-Marchand et al., 1987; Zhu eta/., 1991), when 
expressed with HLA-BW53, was recognised by CD8+ T cells from Gambian subjects with 
the same class I antigen (Hill et al., 1992). Others showed that CD8+T cells from Kenian
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subjects with the same class I antigen were, however, not reacting with the LSA-1 HLA- 
BW53 complex (pers. comm. Sauerwein). Therefore, despite the fact that with reverse 
immunogenetics also CD8+ T cells-epitopes in CSP, TRAP and STARP have been 
identified (Aidoo et al., 1995), this does not automatically mean that these T cell epitopes 
induce proliferation of CD8+ T cells with the same HLA antigen. Hence, more research to 
understand the mechanisms leading to CD8+ T cell mediated protection are warranted.
E r y t h r o c y t ic  v a c c in e s
The prime function of the asexual stage vaccine is to limit replication of the parasite, at 
the stage where it causes illness, and thus to reduce the degree of mortality and morbidity 
associated with malaria. Therefore, it is of prime value to communities resident in highly 
endemic areas, where it would be targeted towards the most vulnerable individuals, the 
young children. Natural infections will aid in maintaining vaccine induced antibody levels, T 
cells, and cytokines. In vitro growth of the blood stages has already been possible for more 
than 20 years (Ponnudurai et al., 1983) and explains why much is known about this stage. 
Several putative vaccine candidate antigens have been described (Holder et al., 1994; 
Jones and Hoffman et al., 1994; Pasloske and Howard et al., 1994), most of which 
conferred variable protection in animals including monkeys. A few of these protecting 
antigens are; (1) native and recombinant products of MSA-1 (Herrera et al., 1992; Daley et 
al., 1993; Ling et al., 1994), (2) the ring-infected erythrocyte surface antigen (Pf155/RESA) 
(a misnomer since it is translocated to internal membranes)(Collins et al., 1986; Gratzer et 
al., 1993) whose protection almost certainly must be of cross-reacting origin (Wahlin et al.,
1992), (3) SERA, a soluble antigen released when merozoites burst out of the erythrocyte, 
(Inselburg et al., 1991), (4) RAP-1 and RAP-2 (Ridley et al., 1990), and (5) AMA-1, a 
molecule also found in the 'rhoptry' organelle (Deans et al., 1988; Anders et al., 1998). 
Clinical testing and field trials are now being prepared, or under way, for MSP-1, SERA, 
AMA-1 and EBA-175 (WHO, 1995). EBA-175 seems, like MSP-1, involved in binding of the 
merozoite to the erythrocyte (Orlandi et al., 1992; Chappel et al., 1993; Holder et al., 1994). 
Several (epitopes) of these antigens are or have been part of the (experimental) multi­
component vaccines Spf66, NYVAC-Pf7 and CDC/NIIMALVAC-1 (vide supra) (Bojang et al., 
1998; Urdaneta et al., 1998; Ockenhouse et al., 1998; Shi et al., 1999).
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TRANSMISSION-BLOCKING VACCINES
The main function of a transmission-blocking (TB) vaccine is to limit spreading of 
disease. Since it offers no personal protection the TB vaccine has also been named an 
'Altruistic Vaccine'. The reduction or elimination of malaria transmission in endemic regions 
can be achieved by reducing the malaria inoculation rate (i.e. lowering the number of 
infective mosquito bites). In areas of low transmission this might be sufficient to eradicate 
the disease malaria. However, in areas of high transmission it is controversial whether 
reduced inoculation-rates do correlate with reduced incidences of severe malaria 
(Greenwood, 1997). Nevertheless, a TB component is of high value since - even in areas of 
high transmission - it reduces the chances of spreading of drug-resistant parasites, or 
parasites with other undesirable traits like 'vaccine-escape' mutants. The TB vaccine would, 
hence, increase the efficiency of anti-malarial drugs or of a vaccine directed against both 
the pre-erythrocytic and asexual blood stages. Furthermore, it might be valuable in the 
prevention of re-entry of the disease in malaria-free regions. For these reasons it has also 
been named a 'quarantine vaccine'.
Natural TB immunity is primarily mediated by antibodies which can act in conjunction 
with cytokines and complement. This results, for instance, in a more efficient opsonisation of 
parasites by phagocytic leucocytes, which event is known to take place in the mosquito 
midgut (Sinden and Smalley, 1976; Lensen et al., 1997). This opsonisation may be 
enhanced by the binding of antibody and/or complement to the parasites (Lensen et al.,
1996). In the presence of leucocytes TNF is one of the non-specific factors associated with 
TB immunity (Naotunne et al., 1993; Lensen et al., 1998). There is also some evidence that 
cytokines and/or inflammatory mediators themselves, including reactive nitrogen 
intermediates, can induce (partial) TB immunity (Motard etal., 1993; Naotunne etal., 1993).
TB antibodies directed against gametocyte antigens can be found in sera of people 
living in malaria endemic regions (Munesinghe etal., 1986; Graves etal., 1988; Roeffen et 
al., 1995b). A TB vaccine should, however, also induce antibodies to gametes and other 
mosquito stages, which would have their effect inside the mosquito midgut on the respective 
stages in order to block further development of these stages. Some of these effects have 
been studied in great detail with mAbs directed against gametocytes, gametes, or purified 
antigens. It was found that these mAbs could, indeed, either block fertilisation, or inhibit 
growth and development of the parasite in the respective stages, or prevent sporozoites 
from invading salivary glands (Rener et al., 1983; Vermeulen et al., 1985; Munesinghe et
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al., 1986; Warburg et al., 1992). Furthermore, the mAbs enabled identification of several 
vaccine candidate antigens as will be described in detail in the next section.
The TB vaccine candidate antigens can be divided into two groups, i.e. pre-fertilisation 
target antigens and post-fertilisation target antigens. Both groups contain excellent 
candidates for usage in a vaccine, as is shown in Table 2. The target antigens of the first 
group have the potential advantage of boosting of immune responses by natural infection. 
The most importans targets are Pfs230 (Williamson et al., 1993), Pfs48/45 (Kocken et al., 
1993), and possibly Pfs2400 (Feng et al., 1993; Scherf et al., 1992) and Pfg27/25 (Wizel 
and Kumar, 1991; Ploton et al., 1995). The group post-fertilisation antigens consists of 
Pfs25 (Kaslow etal., 1988), Pfs28 (Duffy and Kaslow, 1997), chitinase (Shahabuddin etal.,
1993) and mosquito midgut late trypsin (Shahabuddin et al., 1996). Antigens Pfs230, 
Pfs48/45, Pfs25 and Pfs28 are considered to be the most promising candidate antigens for 
the development of a TB vaccine. Antigen Pfs48/45 is subject of this thesis. Immunological 
and biochemical characteristics are discussed in chapter 2. The characteristics and current 
state of knowledge of the antigens Pfs230 and Pfs25/Pfs28 in regard to vaccine 
development is discussed below.
PFS25 AND P fs28
Pfs25 and Pfs28 are two genetically linked but distinct sexual stage-specific antigens 
which both are able to induce TB immunity (Duffy and Kaslow, 1997). Pfs25 is present on 
the surface of zygotes, retorts, ookinetes and oocysts (Vermeulen et al., 1986; Lensen et 
al., 1993), and Pfs28 seems to be located on the surface of retort cells (Duffy and Kaslow,
1997). Both proteins contain epidermal growth factor (EGF)-like domains which may be 
involved in binding to receptors on mosquito epithelial cells (Kaslow et al., 1988). Two 
distinct antibody binding sites have been identified in Pfs25, one of which is target for TB 
immunity. Both epitopes are discontinuous and dependent on the presence of linked fatty 
acids, but independent of carbohydrate groups (Vermeulen et al., 1985; Fries et al., 1989). 
The third EGF-like domain of Pfs25 contains at least a portion of the major TB B-cell epitope 
(Van Amerongen et al., 1989). Nothing is known about the nature of the TB epitopes of 
Pfs28 yet, but the target epitopes for TB antibodies of the P. gallinaceum homologue Pgs28 
appeared to be conformation dependent as well (Duffy et al., 1993).
The primary translation products of genes pfs25 and pfs28 have deduced molecular 
weights of 24- and 26 kDa, but native Pfs28 has a lower electrophoretic mobility than Pfs25
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Protein Mr' Location of protein Capacity to 
induce TB 
immunity
References
Pfs2400 / 
Pfll.1
> 2 mDa in cytoplasm of infected erythrocytes, at 
the parasitophorous vacuolar membrane, 
and very briefly also on the surface of 
emerging gametes
yes Feng et al., 1993 
Scherf et al., 1992; 1993 
Marelli et al, 1995
Pfg377 377 kDa in the osmiophilic bodies of gametocytes not likely Alano et al., 1995
Pfs230 360 / 
310 kDa
gametocyte and gamete surface yes Williamson et al., 1993 
Roeffen et al, 1995b
Pf77 unknown not likely Baker et al., 1995
Pfs48/45 58 kDa gametocyte and gamete surface yes Kocken et al, 1993; 
1995
Pfs28 21 kDa surface of retort cells yes Duffy and Kaslow, 1997
Pfg27 27 / 25 
kDa
cytoplasm of gametocytes and gametes not likely Alano et al, 1991 
Wizel and Kumar, 1991 
Ploton et al, 1995
C hitinase 30 kDa excreted from ookinetes potentially Shahabuddin et al, 
1994; 1 993a; 1993b
Midgut-
trypsin
? excreted from mosquito midgut yes Shahabuddin et al, 1996
Pfs25 19 kDa gamete, ookinete and oocyst surface yes Kaslow et al, 1988; 
1989; 1992; 1994
Pfs16 16 kDa gametocyte parasitophorous membrane 
and in Barnham bodies of infected 
erythrocytes.
no Moelans et al, 1991 
Bruce et al, 1994 
Baker et al, 1994
Pf12 40 kDa poorly defined, may be expressed at the 
surface of trophozoites, schizonts, and 
possibly also on gametocytes.
unknown Elliot et al., 1990
1 relative molecular weights under reducing conditions.
Pf; Plasmodium falciparum; Pfs, Pf sexual stage; Pfg, Pf gametocyte/gamete.
TABLE 2. Sexual and mosquito stage expressed antigens of Plasmodium falciparum.
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on an SDS-polyacrylamide gel (Duffy and Kaslow, 1997). Both single-exon genes encode 
proteins with an amino-terminal signal sequence, a cysteine rich central region containing 
four EGF-like domains, and a carboxy terminal sequence which is diagnostic for GPI-anchor 
attachment (Kaslow et al., 1988; Duffy and Kaslow, 1997). The hypothesis that Pfs25 
contains a GPI anchor is in line with the finding of covalently attached fatty acid to native 
Pfs25 (Vermeulen et al., 1986), and with the demonstration of a GPI anchor in recombinant 
Pfs25 produced in mammalian cells (Kaslow et al., 1992).
Both genes with lengths of 651 and 654 bp show limited genetic variability (Duffy and 
Kaslow, 1997; Hafalla et al., 1997). This is in line with the observed low antigenic diversity 
of Pfs25, only epitope I but not epitope II varied among 45 Malaysian isolates (Foo et al., 
1991; Kaslow etal., 1989), and is consistent with the view that Pfs25 and Pfs28 are not 
subjected to immunological pressure in the human host. However, since T-cell reactivity to 
recombinant Pfs25 is found to be present in endemic sera (Sauerwein, unpublished results), 
and purified gametes and/or recombinant Pfs25 (rPfs25) induce T-cell responses in mice 
(Sauerwein, unpublished results) boosting for T cell and not B cells may be possible upon 
natural infections.
In order to develop a malaria TB vaccine based on Pfs25 and/or Pfs28, both genes have 
been successfully expressed in several expression systems. Direct expression of gene 
pfs25 in rabbits with aid of a DNA vaccine resulted in the induction of TB antibodies (Lobo et 
al., 1999). In E. coli expression of a large part of gene pfs25 in fusion with the gene 
encoding TrpE was possible (Kaslow et al., 1994a). Recombinant protein could be purified 
from inclusion bodies, but was not recognised by Pfs25-specific mAbs (Kaslow, 1994a), nor 
could the antigen induce TB immunity (Kaslow et al., 1994a). In contrast, rPfs25 
synthesised in mammalian cells with aid of a recombinant eukaryotic shuttle plasmid 
(Kaslow, 1992) or with a recombinant vaccinia virus (Kaslow et al., 1991) specifically bound 
to a panel of TB mAbs. Furthermore, it was shown that TB immunity could be induced by 
immunising mice (Kaslow et al., 1991) and Aotus monkeys (Kaslow et al., 1992) with the 
recombinant vaccinia virus, and that the ability to develop TB antibodies was not genetically 
restricted. Also in the yeast S. cerevisiae heterologous gene expression proved successful; 
without signal- and anchor sequences, and without the four W-glycosylation sites, and fusing 
a synthetic gene encoding Pfs25 to the a-mating type factor secretory signal sequence, 
gram amounts of rPfs25 (Pfs25-B) could be purified from yeast culture (Barr et al., 1991). 
Also rPfs28 could be produced in S. cerevisiae, after expression of the central part of the 
natural gene pfs28 fused to six copies of the histidine codon (Duffy and Kaslow, 1997).
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rPfs25 reacted with TB mAbs and could induce TB immunity in mice (Barr et al., 1991) and 
Aotus monkeys (Kaslow et al., 1992), although immunity is relatively short-lived. Also alum 
adsorbed rPfs25 (Pfs25-B) elicited complete TB immunity in monkeys (Kaslow et al., 
1994a). Currently, a second generation yeast product TBV25H (TB vaccine of Pfs25 with a 
histidine tag), which is a better antigen (i.e. more readily recognised by TB mAbs on 
immunoblot) and more immunogenic (Kaslow et al., 1994b), is under investigation. Also 
rPfs28 showed to induce TB immunity in mice, even when emulsified in alum (Duffy and 
Kaslow, 1997). In all systems boosting of the immune-responses is required to elicit TB 
activity. In addition, the antisera with anti-Pfs28 activity could act in synergy with antisera 
with anti-Pfs25 activity to a more potent TB efficiency (Duffy and Kaslow, 1997). In line with 
this, a fusion protein of Pfs25 and Pfs28 produced by S. cerevisiae was more potent in 
eliciting antibodies in mice that blocked oocyst development: complete inhibition of oocyst 
development in the mosquito midgut was achieved with fewer vaccinations, at a lower dose, 
and for a longer duration that with either Pfs25 or Pfs28 alone (Gozar et al., 1998). Gram 
amounts of good manufacturing practice (GMP) grade material of Pfs25 were obtained and 
a vaccine based on the Pfs25 antigen formulated with alum was tested in phase I clinical 
trials in the USA. The vaccine was safe and immunogenic, but did not induce TB antibodies 
(WHO, 1997). A second phase I trial with rPfs25 is currently running, after priming with the 
vaccine NYVAC-Pf7. Additional pre-clinical studies have been started with other adjuvants 
and antigen combinations. Phase I trials with the Pfs25-Pfs28 fusion protein should start 
soon.
PFS230
Pfs230 is a known target for TB mAbs and is present on the surface of gametocytes and 
gametes (Rener et a., 1983; Vermeulen et al., 1985; Quakyi et al., 1987) in a 275 kDa form 
(310 kDa under reducing conditions) (Williamson et al., 1995; 1996). The molecule is 
putatively involved in the fertilisation-process since mAbs against Pfs230 inhibit the 
formation of the zygote. In P. falciparum the anti Pfs230 mAb mediated TB immunity is 
dependent on the presence of active complement (Quakyi et al., 1987). In P. gallinaceum, 
however, two distinct mAbs directed against the Pfs230 homologue are able to reduce 
transmission in the absence of complement (Kaushal et al., 1983). By using a set of mAbs 
five distinct epitopes have been identified (Roeffen et al., 1995b). TB activity is restricted to 
complement fixing IgG2a isotypes (Roeffen et a., 1995c). The target epitopes of TB
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antibodies were shown to be conformation dependent (Carter et al., 1988; Roeffen et al., 
1995b). The antigen is immunogenic, and most people in endemic areas develop antibodies 
which are directed against Pfs230 (Graves et al., 1988; Carter et al., 1989; Riley et al., 
1994; Roeffen etal., 1995b). Therefore, boosting of a vaccine induced immune response by 
natural infection is to be expected. Whether or not in field-sera TB activity is correlated with 
anti-Pfs230 antibodies remains unclear. Despite the demonstration of such correlation (by 
immunoprecipitation) in sera collected from people living in malaria-endemic regions of 
Papua New Guinea (Graves et al., 1988) and a positive association between in vitro 
complement-mediated lysis of P. falciparum gametes and the presence of antibodies to 
Pfs230 (Healer etal., 1997), no correlation between TB activity and antibodies to Pfs230 
could be demonstrated (by immunoprecipitation) in sera obtained in Sri Lanka 
(Premawansa et a., 1994) or (by competition ELISA) in Cameroon (Roeffen et a., 1995b; 
Mulder et al., 1999). This raises the question whether under field conditions TB activity can 
be anti-Pfs230 mediated.
The intronless gene pfs230 was cloned by Williamson et a. (1993a; 1993b). It has a 
length of 9.4 kb and the genetic variation is very limited, which is in line with the 
immunological data suggesting conserved epitopes (Foo et al., 1991). The primary 
translation product of 363 kDa contains an N-terminal signal sequence, but there are no 
other predicted hydrophobic or transmembrane regions, which is consistent with Pfs230 
being a water-soluble non-integral membrane protein (Kumar and Wizel, 1992). A stretch of 
25 contiguous glutamic acids plus a four-amino acid glutamic acid-rich (EEVG) repeat is 
present tandemly eight times followed by four copies of an eight-amino acid (EEVGE-E/G- 
E/V-G) repeat in the 50 kDa amino terminal part of the protein. This fragment is clipped from 
the protein as the parasite emerges from the erythrocyte (Williamson etal., 1995 and 1996) 
and contains an immunodominant region which might be involved in an immune evasion 
strategy of the parasite (Riley et a., 1995). The 310 kDa protein contains four regions of 
negative net charge, and there are six copies of a motif containing seven cysteine residues. 
On basis of these motifs Carter etal. (1995) proposed a model for the structure of Pfs230. 
Remarkable is that, despite the limited genetic variation of the gene, only two of the six 
copies of the seven-cysteine motif are identical in strains 3D7 and 7G8 (Williamson et a., 
1993b). The implication of this observation is not clear. Similar seven-cysteine motifs are 
also (partially) present in Pf12 and Pfs48/45 (Carter etal., 1995). They may share a similar 
or common function since it has been found that repeated structural modules are often 
involved in noncovalent protein-protein interactions (Baron etal., 1991). These motifs might,
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therefore, be involved in the interaction with antigen Pfs48/45 with which Pfs230 forms 
partially a stable membrane-bound complex (Kumar et al., 1987). Finally, Pfs230 contains 
70 cysteines, of which many are assumed to be involved in disulphide-bonding and thus 
stabilise its tertiary structure and the formation of discontinuous and TB epitopes.
In efforts to develop a TB vaccine based on Pfs230, six regions of Pfs230 have been 
expressed in E. coli as fusions with maltose-binding protein (Riley et al., 1995). Antibodies 
induced against one of these cytoplasmically produced products (amino acids 443-1132 = 
76 kDa) (emulsified in complete Freund's adjuvant) bound to the surface of intact gametes 
and significantly reduced the infectivity of P. falciparum parasites to mosquitoes in the 
presence of active complement (Williamson et al., 1995). The TB capacity of these 
antibodies was suprising when is considered that the known TB mAbs do not recognise any 
of the recombinant products that were used for immunisation in an enzyme-linked 
immunosorbent assay (ELISA) (Riley et al., 1995).
29
30
Pfs48/45
C h a pte r  2
PFS48/45
31
Chapter 2
E p ito p e s  o f  P fs4 8 /45
The B-cell epitopes of Pfs48/45 were characterised immunologically by the research 
groups of Carter (1990) and Targett (1990). In competition ELISA with a panel of Pfs48/45- 
specific mAbs six different epitopes were demonstrated, designated I, IIa/IIb, III, IV and V. In 
ELISA it was shown that when Pfs48/45 was captured with one epitope-specific (unlabelled) 
mAb, the same (labelled) epitope-specific mAb did not recognise the antigen, indicating that 
all epitopes are non-repetitive. Based on the fact that not all mAbs directed against these 
epitopes had the same characteristics, some epitopes were subdivided into sub-epitopes, 
as is presented in Table 1. MAbs against epitope region I block transmission effectively 
(Vermeulen et al., 1985; Carter et al., 1985 and 1988). The affinity of mAb 3E12 is higher 
than that of mAb 32F3 (see Table 2; in competition ELISA antisera do more easily compete 
with 32F3 than with 3E12 for binding to Pfs48/45). According to Carter (1985) and Rener 
(1983) mAbs against epitope regions IIa and IIIa reduce transmission only in the presence 
of active complement. Without complement, a combination of mAbs against epitopes IIa and 
IIIa can act synergistically to reduce transmission (Rener et al., 1983; Carter et al., 1985). 
Possibly, because the binding of one mAb can enhance the binding of the other mAb. 
However, this is not a general characteristic of the respective epitopes, since Targett et al. 
(1988, 1990) mentioned that a transmission-blocking (TB) effect of antibodies to IIc and IIIb 
and IIIc does not require synergy (Targett et al., 1988, 1990). Whether this TB effect was 
tested with or without added complement is unclear, but of the mAbs 82D6 and 42A6 (IIc), 
82C4 (IIIb) and 81D3 (IIIc) only the first is of the complement binding IgG2a isotype. 
Whether recognition of epitope III is important for TB activity of field sera is currently 
uncertain. The latest data with newly developed IgG purified mAbs against this epitope 
show that transmission reduction is only achieved at concentrations which need to be 50 
times higher than those of IgG purified mAbs against epitope I (W. Roeffen, pers. comm.). 
(It is not known at what concentrations Targett et al. (1988), who also reported TB epitope 
III-specific mAbs (of IgM subtype), tested these mAbs). Furthermore, the newly developed 
rat mAb 85RF45.3 does (probably) not block transmission. The epitopes I to III have a 
discontinuous disulphide-dependent conformational character; their affinity for mAbs is lost 
upon reduction of the antigen, both on Western blot (Vermeulen et al., 1985; Carter et al., 
1990) and in ELISA (Targett et al., 1990) and, hence, the epitopes are dependent on the 
formation of disulphide-bridges. Epitope IV is non-conformational. The epitope IV-specific 
non-transmission-blocking mAb 3G12 recognises Pfs48/45 particularly well when the
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epitope
mAb1 isotype source transmission-blocking activity2
la 32F33
32F36
32F53
3E124
85RF45.16
b2
Vermeulen, 1985 
Roeffen, non publ. 
Vermeulen, 1985 
Carter, 1990 
Roeffen, non publ.
+ + + 
+ + + 
+ + 
+ + + 
+ + +
lb 84B3H10 lgA Targett, 1990
lla 1A3B85 lgG2a Rener, 1983 + + +
when combined with IIC5B10
+/-
without active complement 
++
with active complement
llb 32F1
32F16
85RF45.2b6
lgG1
lgG2a
lgG1
Vermeulen, 1985 
Roeffen, non publ. 
Roeffen, non publ.
llc 42A6
82D6
lgG1
lgG2a
Targett, 1988 
Targett, 1988
+
++
lll llC5B106 lgG2a Rener, 1983 +++ at 500 pg ml-1 and 
when combined with IA3-B8 
+/-
with or without active complement
85RF45.36
82F45.36
lgG1
lgG1
Roeffen, non publ. 
Roeffen, non publ.
82C4 lgM Targett, 1988 + + +
81D3 lgM Targett, 1988 + + +
lV 3G12 lgG1 Carter, 1985
V 84A2
85RF45.56
lgG2a
lgG2a
Targett, 1990 
Roeffen, non publ.
+ + + 
+ + +
1 mAbs 85RF45.1/85RF45.2b/82F45.3/85RF45.3/85RF45.5 were from rat origin, all other mAbs were from 
mice origin. 2 no transmission reduction; +/-, 55-70% transmission reduction; +, ~ 85% transmission 
reduction; ++, ~ 95% transmission reduction; +++. > 98% transmission reduction (estimated from mean 
number of oocysts per gut after mAb feeding compared to control feeding). Tested mAb concentrations were; 
3E12, >40pg ml-1; 32F3 IgG1, 3 mg ml1; 32F3 IgG2a/2b, 25 pg mf ; 32F5, 3 mg mH ; 85RF45.1, 25 pg ml ; 
32F1 IgG1, 3 mg ml-1; 32F1 IgG2a,<50 pg ml-1; IA3B8/IIC5B10; 0.5-4 mg m-1; 85RF45.2b/85RF45.3, 100 pg 
ml-1; 85RF45.5, 50 pg ml-1; 42A6/82D6/84A2/82C4/81D3, non-published; 3G12, diluted ascites fluid.
3 ammonium sulfate precipitated from ascites fluid, dialysed against PBS, FPLC purified. ammonium 
sulphate precipitated from ascites fluid, dialysed against BBS, prot.A sepharose purified. 5 ammonium 
sulphate precipitated from ascites fluid, dialysed against PBS, not further purified. 6 purified from hybridoma 
supernatant.
TABLE 1: B-cell epitopes of the sexual stage-specific antigen Pfs48/45.
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antigen is reduced (Carter et al., 1990). However, also non-reduced antigen is recognised, 
as was shown by immunoprecipitation of Pfs48/45 from extracts of surface labelled gametes 
(Carter et al., 1990), in IFAs on aceton-fixated air-dried gametocytes (Roeffen et al., 1996), 
and in ELISAs (Graves etal., 1992), though the latter could not be repeated by Roeffen et 
al. (1996) with two-site (capture) ELISAs. MAbs against epitope V also block transmission 
very effectively (Targett, 1990; Sauerwein, pers. comm.). Since the epitope V-specific mAb 
84A2 has shown to influence binding of mAbs to epitope Ib and IIc, it was concluded that 
epitopes I and II are close to each other, and the linear epitope V is constituted of parts of 
each of these (Targett etal., 1990). Since mAb 84A2 recognises reduced antigen, but mAb 
85RF45.5 does not (Sauerwein, pers. comm.), epitope V may be constituted out of two 
subregions, one linear and one conformational in character.
The immunologic variation, as well as the genetic variation, between different isolates 
was shown to be extremely limited (Graves et al., 1985; Foo et al., 1991; Kocken et al.,
1993). There was only immunologic variation in epitope region II (Graves etal., 1985; Foo 
etal., 1991). The presence of epitope IIa seemed to exclude the presence of epitope IIc 
(Foo et al., 1991). Kocken et al. (1993) studied the genetic variation in seven in vitro 
cultivated P. falciparum strains isolated form Brazil, Liberia, Ghana, Honduras, Malaysia, 
Indochina and Schiphol airport (african origin). Since the differences between two isolates 
(NF54 and 7G8) which are IIa-/IIc+ and IIa+/IIc-, respectively, were only at positions defining 
the amino acids of residues 253 and 254, and a third isolate (HB3) which was IIa+/IIc- was 
also different at amino acid residue 254, it was concluded that, apparently, amino acid 
residue 254 determines whether epitope IIa or IIc is expressed (this thesis, chapter 3a; 
Kocken et al., 1993). The results described in chapter 3 are supported by a later study of 
Drakeley et al. (1996) who suggested a regional selection for either epitope IIa, 
predominantly present in South America (two lysine residues at position 253 and 254) and 
South-east Asia (glutamic acid at position 253 and a lysine residue at position 254), or 
epitope IIc (an asparagine residue at position 254), predominantly present in Africa 
(Drakeley et al., 1996). ELISA data also indicated limited variation in epitope III, since mAb 
IIC5B10 reacted stronger with NF54 than with 7G8 (Carter et al., 1990). Possibly, there 
might also be (limited) strain variation in epitope I, since Graves et al. showed in 1992 that 
there was variation in response to epitope Ia with time in one village, with the proportion of 
sera inhibiting mAb binding in competition ELISA increasing for 3E12 and decreasing for 
32F3. One possible explanation could be the existence of previously unrecognised strain 
variation in the targets of these mAbs, together with the change in the relative prevalence of
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the variants with time (Graves et al, 1992).
The T-cell epitopes of Pfs48/45 have not been characterised yet.
Im m u n o l o g ic a l  r e s p o n s e s  to  P fs 4 8 /45
Immunological humoral responses to Pfs48/45 have been described in numerous 
studies. From immunoprecipitation studies it was initially concluded that responses to 
Pfs48/45 were low and variable; The actual number of antisera which were able to 
immunoprecipitate radio-iodinated Pfs48/45 from gametocyte-extracts ranged from a low 
9% of 35 Gambian antisera (Quakyi et al, 1989), and 27% of 44 Papua New Guinea (PNG) 
sera (Graves eta l, 1988b) to 33% of 48 (partially the same) sera (Graves et al., 1988a). 
Later Premawansa reported a similar 28% response with sera from low-endemic Sri Lankan 
people, despite the fact that almost all Papua New Guinea and Sri Lankan sera contained 
antibodies directed against Pfg27 (Premawansa eta l., 1994). These initial studies were 
later extended in ELISAs; antisera were tested for their ability to compete for binding to 
native Pfs48/45 in a gametocyte extract with Pfs48/45-specific mAbs. In Table 2 it is shown 
that antisera contain antibodies directed against all known epitopes, in varying quantities 
and/or affinities. Also seasonal effects and (putative) presence of gametocytes might 
contribute to the observed variety. What is not stated in this Table, but should be noted, is 
that the antibody responses to each of the five epitopes also can vary widely within different 
individual sera (Roeffen et al., 1996). It was shown that non-immune people who encounter 
their first malaria attack immediately develop anti-Pfs48/45 antibodies, but the responses 
are higher and/or contain higher-affinity antibodies in people who experienced previous 
infections (Graves etal., 1990; Ong etal, 1990; Targett etal, 1990). It was also shown that 
schoolchildren (aged 7-15 years) in the Gambia and New Guinea contained antibodies 
against Pfs48/45. In a large-scale test in Papua New Guinea among almost 500 people 
Graves et al. reported that the proportion of positive sera was always < 40% in 0-4 year old 
children and always > 40% in individuals over 20 year of age for all mAbs tested (Graves et 
al, 1992).
Both the data obtained from non-immune adults and from children compared to those 
obtained from immune adults imply that there must be a memory present against Pfs48/45 
in these people. Besides the immunereaction in children and non-immune adults also adults 
who live in areas with a more or less continuous transmission contain similarly high anti- 
Pfs48/45 antibody levels (Carter etal., 1988; Graves et al., 1988b; Graves et al., 1992;
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serum group
( n)1 
[reference]2
Epitopes of Pfs48/45 
Competitive inhibition of mAbs3
la
3E12
la
32F3
Ila
IA3
llb
32F1
llc
42A6
llla
llC5
lllc
81D3
lV
3G12
V
84A2
PNG4 highland (62) 
[C]
35% 61% 32% nt nt 26% nt 47% nt
PNG highland P.falc.
positive
(16) [C]
40% 81% 50% nt nt 44% nt 69% nt
PNG highland 
gametocyte po-sitive 
(8) [C]
57% 75% 38% nt nt 25% nt 63% nt
PNG highland 
primary infection (17) 
[C]
20% 65% 12% nt nt 6% nt 41% nt
PNG highland 
non primary infection 
(11) [C]
67% 73% 55% nt nt 55% nt 64% nt
London patients 
primary infection (14) 
[F]
nt nt nt nt 21% nt 23% nt 36%
London patients 
non primary infection 
(15) [F]
nt nt nt nt 27% nt 33% nt 40%
Gambian 
schoolchildren 
(22) [F]
nt nt nt nt 4% nt 13% nt 9%
PNG
schoolchildren 
(15) [F]
nt nt nt nt 20% nt 0% nt 8%
TABLE 2. Competitive ELISA antibody responses to Pfs48/45 epitopes in different antisera. See also next 
page.
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serum group
( n)1 
[reference]2
Epitopes of Pfs48/45 
Competitive inhibition of mAbs3
la
3E12
la
32F3
lla
lA3
llb
32F1
llc
42A6
llla
llC5
lllc
81D3
lV
3G12
V
84A2
PNG4
schoolchildren 
(44) [D]
14% nt 31% nt nt 48% nt 85% nt
PNG
schoolchildren 
follow up 
(37) [D]
38% nt 19% nt nt 46% nt 53% nt
PNG 
(44)[A]
nt nt nt nt nt 23% nt nt nt
PNG 
(46) [B]
nt nt 48% nt nt 33% nt nt nt
Gambia 
(30) [F]
nt nt nt nt 3% nt 3% nt 13%
PNG (498) 
(232) [E]
39%
49%
33% nt nt 50% nt nt nt
Cameroon 
(52) [G]
nt 13% nt 21% 29% 33% nt nt 31%
Cameroon 
noninfectious 
gametocyte carriers 
(28)[G]
nt 25% nt 39% 61% 54% nt nt 57%
Thailand and PNG 
(26) [E]
46% nt 23% nt nt 19% nt nt nt
1 Number of sera tested
2 References; [A], Graves et a!,, 1988b; [B], Graves et a!,, 1989; [C], Graves et al., 1990; [D], Graves et a!,, 1991; [E], 
Graves etal., 1992; [F], Targett etal., 1990; [G], Roeffen etal., 1996
3 Shown are percentages of sera competing with Pfs48/45 epitope-specific mAbs. Antibodies against epitopes la, Ila, Ilb, Ilc, 
llla, IIIc, IV and V, were identified with mAbs 3E12, 32F3, IA3, 32F1, 42A6, IIC5, 81D3, 3G12, and 84A2, respectively, as 
indicated. nt, not tested.
4 PNG, Papua New Guinea
TABLE 2 continued. Competitive ELISA antibody responses to Pfs48/45 epitopes in different antisera.
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Roeffen et al., 1996), and sera which block transmission effectively contain higher levels of 
Pfs48/45-specific antibodies (Roeffen et al., 1996; Mulder et al., 1999). Down- regulation of 
the immune-response, as was suggested by Targett et al. (1990) since people in the 
Gambia had much lower anti-Pfs48/45 responses than non-immune malaria patients, is 
therefore not very likely.
Also immunological cellular responses to Pfs48/45 have been described. Riley et al. 
(1990) demonstrated that cellular responses to purified Pfs48/45, measured by 
lymphoproliferation and production of interferon- of peripheral blood mononuclear cells 
(PBMC) isolated from Gambian immune adults, were detectable in only some individuals. 
Five out of 30 individuals showed significant lymphoproliferation, and 10 out of 30 produced 
interferon^. However, in the same study only 3 out of 30 samples produced anti-Pfs48/45 
antibodies1 (as measured by competition ELISA with either mAb 42A6 or mAb 84A2), and 
there was no significant association between serologic responses and proliferation or IFN- 
production. In previous secions it has been described that the humoral response to 
Pfs48/45 was sometimes much higher, and large variations in cellular immunologic 
responses are, therefore, also not excluded.
Finally, it should be noted that, although Good et al. (1988) reported apparent (MHC) 
restricted immunogenicity of Pfs48/45 in congenic mice, this was not observed when 
different congenic mouse strains were either immunised with gametes emulsified in 
monophosphoryl lipid A and trehalose dimycolate adjuvant (Rawlings and Kaslow, 1992) or 
with E. coli derived recombinant Pfs48/45 (this thesis, chapter 4a). Also in man the 
differences in response to Pfs48/45 can not be immuneresponsiveness gene controlled 
since among 30 Gambian adults specific MHC class II haplotypes (i.e. HLA-DR or -DQ 
genotype) were represented among both responders and non-responders (Riley et al., 
1990). Graves et al. (1989) have reported similar results with 46 Papua New Guinea sera, 
with no apparent association between antibody response and HLA type (i.e. HLA-A, -B, -C, 
or -DR). (HLA-C = allele undetectable with reagents which were present at that date).
1 Probably Targett et al. described the presence of Pfs48/45-specific antibodies in the same 30 Gambian sera, but now with 
4/30 competing with 84A2 (V), 1/30 competing with 42A6 (llc), and 1/30 competing with 81D3 (lllc) (Targett et al., 1990).
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T he  r e l a t io n s h ip  b e t w e e n  t r a n s m is s io n -b l o c k in g  im m u n it y  a n d  P f s 4 8 /4 5 -s p e c if ic
ANTIBODIES IN ENDEMIC SERA
It is important to know whether there is a significant correlation between the presence of 
antibodies against Pfs48/45 and transmission-blocking immunity (TBI) in endemic sera, 
since it increases the chances that a Pfs48/45-specific TB vaccine will be effective. The 
knowledge that native Pfs48/45 is recognised by TB mAbs (Rener et al., 1983; Vermeulen 
et al., 1985; Carter et al., 1990; Targett et al., 1990) is only a prerequisite for the ability of 
Pfs48/45 to induce longlasting TBI with immunological memory against TB epitopes.
Some research groups have tried to define the relationship between TBI and antibodies 
against Pfs48/45 in sera obtained from people living in malaria endemic regions. Graves et 
al. (1988a) reported a significant negative correlation between infectivity and radioactive 
counts associated with immunoprecipitated Pfs230 from radio-iodinated gametocytes. 
Correlation with immunoprecipitated Pfs48/45 was not significant (Graves et al., 1988a). 
Later Graves et al. (1992) showed that in Papua New Guinea sera there was a significant 
association between lack of infectivity of 51 P. falciparum gametocyte carriers from Papua 
New Guinea and Thailand and recognition of epitope lla on Pfs48/45 by antibodies in their 
sera (Graves et al., 1992). Roeffen et al. (1995a) showed that a positive competition ELISA 
based on competition of serum with two Pfs48/45-specific mAbs is indicative for TB activity 
of the serum when tested in the membrane-feeder TB assay, while a negative result does 
not exclude TB activity (Roeffen et al., 1995a). They analysed sera from european travellers 
exposed to malaria, gametocyte carriers from Cameroon, and schoolchildren from a malaria 
endemic region in Cameroon, and showed a fair-to-moderate agreement between the 
presence of competing anti-Pfs48/45 antibodies in the human sera and the TB capacity of 
these sera2. In an extension of this study, in which 52 sera from Cameroon were screened 
in a competition ELISA with 6 different mAbs directed against epitopes I, II, Ill, and V, 28 
(54%) reduced transmission for more than 80%, and 21 of these (75%) showed competition 
with one or more of the mAbs tested. None of the non-blocking sera exhibited activity in the 
competition ELISAs (Roeffen et al., 1996). In the last study of this group with the sera of 48 
gametocyte carriers from Cameroon the positive correlation found between the presence of 
antibodies against Pfs48/45 and TB activity was less clear (25-35% of antisera containing
2 The index of agreement K, which is 1.00 for perfect agreement, and based on at least 85% transmission reduction, was 
0.4 for gametocyte carriers, 0.47 for travelers and 0.22 (not beyond chance) for school children (Roeffen et al, 1995a)
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Pfs48/45-specific antibodies did not block transmission), but still TB sera contained 
significantly higher prevalences of positive titres against epitopes I, IIb and III in the 
Pfs48/45 competition ELISA (Mulder et al., 1999). Possibly, the observed differences are 
the result of strain-specific TB immunity as suggested by Drakeley et al. (1998). In 
conclusion; there seems indeed to be a tendency between the presence of antibodies 
directed against Pfs48/45 in human sera and the TB capacity of these sera.
B io l o g ic a l  fu n c t io n  o f  P fs4 8 /45
The biological function of Pfs48/45 is still not defined. It is known, however, that mAbs 
directed against Pfs48/45 block the fertilisation-process (Vermeulen et al., 1985). This is in 
part caused by non-specific effects like agglutination of gametes since the effectivity of the 
mAbs used to inhibit fertilisation can be lost when the density of gametes in the bloodmeal 
is reduced (Ponnudurai et al., 1987). However, the TB capacity of the mAbs 3E12 and 32F3 
was also achieved with monovalent Fab fragments (Carter et al., 1990), and agglutination 
is, therefore, not the only mechanism of TBI. The same holds true for the binding of 
complement, especially since it is known that many Pfs48/45-specific mAbs can act in the 
absence of complement (Rener et al., 1983; Targett, 1988). The effect must thus be due to 
interference by the antibody with some essential biological function mediated on the gamete 
surface. It is tempting to speculate that Pfs48/45 is the receptor and/or ligand for binding of 
two gametes. Further studies to prove this assumption are highly warranted.
B io s y n t h e s is  o f  P f s 4 8 /45
Gametocytogenesis is a process which takes approximately seven days (Hawking etal., 
1971). Pfs48/45, like Pfs230, is synthesised from day two of gametocytogenesis onwards 
(Vermeulen etal., 1986; Kumar etal., 1984). There are no indications that Pfs48/45 is 
produced in gametes, since in metabolically labelled gametes no labelled Pfs48/45 could be 
detected (Vermeulen etal., 1986). The antigen can, however, still be found on the gamete's 
surface, as was shown by surface-iodination of macrogametes (Vermeulen et al., 1985). In 
P. gallinaceum both on the surface of male micro- and female macro-gametes the 48/45 
kDa proteindoublet can be found (Kaushal and Carter, 1984). At the following intermediate 
stage (retort cell), between zygote and ookinete, Pfs48/45 could no longer be detected 
(Vermeulen et al., 1985). It is, therefore, likely that the Pfs48/45 proteins are shed during
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ookinete development in analogy to the process in P. gallinaceum, where the Pgs230 and 
Pgs48/45 proteins were found in the extracellular fluid of zygotes transforming into 
ookinetes (Carter and Kaushal, 1984).
P h y s ic a l  c h a r a c t e r is t ic s  o f  P fs4 8 /45
The antigen Pfs48/45 consists of a protein doublet with molecular weights of 48 and 45 
kDa under non-reducing conditions. The 48/45 kDa proteins were shown to be hydrophobic 
in nature. When using phase-separation in Triton X-114 it was found that they partitioned in 
the detergent phase, whereas the 230 kDa protein partitions in the aqueous phase (Kumar 
et al., 1985). Furthermore, the 48/45 kDa protein had a strong tendency to interact with lipid 
bilayers and a hydrophobic matrix phenyl-sepharose (Kumar etal., 1985).
Kumar and coworkers also showed that immunoprecipitation with anti 48/45 kDa-specific 
mAbs lead to co-precipitation of the 230 kDa protein, and that immunoprecipitation of the 
230 kDa molecule lead to co-precipitation of the 48/45 kDa molecules. This lead to the 
assumption that the 230 kDa and 48/45 kDa proteins form a (hetero)complex (Kumar et al., 
1985; 1987). In 1987 Kumar showed by gel permeation chromatography and chemical 
cross-linking that both proteins form indeed a complex (Kumar, 1987). Since the cross­
linked product had a Mr of approximately 300 kDa it was concluded that both antigens exist 
in a stoichiometry of 1:1. However, evidence was also obtained for the existence of a 
subpopulation of 48/45 kDa 
proteins in an uncomplexed 
form. The complex can be 
dissociated with increasing 
concentrations chaotropic 
agents such as guanidine 
hydrochloride urea, or 5M 
NaCl, and by incubation at 
either acidic or basic pH 
(Kumar et al., 1992). SDS, 
unlike Triton X-100, is also 
known to disrupt the 
association between the 
Pfs230 and Pfs48/45 (Kumar
nonreduced reduced
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Fig. 1. Western blot analysis with gametocyte equivalents under 
nonreducing and reducing conditions, showing that Pfs48/45 
resolves in one band of 58 kDa under reducing conditions, and in 
two bands of 48- and 45 kDa, respectively, under non-reducing 
conditions. Concentrations diminished from the left to the right. 
Pfs48/45 was visualised with aid of the antiserum K96 (anti 
rPfs48/45, aa 56-401, see chapter 4a). (Boerman, non-published 
results)
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et al., 1992; 1987). The association seemed also to be disturbed by antibodies (Kumar et 
al., 1992). Once perturbed either by chaotropic agents or by phase separation, dissociated 
forms of antigens do not spontaneously reassociate (Kumar etal., 1985; 1992).
The iso-electric points of Pfs48 and Pfs45 were determined using two-dimensional 
PAGE. The approximate pi values were for both Pfs48 and Pfs45: pi = 6.0 ± 0.1 
(Vermeulen etal., 1986). Later Kumar reported p i values of 5.8 ± 0.1 and 5.9 ± 0.1 before 
and after reduction, respectively (Kumar etal., 1992). This is in complete accordance with 
the calculated p i on basis of the deduced amino acid sequence, with a p i = 6.075 for the 
entire primary translation product, and a p i = 5.558 for the amino acid sequence without 
amino- and carboxy-terminal signal sequences.
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Fig. 2. HPLC profiles of tryptic digests of Pfs45 
(top) and Pfs48 (bottom). Tryptic peptides wer 
fractionated on a reverse phase HPLC column 
using a 0-80% acetonitrile gradient with 0.1% am­
monium acetate. Numbered peaks were collected, 
dried, and microsequenced (non-published results 
described in: Kocken eta l, 1991)
Since there is only one gene, it is 
remarkable that there are two protein- 
products of 48- and 45 kDa, respectively, 
when analysing the doublet under non­
reducing conditions. It is tentative to 
speculate about possible structural 
differences between the two proteins. Both 
share the same tryptic peptide pattern (Fig. 
2), and share the same iso-electric point of 
pH 6.0. A putative difference would, hence, 
be of non-charged origin, like for instance 
modification with sugar moieties, or the 
presence of a GPI-anchor in only one of 
the two forms. We think, however, that the 
differences between the two proteins are 
solely conformational. When the proteins 
are reduced under conditions of increasing 
concentrations of dithiothreitol (DTT), the 
Mr of both proteins increases until their 
electrophoretic mobility is identical. 
Furthermore, Western blot analysis of the 
proteins in varying concentrations shows 
that reduced antigen resolves in one band, 
and non-reduced antigen in two bands (Fig.
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1). These results seem contradictory to data published previously (Rener et al., 1983; 
Kumar, 1985). Nevertheless, also Kumar et al. (1984) have reported the presence of one 
(broad) band after reduction as did Vermeulen (1985). Furthermore, in 1992 Kumar and 
Wizel reported that after iodoacetamide treatment of Pfs48 and Pfs45 the 48 kDa molecule 
migrated with the 45 kDa molecule suggesting free -SH groups in the 48 kDa molecule 
which were susceptible to alkylation (Kumar etal., 1992).
Is o l a t io n  o f  g e n e  p fs 4 8 /45
Gene pfs48/45 was isolated and characterised by Kocken et al. (1993). The protein was 
extracted from 5x109 gametocytes in Triton-X114, and subsequently used for the purification 
of Pfs48 and Pfs45 by immuno-affinity chromatography. In short, the TB mAb 32F5 
(Vermeulen etal., 1985) coupled to CL-sepharose (Pharmacia) was used for this purpose. 
Elution of the antigens from the column was in 1% SDS, and the proteins were fractionated 
by SDS-gel electrophoresis. Both the 48 kDa and the 45 kDa proteins (approximately 20 |jg 
each) were excised from gel, separately digested with trypsin, and the eluted tryptic 
peptides were fractionated by HPLC. The elution profiles of both protein digests were very 
similar, if not identical (Fig. 1). The peptides were dried and micro-sequenced, and some of 
the peptides yielded reliable amino acid sequences. Two of these sequences were used to 
synthesise 2 sets of degenerated oligonucleotides and were used for PCR amplification of 
genomic DNA of the isolate NF54. One of the PCR fragments was found to contain 
sequences corresponding to the amino acid sequences of some of the sequenced tryptic 
peptides. Then this PCR fragment was used to screen a gametocyte cDNA library in 
pcDNAII (Rawlings and Kaslow, 1992) of the clone 3D7 of the Amsterdam airport isolate 
NF54 (Walliker et al., 1987). This resulted in 12 clones that were used to determine the 
entire sequence of Pfs48/45, as presented in Fig. 3 (Kocken et a, 1993).
GENE PFS48/45
The coding region of gene pfs48/45 has a length of 1344 bp and codes for a polypeptide 
that is 448 amino acid residues long (Fig. 3). Computer search analysis at the DNA and 
protein levels indicated that the Pfs48/45 sequence has no significant similarity to any other 
DNA or protein sequence known. The 5' and 3' noncoding sequences are incomplete and 
have only been determined up to 329 bp and 560 bp, respectively. Both have an A+T
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1
1
ATG
MET
ATG
MET
TTA
Leu
TAT
Tyr
ATT
Ile
TCT
Ser
GCG
Ala
AAA
Lys
AAG
Lys
GCT
Ala
64
22
TTA
Leu
AGA
Arg
ATA
Ile
ATA
Ile
AGT
Ser
GGA
Gly
AAC
Asn
AAT
Asn
GAT
Asp
TTT
Phe
127
43
GGA
Gly
TTC
Phe
ATA
Ile
GGA
Gly
TAT
Tyr
AAG
Lys
TGT
Cys
AAT
Asn
TTT
Phe
TCA
Ser
190
64
CGT
Arg
GAA
Glu
CGT
Arg
AGG
Arg
TCT
Ser
ATT
Ile
TTT
Phe
TGC
Cys
ACC
Thr
ATC
Ile
253
85
ATA
Ile
ATA
Ile
CCT
Pro
AAA
Lys
AAA
Lys
AGT
Ser
TCG
Ser
TCT
Ser
CCT
Pro
GAG
Glu
316
106
GTA
Val
TAT
Tyr
ACT
Thr
GAT
Asp
TAT
Tyr
GAG
Glu
AAT
Asn
AGA
Arg
GTT
Val
GAA
Glu
379
127
GAA
Glu
ATA
Ile
GAA
Glu
GAA
Glu
AAT
Asn
GAT
Asp
ACA
Thr
AAC
Asn
CCT
Pro
AAT
Asn
442
148
AGT
Ser
CCA
Pro
AAA
Lys
GAC
Asp
ATT
Ile
GAA
Glu
TTT
Phe
TTT
Phe
TGT
Cys
TTT
Phe
505
169
GAA
Glu
GGG
Gly
AGA
Arg
AGT
Ser
GCT
Ala
ATG
MET
GTA
Val
CAT
His
GTA
Val
CGT
Arg
568
190
AAT
Asn
TTA
Leu
ACA
Thr
AAT
Asn
GAT
Asp
CTT
Leu
TTT
Phe
ACA
Thr
TAT
Tyr
TTG
Leu
631
211
AAT
Asn
GTA
Val
TTA
Leu
GAA
Glu
GTA
Val
GAA
Glu
TTG
Leu
AAT
Asn
GAT
Asp
GGA
Gly
694
232
AAA
Lys
AAA
Lys
TGT
Cys
TTT
Phe
CAA
Gln
GAA
Glu
GGA
Gly
AAA
Lys
GAA
Glu
AAA
Lys
757
253
AAA
Lys
AAC
Asn
TTA
Leu
ACT
Thr
ATC
Ile
TTT
Phe
AAA
Lys
GCT
Ala
CCA
Pro
TTT
Phe
820
274
ACA
Thr
TGC
Cys
AAA
Lys
TTT
Phe
AAA
Lys
AAT
Asn
AAT
Asn
AAT
Asn
TAT
Tyr
AAA
Lys
883
295
ATA
Ile
CAC
His
GGA
Gly
TGT
Cys
AAC
Asn
TTC
Phe
TCT
Ser
TCA
Ser
AAT
Asn
GTT
Val
946
316
ATT
Ile
TCT
Ser
TTA
Leu
GTT
Val
GAT
Asp
GAT
Asp
AGT
Ser
GCA
Ala
CAT
His
ATT
Ile
1009
337
AAT
Asn
CAT
His
TTG
Leu
GTA
Val
GGT
Gly
TTA
Leu
AAT
Asn
TGT
Cys
CCT
Pro
GGT
Gly
1072
358
CAA
Gln
CCT
Pro
GAA
Glu
TCA
Ser
GAA
Glu
GAA
Glu
CTT
Leu
GAA
Glu
CCA
Pro
TCC
Ser
1135
379
GGA
Gly
GAT
Asp
ATT
Ile
GAA
Glu
TAT
Tyr
TAT
Tyr
GAA
Glu
GAT
Asp
GCT
Ala
GAA
Glu
1198
400
GGA
Gly
AGT
Ser
ATA
Ile
CCA
Pro
AAA
Lys
ACG
Thr
ACA
Thr
TCT
Ser
TTT
Phe
ACT
Thr
1261
421
ATG
MET
ACA
Thr
GTT
Val
ACT
Thr
ATA
Ile
GAT
Asp
TCA
Ser
GCA
Ala
TAT
Tyr
TAT
Tyr
1324
442
GTA
Val
GCA
Ala
ATA
Ile
TTA
Leu
TTA
Leu
TAT
Tyr
ATT
Ile
TAG
stop
CAA
Gln
GTT
Val
GCT
Ala
TTT
Phe
ATC
Ile
TTA
Leu
TAT
Tyr
ATA
Ile
GTA
Val
TTA
Leu
GTA
Val
TGT
Cys
AAG
Lys
CCT
Pro
AGC
Ser
TCT
Ser
TTG
Leu
AAT
Asn
AGT
Ser
GAA
Glu
ATA
Ile
TCT
Ser
AAT
Asn
GAA
Glu
GGT
Gly
GTT
Val
CAT
His
AAT
Asn
TTA
Leu
AAG
Lys
CCA
Pro
GAT
Asp
ATG
MET
CAT
His
TCG
Ser
TAT
Tyr
TTT
Phe
ATA
Ile
TAT
Tyr
GAT
Asp
AAG
Lys
ATA
Ile
AGA
Arg
TTA
Leu
TTT
Phe
AAA
Lys
ATA
Ile
TTA
Leu
CCA
Pro
GAA
Glu
AAA
Lys
TGT
Cys
TTT
Phe
CAA
Gln
AAA
Lys
ACT
Thr
GAT
Asp
ATA
Ile
TCG
Ser
GAA
Glu
TTA
Leu
GGT
Gly
TTA
Leu
ATT
Ile
GAA
Glu
TAT
Tyr
TAT
Tyr
AAT
Asn
GAA
Glu
AGG
Arg
ACA
Thr
ATA
Ile
ACT
Thr
ATA
Ile
TCT
Ser
CCA
Pro
TTT
Phe
TGT
Cys
GAT
Asp
AAT
Asn
ACT
Thr
GAA
Glu
AAG
Lys
GTT
Val
ATA
Ile
TCA
Ser
AGT
Ser
ATA
Ile
GTA
Val
TTA
Leu
AAA
Lys
TAT
Tyr
CCA
Pro
CAT
His
AAT
Asn
ATT
Ile
TTA
Leu
TTT
Phe
ACT
Thr
CCG
Pro
AAA
Lys
ACA
Thr
TAT
Tyr
AAT
Asn
GAA
Glu
TCT
Ser
AAT
Asn
TTT
Phe
GTA
Val
AGT
Ser
GAA
Glu
TTA
Leu
TTT
Phe
GTT
Val
TTA
Leu
GCT
Ala
TGT
Cys
GAA
Glu
CTA
Leu
ATT
Ile
AAT
Asn
GCC
Ala
TTA
Leu
TAT
Tyr
AAA
Lys
AGT
Ser
AAT
Asn
AAA
Lys
ATA
Ile
ATT
Ile
TAT
Tyr
CAT
His
TAT
Tyr
GTT
Val
ACA
Thr
TCA
Ser
AAA
Lys
GAT
Asp
GTT
Val
AAT
Asn
ACA
Thr
GAA
Glu
TGT
Cys
ATA
Ile
GTT
Val
TTA
Leu
AAA
Lys
CCA
Pro
AAA
Lys
TAT
Tyr
GAA
Glu
AAA
Lys
AAA
Lys
GTC
Val
AGT
Ser
TCT
Ser
AAA
Lys
CAT
His
ACT
Thr
TTT
Phe
ACA
Thr
GAT
Asp
AGT
Ser
TTA
Leu
GAT
Asp
TCA
Ser
TGT
Cys
AAC
Asn
GTA
Val
CAT
His
TTG
Leu
TCT
Ser
GAA
Glu
CCA
Pro
AAA
Lys
TAT
Tyr
GAT
Asp
ATT
Ile
ATA
Ile
CCA
Pro
GAT
Asp
TGC
Cys
TTT
Phe
TTT
Phe
CAA
Gln
GTA
Val
TAT
Tyr
AAC
Asn
ATT
Ile
GTT
Val
TAT
Tyr
TTA
Leu
GAT
Asp
TCA
Ser
CAA
Gln
ATA
Ile
AAT
Asn
ATA
Ile
GGA
Gly
GAT
Asp
GAT
Asp
AAA
Lys
ATT
Ile
AAA
Lys
TTA
Leu
TTT
Phe
GGT
Gly
ATA
Ile
GTT
Val
TGT
Cys
ATA
Ile
TGT
Cys
AAG
Lys
AAG
Lys
GAT
Asp
AAA
Lys
AAA
Lys
AGT
Ser
GCT
Ala
TAT
Tyr
GGA
Gly
TTT
Phe
TTG
Leu
GCT
Ala
AAA
Lys
ACA
Thr
TTT
Phe
ATA
Ile
TTC
Phe
CTA
Leu
ATT
Ile
Fig. 3; Nucleotide- and deduced amino acid sequence of gene pfs48/45. The putative signal sequences for 
ER translocation and GPI attachment are shown in italics. The first nucleotide- and amino acid residue of 
each line is numbered (Kocken et al, 1993) (Genbank accession no. Z22145).
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composition of 87.3%, whereas the coding region has an A+T composition of 74.9%. These 
values are similar to those found for other genes of P.falciparum (Weber et a/., 1987). No 
introns are present within the coding region, as could be deduced from sequence analysis 
of amplified genomic DNA fragments. Southern hybridisation studies with several restriction 
digests of P. falciparum DNA, using 5' and 3' cDNA probes, or a 700 bp PCR fragment 
(Kocken etal, 1993) showed the presence of only one single gene.
A recent survey, based on cysteine domains described by Carter in 1995, in the Malaria 
Genome Sequencing Project sequence databases has lead to the identification of a 
Pfs48/45 gene-family. Until now this family contains besides pfs48/45 genes encoding the 
presumed antigens Pf12, Pf36, Pf41 and Pf47. As genome sequence information 
accumulates possibly other members of this family will be identified. Future experiments 
should give a clue to functions and relationships (Templeton and Kaslow, 1999).
S e x u a l  s t a g e -s p e c if ic  e x p r e s s io n  o f  g e n e  p fs 48 /45
Gene pfs48/45 is solely expressed in the sexual stages of the P. falciparum. This was 
shown by Vermeulen et al. (1986), who could only demonstrate metabolically labelled 
Pfs48/45 in gametocytes but not in gametes and asexual parasites, and by Kocken et al. 
(1993) who showed that Pfs48/45-specific mRNA is present only in the sexual stages. In 
gametocytes and, to a lesser extent in gametes, 2 mRNA species of 2.3 and 2.8 kb are 
present. The finding of multiple transcripts of a single copy gene is not unique in P. 
falciparum. Multiple mRNAs are found for the gametocyte-specific protein Pfg27/25 and the 
circumsporozoite protein of Plasmodium berghei (Delves et al., 1990; Ruvulo et al., 1993), 
whereas the gametocyte p-tubulin is encoded by 3 mRNAs (Delves et al., 1990). Whether 
the Pfs48/45 transcripts are generated by differential polyadenylation as reported for the CS 
protein (Ruvulo et al., 1993) and the HMG-like protein of trypanosomes (Erondu et al., 
1992), or are the results of transcription initiation at different promoter sites or due to the 
presence of introns in the 5' untranslated regions is unknown.
P r o c e s s in g  o f - a n d  p o s t t r a n s l a t io n a l  m o d if ic a t io n s  o n - th e  p r im a r y  t r a n s l a t io n  
PRODUCT OF PFS48/45
The deduced amino acid sequence reveals a protein with a length of 448 amino acids. 
In Fig. 4 the putative hydrophilicity of the protein as analysed with the method developed by
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Kyte and Doolittle (1982) is shown. The primary translation product possesses the typical 
characteristics of a protein which is destined to be anchored into the plasma membrane by a 
phosphatidyl-inositol glycan (GPI) moiety. The N-terminal signal peptide is cleaved off the 
protein after translocation across the membrane of the endoplasmic reticulum (ER) 
(Johnson et a/., 1997; Blobel et al., 1983). The C-terminal signal peptide is recognised by a 
transamidase that cleaves the peptide and concomitantly adds the GPI moiety (Lublin, 
1992). Both signal-sequences are generally 15-30 amino acids long. The sites of cleavage 
in both the N- and C-terminal sequences can be predicted with a 75-80% degree of 
certainty (Micanovic etal., 1990; Kodukula et al., 1991; Gerber etal., 1992). At the N- 
terminal end the most likely cleavage point is located between the amino acid residues 25 
and 26, according to the '-1, -3 rule' of von Heijne and colleagues, with at -3 an Ile and at -1 
a Ser. At the C-terminal end the putative cleavage/attachment site 0) is located between the 
amino acid residues 426 and 427. The sequence here is o)=Asp, 0)+1=Ser and 0)+2=Ala. 
Also the finding that this -site is located just in front of a strong hydrophobic domain and 
that is located between 15 and 30 aa from the C-terminal amino acid residue of the primary 
translation product points to the correctness of this prediction.
The predicted Mr of Pfs48/45 according to the primary translation-product is 51.6 kDa. 
After removal of the N- and C- terminal signal sequences a 400 amino acid residues long 
protein is left with a Mr of 46.0 kDa. Post-translational modifications will increase this 
molecular weight. Glycosylation and/or GPI-anchoring is thought to take place, since native 
Pfs48/45 can be labelled with (3H)-mannose and 3( H)-glucosamine (Kumar and Carter, 
1984; Vermeulen et al., 1986). Kumar and Carter reported a higher incorporation rate of 
(3H)mannose compared to 3 H) glucosamine (1984). As discussed, the primary amino acid
sequence favours GPI-anchoring, 
however, incubation of gametocytes 
with (3H)-ethanolamine, a compound 
which links the C-terminus of the 
protein with the phosphatidyl inositol 
glycan moiety (Menon et al., 1994), 
did not to result in detectable 
amounts of labelled Pfs48/45 (R. 
Milek and M. Boerman, unpublished 
results). Nevertheless, Carter and 
colleagues suggested the presence
Fig. 4. Hydrophilicity plot of Pfs48/45 calculated with the pro­
gram DNASTAR™ according to the method developed by Kyte 
and Doolittle (1982). Hydrophathy values of each amino acid 
residue are averaged over a window of 9 residues. Plotted is 
hydrophilicity (>0) against the respective amino acid residue.
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of fatty acid chains in the structure of Pfs48/45 which points to GPI anchoring (Carter et al.,
1990). Although Pfs48/45 contains seven putative W-glycosylation sites (Asn-X-Ser/Thr), it is 
not very likely that it is N-glycosylated because we have not observed any effect on the 
electrophoretic mobilites of the proteins after incubation in the presence of the 
deglycosylation enzyme W-glycosidase F (Chapter 5). Secondly, incubation of gametocytes 
and gametes in the presence of tunicamycin (8h, 20 pg ml-1), a specific inhibitor of W- 
glycosylation (Elbein, 1987), does not affect the level of incorporation of (3H)-glucosamine 
or (3H)-mannose in Pfs48/45 (J. v. Deursen; unpublished results). It, furthermore, has been 
observed that native Pfs48/45 binds only very weakly or not at all to the lectins concavalin 
A, triticum vulgaris, and Bandeireae simplicifolia 1 (H. Fries, unpublished results). Finally, 
the Mr of deglycosylated recombinant Pfs48/45, when expressed heterologously in 
mammalian- or insect cells, is identical to that of the native Pfs48/45. Nevertheless should 
be noted that Fries and colleagues reported a diminished binding of Pfs48/45-specific mAbs 
(32F3 and 32F1) in an ELISA when parasite extracts had been treated with either W- 
glycosidase F or periodate (Fries, 1991). However, in the case of W-glycosidase F treatment 
unspecific effects, like protein degradation, can not be ruled out, and mock-treament was 
not assessed. Also in the case of periodate oxidation unspecific effects can not be ruled out, 
since no periodate-insensitive control protein and/or mAb was tested, and periodate 
oxidation may also affect O-linked glycans (Woodward etal., 1985).
Whether W-glycosylation occurs in the gametocyte stage is not known. Numerous 
studies claim that glycoproteins of the asexual stages of P. falciparum are mainly, if not 
solely, O-glycosylated, whereas W-glycans seem to be lacking (Ramasamy eta., 1985 and 
1987; Dayal-Drager etal., 1991; Din etal., 1992; Dieckmann-Schuppert etal., 1992 and
1994). There are, nevertheless, two reports which provided some evidence that W- 
glycosylation might occur. In 1985 Nillni etal. provided evidence for the W-glycosylation of 
asexual stage-specific proteins of P. knowlesi, and in 1996 Kimura and colleagues proved 
that W-glycosylation may occur in the intraerythrocytic stages of P. falciparum, and more 
specifically, in the ring stage and young trophozoites. They reached this conclusion after 
analysing proteins and sugars released after W-glycanase-treatment (Kimura et al., 1996), 
as well as after measuring the (decreased) incorporation rate of labelled glucosamine into 
proteins following tunicamycin treatment (Kimura et al., 1996; Nillni et a/., 1985). The 
incorporation rate of labelled glucosamine also increased when dolicholphosphate, the lipid 
carrier on which the oligosaccharide chain is assembled in the ER (Kornfeld and Kornfeld, 
1985), was added (Nillni et al., 1985) suggesting incorporation in W-linked glycans. W-
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glycosylation, therefore, seems to be a tightly controlled stage-specific event in P. 
falciparum.
P r e d ic t e d  d is u l p h id e - b o n d e d  s t r u c t u r e  o f  P fs4 8 /4 5 , p u ta tiv e  l o c a l is a t io n  o f  e p ito p e s
Although nothing can be said about the structure of Pfs48/45 it is known that almost all 
mAbs against the native form of Pfs48/45 react with disulphide-bridge constrained epitopes. 
This suggests that the disulphide-bonded regions are exposed to the surface of the 
molecule on intact gametes. Carter et al. (1995) predicted a disulphide-bonded structure for 
the proteins Pfs230, Pfs48/45 and Pf12. Within these unrelated proteins four distinct sets of 
cysteine-containing motifs and one cysteine-less motif were recognised. The proposed 
models are based on two assumptions: each set of motifs forms a disulphide-bridge linked 
structural domain containing 1, 2 or 3 disulphide-bridges and in each domain analogous 
pairs of cysteines are always coupled to each other. The model for Pfs48/45 is depicted in
Fig. 6. Domain I is absent. Domain II is 
linked by a short J segment to domain 
III which is linked by a B segment to 
domain IV. Carter thinks that the TB 
disulphide bridge constrained epitopes 
are present in motifs 2 to 5 together 
with the small 'a-loops', and are thus 
directed to the outfacing surface of the 
molecule, and that the b-loops and J 
regions might be internal to the 
molecule or in close contact with the 
gamete surface.
The hypothesis that b-loops are 
hidden is in line with observations that 
sera directed against b-loops, i.e. 
derived from rabbits or rats immunised 
with either recombinant E. coli antigens 
or peptide-pools, do not recognise 
native antigen as it is present on the 
surface of the gametocyte (chapter 4a).
n  M otif in
□  M otif IV
■  M otif V
Fig. 6 . Predicted disulphide-bond structure for Pfs48/45. N- 
and C-terminal ends are indicated with 'N' and 'C', respecti­
vely, and the first and last amino acid residue are numbered 
in italics. Motifs are indicated in color, and domains with 
Roman numerals. The numbered position of each cysteine is 
marked by a closed circle; the position of each Proline is 
marked by a stroke. The loop regions associated with each 
domain are marked 'a' and 'b' respectively, the 'bridge' secti­
ons connecting odd-to even-numbered domains are marked 
'B' and the 'junction' sections connecting even- to odd-num­
bered domains are marked 'J' (Carter et al., 1995).
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However, that the hypothesis must be looked at with greatest caution is illustrated with the 
observation that (part of) loop b of region III must be localised at the outer surface of the 
molecule since it contains (part of) the TB epitope Ila or IIc, i.e. amino acid residue 254 
(chapter 3a). Furthermore, Kumar and Wizel (1992) demonstrated that disulphide-bonds are 
not accessible for reduction on intact gametes or in Triton X-100 extracts, but only after 
treatment with chaotropic agents or at acidic and basic pH, suggesting that the disulphide- 
bonds are internal and 'hidden' inside the molecule, and thus not facing outwarts as 
suggested by Carter.
The hypothesis of Carter that cysteine residue 32 is not involved in disulphide bonding 
and hence unimportant for the stabilisation of the antigen, is in line with the observation that 
the cysteine residue at position 32 is missing in the P. reichenowi antigen Prs48/45 (chapter 
3b).
Ho m o l o g o u s  p r o te in s  o f  P fs4 8 /4 5  in  o t h e r  p la s m o d ia e  s p e c ie s
The presence of homologous proteins to Pfs48/45 could be beneficial for the 
characterisation of the function of Pfs48/45. Model-systems would facilitate research 
towards this characterisation as well as to the mechanisms underlying induction of TBI. Until 
now, a pfs48/45-homologous gene has been found only in the chimpanzee parasite P. 
reichenowi (chapter 3b). However, the chimpanzee is not an ideal model-system due to high 
maintenance costs and out of ethical reasons, and awaits for instance the elucidation of its 
mosquito vector. A better model-system would be that of chickens in combination with the 
chicken parasite P. gallinaceum. On the protein level the analogous proteins present in P. 
gallinaceum are most convincingly Pfs48/45 analogous. The protein-doublet Pgs48/45 has 
exactly the same chemical and immunological characteristics, and forms also a stable 
membrane bound complex with a large protein, i.e. the Pfs230 homologue (Kumar, 1985; 
1987). Also in P. yoelii potentially homologous protein has been described, a 42 kDa protein 
which is recognised by a TB mAb and also induces TBI (Harte et al., 1985). Biochemical or 
immunological data are not available on the occurence of homologous proteins in the the 
murine parasite P. berghei. Also nothing is known about the occurrence of homologous 
proteins in the simian parasite P. knowlesi. Finally, also in the human malaria parasite P. 
vivax Pfs48/45 homologous proteins with an Mr of 42/37 kDa have been identified with TB 
mAbs. The epitopes of these proteins were shown to be disulphide-bridge constrained, but 
in contrast to Pfs48/45, were shown to be highly polymorphic (Premawansa et al., 1990). On
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the DNA level, genes homologous to gene pfs48/45 have been shown to be present in P. 
berghei, P. yoelii and P. gallinaceum (Dodemont and Konings), which await further 
characterisation.
Chapter 2____________________________________________________________
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Recently, we reported the isolation and characterisation of the Plasmodium falciparum 
gene Pfs48/45 (strain NF54) that coded for a gametocyte/gamete-specific surface antigen, 
which is an important target antigen for transmission-blocking immunity (Kocken et al., 
1993; Rener et a., 1983; Vermeulen et al., 1985). To assess the suitability of this antigen 
for incorporation in a transmission-blocking subunit vaccine, it is important to know its 
antigenic diversity as it occurs in the field. Therefore we analysed the nucleotide sequences 
of the Pfs48/45 genes in 7 in vitro cultivated P. falciparum strains collected from various 
geographic areas, i.e. Brazil (7G8) (Burkot et a., 1984), Liberia (LE5, LF4) (Graves et a.,
1984), Ghana (GH1), Honduras (HB3) (Walliker et al., 1987), Malaysia (CAMP) (Degowin et 
a., 1965) and Indochina (Dd2) (Wellems et al) and compared these with that of NF54 
(Ponnudurai et a., 1982), thought to be of African origin.
Immunological studies with Pfs48/45-specific monoclonal antibodies have shown that 
antigen Pfs48/45 contains at least five B-cell epitopes, I, Ila or Ilc, Ilb, III and IV (Graves et 
al., 1985; Carter et al., 1990; Foo et a., 1991), of which the first 4 are tertiary structure 
dependent. The only polymorphic epitopes identified thus far are Ila and Ilc, which behave 
as though they are mutually exclusive (Foo et a., 1991). Because epitope Ila is absent from 
gene pfs48/45 of isolate NF54, but present in that of 7G8 (Carter et al., 1990; Foo et a.,
1991), and conversely epitope Ilc is absent from 7G8 but present in NF54 (Foo et al., 1991) 
(Pieter Beckers and Ton Lensen, personal communication), the entire nucleotide sequence 
of the intronless gene Pfs48/45 of 7G8 was established. First the coding region (1347 base 
pairs) was amplified with the polymerase chain reaction (PCR) using primers previously 
described (Kocken et al., 1993). Subsequently the PCR products were sequenced without 
intermediate subcloning (Casanova et al., 1990). Between the Pfs48/45 genes of 7G8 and 
NF54 only 2 nucleotides were found to be different (fig. 1A). In 7G8 at nucleotide position 
757 there is a G instead of an A, and at nucleotide position 762 a G instead of a C, with the 
consequence that the consecutive amino acids lysine and asparagine at positions 253 and 
254 in Pfs48/45 of NF54 are replaced by a glutamic acid and lysine residue, respectively, in 
7G8.
Because epitopes other than Ila and Ilc are highly conserved (Graves et al., 1985; 
Carter et al., 1990; Foo et al., 1991), initially of the other strains only the DNA region of 
Pfs48/45 hat is different in NF54 and 7G8 (vide supra) was sequenced (Fig. 1A). In CAMP 
the sequence of this region is identical to that of 7G8, while in GH1, LF4 and LE5, of which 
the latter two have the same epitope structure as NF54 (Graves et a., 1985; Carter et a., 
1990), the sequence of this region is identical to that of NF54. The Pfs48/45 genes of the
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A Epitope
NF54 751 TAT CAT AAA AAC TTA ACT ATC 771 IIa-/IIc+
251 Tyr His Lys Asn Leu Thr Ile 257
7G8, CAMP .........G.. . . G ................. IIa+/IIc-
Glu Lys
Dd2, HB3 ....................G ................ IIa+/IIc-
Lys
HB3 ....................G ................
Lys
GH1, LF4, LE5 ........................................ IIa-/IIc +
B
NF54 9 04 TCA AAT GTT AGT TCT AAA CAT ACT TTT ACA GAT AGT TTA GAT
3 02 Ser Asn Val Ser Ser Lys His Thr Phe Thr Asp Ser Leu Asp
Dd2 ............A ....................................................................
Asp
LF4, LE5 ......................................................................A ..........
Ile
HB3 .................................................................................
NF54 946 ATT TCT TTA GTT GAT GAT AGT GCA CAT ATT TCA TGT AAC GTA
316 Ile Ser Leu Val Asp Asp Ser Ala His Ile Ser Cys Asn Val
Dd2, LF4, LE5 .................................................................................
HB3 .....................................A ..........................................
Asn
Fig. 1: Nucleotide and amino acid sequence differences between the pfs48/45 genes of 8 different strains of 
P. falciparum. (A) Comparison of the nucleotide and amino acid sequence of the putative epitope region Ilc of 
NF54 with those of the other 7 strains examined. Only nucleotides and deduced amino acids that are 
different, are indicated. Whether (part of) the amino acid sequence of this region is recognized by monoclonal 
antibodies that are specific for epitope region lla or Ilc, is also indicated (Graves et a/., 1985; Carter et a/., 
1990; Foo et a/., 1991). (B) Nucleotide and amino acid sequence of the polymorphic region in Pfs48/45 of 
NF54 as detected by SSCP analysis and comparison with the nucleotide and amino acid sequences in the 
respective strains examined. Only nucleotides and amino acids that are different are indicated.
strains that possess the same epitope structure as 7G8 (Foo et a/., 1991), i.e., Dd2 and 
HB3, when compared to Pfs48/45 of NF54 contain at position 762 a G instead of a C, and 
consequently at amino acid position 254 a lysine instead of an asparagine residue.
Taken together, the results of the immunological (Graves et a/., 1985; Carter et a/., 
1990; Foo et a/., 1991) and structural studies (Fig. 1A) suggest that the amino acid residue 
at position 254 in Pfs48/45 dictates whether antigen Pfs48/45 will bind to a monoclonal 
antibody that is specific for epitope lla or epitope Ilc.
Whether these differences in affinity are caused by differences in the conformations of
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the respective epitopes, or due to a differential posttranslational modification, awaits further 
investigation.
To investigate whether the Pfs48/45 genes of the respective strains differ at other 
nucleotide positions, polymorphic regions were identified using the single-strand confor­
mation polymorphism (SSCP) technique of PCR-products (Hayashi, 1991; Hayashi and 
Yandell, 1993). Because gene Pfs48/45 (1344 bp) is too long for a reliable SSCP-analysis, 
several restricition enzymes were used to cleave the PCR-amplified gene into subfragments 
that are smaller than 400 bp (Hayashi, 1991)). Only one singly polymorphic region was 
observed, which surprisingly (see below) was found to be situated within the 181-bp-long 
Fokl fragment (nucleotide positions 903-1084) of a FokI-Sau3a digest (Fig. 2), and after 
comparison of all SSCP-data (see legend to Fig. 2), also within a 83-bp-long Fokl-Rsal 
fragment (nucleotide positions 903-986). For unknown reasons (see also Hayashi and 
Yandell, 1993, in which similar observations are described) polymorphic fragments that 
contained the nucleotide changes identified in Fig. 1A were not detected by this technique. 
Thus, if one accepts the assumption that the latter region is the only polymorphic region that 
escaped detection in the SSCP analyses, it can be concluded that, with the exception of the 
nucleotide differences already given in Fig.1A, the nucleotide sequence of Pfs48/45 in GH1, 
7G8 and CAMP is identical to that of NF54. Upon sequence analysis of the 83-bp Fokl-Rsal 
fragment of Dd2, HB3, LF4 and LE5, only single nucleotide differences were noted from 
NF54 (Fig. 1B). LF4 and LE5, which are derivatives of the same isolate, both have the same 
T-A transversion at nucleotide position 940, resultingin a conservative substitution of a 
leucine (amino acid position 314) for an isoleucine residue. Isolate Dd2 has a T-A trans­
version at nucleotide position 911, resulting in a non-conservative substitution of a valine 
(position 304) for an aspartic acid residue, and isolate HB3 has a G-A transition at nucleo­
tide position 965, resulting in a non-conservative substitution of a serine (position 322) for 
an aparagine residue. The data presented, together with the results of the immunological 
studies published previously (Graves et al., 1985; Carter et al., 1990; Foo et a/., 1991), 
show clearly that, similarly to the sexual stage-specific surface antigens Pfs25 (Kaslow et 
al., 1989) and Pfs230 (Williamson and Kaslow, 1993), the antigenic diversity of Pfs48/45 as 
it occurs in the field is exceedingly low. This observation further strengthens earlier 
conclusions that Pfs48/45 is an important candidate antigen for the development of a 
transmission-blocking subunit vaccine.
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Fig. 2. SSCP-analysis of DNA fragments ob tained after incuba­
tion of PCR-amplified pfs48/45 DNA with the restriction endonu­
cleases Fokl and Sau3A. Lanes: single- stranded DNA 
fragments of (1) NF54, (2) GH1, (3) CAMP, (4) 7G8, (5) Dd2, (6)
HB3, (7) LF4, (8) LE5. Products of a negative control 373  Q
experiment, amplification in the absence of exogenous DNA,
were analyzed in lane 9. Sizes of the fragments in nucleotides
(nt) are indicated. Note that the 181 nt long (Fokl) fragment is
the only polymorphic fragment detected. The pfs48/45 coding T
region was PCR-amplified (Kocken et al., 1993) and 323  |_
subsequently fragmented with restriction enzymes. After 
dissolution of the fragments in 3pl H2O and 15 pl of 95% 
formamide / 0.05% bromophenol blue / 0.05% xylene cyanol, 
they were heat-denatured (5 min at 100°C) and after chilling in 
ice-water loaded (4pl) onto a 6% nondenaturing poly- 274  T  
acrylamide gel containing 45 mM Tris-borate, pH 8.3 / 4 mM L  
EDTA / 5% glycerol (Hayashi, 1991). After electrophoresis 
(Pharmacia / LKB Macrophor; 45 W at constant power, 6 - 7 h at 
18°C), the gel was dried and subjected to autoradiography. To 
assure that none of the polymorphic regions would escape 
detection, a total of six different digests (Fokl / Sau3A, Alul /
Mboll, Sspl, Rsal, Accl / Dra I/ Sau3A and Alul / Accl / Sspl) 
were analysed, some both at 22°C and 18°C. (data not shown).
For some fragments different conformers of the same sequence r -  
were found at 18°C (Hayashi, 1991), resulting in more than two 209  
bands per restriction fragment (compare for example the bands 
for the fragments that are, respectively, 209 nt and 274 nt long). L  
The finding of faint bands proximal to the 209 nt fragments in 
GH1 and 7G8 (lanes 2 and 4, respectively) was not 
reproducible. 'Ghost' bands were also observed in genomic 
DNA digests of other strains and no sequences different from 181 
NF54 was found in this fragment of 7G8. The same is true for •— 
the faint bands around the 181 nt long fragment of NF54 and 
CAMP (lanes 1 and 3, respectively). The 'ghost' bands are 
probably the result of the occurrence of two or more thermo­
dynamically stable conformations under the respective experimental conditions
1 2 3 4 5 6 7 8 9
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Previously, we reported the isolation and characterisation of the gene, pfs48/45, of the 
human malaria parasite Plasmodium falciparum (Kocken et al. 1993). The protein-doublet 
Pfs48/45 encoded by this intronless gene is a target for transmission-blocking (TB) immunity 
and thus a prime candidate for the development of a TB malaria vaccine (Vermeulen et al.
1985). Because the chimpanzee malaria parasite, P. reichenowi, is from all known 
Plasmodium species most closely related to P. falciparum (Coatney et al. 1971; Escalante 
et al. 1994; 1995), we studied whether a gene homologous to pfs48/45 was present in its 
genome and to what extent this gene and its encoded antigen varied from those of P. 
falciparum.
PCR amplifications with pfs48/45-specific primers demonstrated that a homologue of 
pfs48/45 was present in the genome of P. reichenowi. To establish the nucleotide sequence 
of prs48/45, its coding region was PCR amplified from genomic DNA with the 5' and 3' 
pfs48/45-specific primers described by Kocken et al. (1993) and overlapping with the start 
and stopcodons of pfs48/45, respectively (Fig. 1). Although we can not explicitely exclude 
that by following this strategy coding sequences 5', and possibly also 3', from the amplified 
product are missed, the enormous overall identity between pfs48/45 and prs48/45 (vide in­
fra) suggests that this is highly unlikely. To eliminate sequencing errors caused by Taq 
polymerase misincorporation, the nucleotide sequence of the unique PCR product (1347 
bp) was established without intermediate subcloning by the method described by Casanova 
et al. (1990).
As can be concluded from the sequences presented in Fig. 1, between genes pfs48/45 
(isolate NF54) and prs48/45 only 28 basepairs were found to be different. Of these, 13 are 
silent and 5 are conservative substitutions. The substitutions found in Prs48/45 at amino 
acid positions 254 and 322 have also been found in Pfs48/45 of strain HB3 (Kocken et al.
1995). The asparagine-lysine substitution at position 254 has also been observed in several 
other in vitro cultivated P. falciparum strains and/or isolates collected from various 
geographic areas (Kocken et a. 1995). The overall identity of the genes pfs48/45 (isolate 
NF54) and prs48/45, and their encoded proteins Pfs48/45 and Prs48/45, is 97.9% and 
96.9%, respectively. This identity is of the same order of magnitude as has been found for 
the P. reichenowi homologues of genes pfs25, pfs16 and pf-CSP (Moelans et al. 1992; Lal 
et al. 1990; 1991).
A remarkable difference between the two sequences is the absence in Prs48/45 of a 
cysteine residue at position 32. Because the conformation of at least four TB B-cell epitopes 
of Pfs48/45 (i.e. epitopes I, lla/llb, llc, and Ill) is constrained by disulphide bridges (Carter et
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1 ATG ATG TTA TAT ATT TCT GCG AAA
T
AAG GCT
A
CAA GTT GCT TTC ATC TTA TAT ATA GTA TTG GTA1 Met Met Leu Tyr Ile Ser Ala Lys Lys Ala Gln Val Ala Phe Ile Leu Tyr Ile Val Leu Val
64 TTA AGA ATA ATA AGT GGA AAC AAT GAT TTT
GTAT GAAT CCT AGC
T
GCT TTG AAT AGT GAA ATA TCT22 Leu Arg Ile Ile Ser Gly Asn Asn Asp Phe Tyr Asn Pro Ser Ala Leu Asn Ser Glu Ile Ser
c Cys Lys Ser
127 GGA TTT ATA GGA TAT AAG TGT AAT TTT TCA AAT GAA GGT GTT CAT AAT TTA AAG CCA GAT ATG43 Gly Phe Ile Gly Tyr Lys Cys Asn Phe Ser Asn Glu Gly Val His Asn Leu Lys Pro Asp Met
190 CGT GAA CGT AGG TCT ATT TTT TGC
C
AAC ATC CAT TCG TAT TTT ATA TAT GAT AAG ATA AGA TTA64 Arg Glu Arg Arg Ser Ile Phe Cys AsnThr Ile His Ser Tyr Phe Ile Tyr Asp Lys Ile Arg Leu
T G A
253 ATA ATA CCT AAA AAA AGT TCG TCA CCT GAA TTT AAA ATA TTA CCC GAA AAA TGT TTT CAA AAA85 Ile Ile Pro Lys Lys Ser Ser Ser Pro Glu Phe Lys Ile Leu Pro Glu Lys Cys Phe Gln Lys
316 GTA TAT ACT GAT TAT GAG AAT AGA GTT GAA ACT GAT ATA TCG GAA TTA
T
GGG TTA ATT GAA TAT106 Val Tyr Thr Asp Tyr Glu Asn Arg Val Glu Thr Asp Ile Ser Glu Leu Gly Leu Ile Glu Tyr
379 GAA ATA GAA GAA AAT GAT ACA AAC CCT AAT TAT AAT GAA AGG ACA ATA ACT ATA TCT CCA TTT127 Glu Ile Glu Glu Asn Asp Thr Asn Pro Asn Tyr Asn Glu Arg Thr Ile Thr Ile Ser Pro Phe
442 AGT
C
ACA AAA GAC ATT GAA TTT TTT TGT TTT TGT GAT AAT ACT GAA
G
AAA
T
GTG ATA TCA AGT ATA
148 Ser ThrPro Lys Asp Ile Glu Phe Phe Cys Phe Cys Asp Asn Thr Glu
Lys Val Ile Ser Ser Ile
505 GAA GGG AGA AGT GCT ATG GTA CAT GTA CGT GTA TTA AAA TAT CCA CAT AAT ATT TTA TTT ACT169 Glu Gly Arg Ser Ala Met Val His Val Arg Val Leu Lys Tyr Pro His Asn Ile Leu Phe Thr
568 AAT TTA ACA AAT GAT CTT TTT ACA TAT TTG
G
CCA AAA ACA TAT AAT GAA TCT AAT TTT GTA AGT190 Asn Leu Thr Asn Asp Leu Phe Thr Tyr Leu Pro Lys Thr Tyr Asn Glu Ser Asn Phe Val Ser
631 AAT GTA TTA GAA GTA GAA
G
TTA AAT GAT GGA GAA TTA TTT GTT TTA GCT TGT GAA CTA ATT AAT211 Asn Val Leu Glu Val Glu Leu Asn Asp Gly Glu Leu Phe Val Leu Ala Cys Glu Leu Ile Asn
GG A A
694 AAA AAA TGT TTT CAA GAA ACA AAT GAT AAA GCC TTA TAT AAA AGT AAT AAA ATA ATT TAT CAT
232 Lys Lys Cys Phe Gln Glu Thr Asn AsP Lys Ala Leu Tyr Lys Ser Asn Lys Ile Ile Tyr His
c Gly Lys Glu
757 AAA AAG TTA ACT ATC TTT AAA GCT CCA TTT TAT GTT ACA TCA AAA GAT GTT AAT ACA GAA TGT
253 Lys LysAsn Leu Thr Ile Phe Lys Ala Pro Phe Tyr Val Thr Ser Lys Asp Val Asn Thr Glu Cys
820 ACA TGC AAA TTT AAA
A
ACT AAT AAT TAT AAA ATA GTT TTA AAA CCA AAA TAT GAA AAA AAA
C
GTT
274 Thr Cys Lys Phe Lys ThrAsn Asn Asn Tyr Lys Ile Val Leu Lys Pro Lys Tyr Glu Lys Lys Val
883 ATA CAC GGA TGT AAC TTC TCT TCA AAT
T
GCT AGT TCT AAA CAT
T
ACA TTT ACA GAT AGT TTA GAT
295 Ile His Gly Cys Asn Phe Ser Ser Asn AlaVal Ser Ser Lys His Thr Phe Thr Asp Ser Leu Asp
946 ATT TCT TTA GTT GAT GAT
G
AAT GCA CAT ATT TCA TGT AAC GTA CAT TTG TCT GAA CCA AAA TAT
316 Ile Ser Leu Val Asp Asp AsnSer Ala His Ile Ser Cys Asn Val His Leu Ser Glu Pro Lys Tyr
1009 AAT CAT TTG GTA GGT TTA AAT TGT CCT GGT GAT ATT
A
GTA CCA GAT TGC TTT TTT CAA GTA TAT
337 Asn His Leu Val Gly Leu Asn Cys Pro Gly Asp Ile ValIle Pro Asp Cys Phe Phe Gln Val Tyr
1072 CAA CCT GAA TCA GAA GAA CTT GAA CCA TCC AAC ATT GTT TAT TTA GAT TCA CAA ATA AAT ATA358 Gln Pro Glu Ser Glu Glu Leu Glu Pro Ser Asn Ile Val Tyr Leu Asp Ser Gln Ile Asn Ile
1135 GGA GAT ATT GAA TAT TAT GAA GAT
C
GTT GAA GGA GAT GAT AAA ATT AAA TTA TTT GGT ATA GTT
379 Gly Asp Ile Glu Tyr Tyr Glu Asp ValAla Glu Gly Asp Asp Lys Ile Lys Leu Phe Gly Ile Val
1198 GGA AGT ATA CCA AAA ACG ACA TCT TTT ACT TGT ATA TGT AAG AAG GAT AAA AAA AGT GCT TAT400 Gly Ser Ile Pro Lys Thr Thr Ser Phe Thr Cys Ile Cys Lys Lys Asp Lys Lys Ser Ala Tyr
1261 ATG ACA GTT ACT ATA GAT TCA GCA TAT TAT GGA TTT TTG GCT AAA ACA TTT ATA TTC CTA ATT421 Met Thr Val Thr Ile Asp Ser Ala Tyr Tyr Gly Phe Leu Ala Lys Thr Phe Ile Phe Leu Ile
1324 GTA GCA ATA TTA TTA TAT ATT TAG442 Val Ala Ile Leu Leu Tyr Ile stop
F ig . 1. Nucleotide- and deduced amino acid sequence of gene prs48/45 of D. reichenow . The observed
differences with gene pfs48/45 of P falciparum (isolate NF54) are indicated in bold face above and below the
sequence. Differences which only have been found in gene pfs48/45 of isolate NF54 but no in that of other
isolates/strains of P. falciparum are indicated with an asterisk. The sequences of the pfs48/45-specific PCR
primers are overlined.
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al. 1990; Targett et al. 1990), the cysteine residue at position 32 could putatively be 
involved in the generation of one of these epitopes. However, from a cross-reactivity study 
with the P. falciparum TB and reduction sensitive epitope l-specific monoclonal antibody 
32F5 (Vermeulen et al. 1985) we know already thatat least this (sexual stage specific) 
epitope is not affected in Prs48/45 (Fig. 2). In this context it is also notable that according to 
the Pfs48/45 folding model, as postulated by Carter and colleagues (1995), and which was 
based on amino acid sequence comparisons of Pfs48/45, Pfs230 and Pf12, this cysteine is 
supposedly not part of a disulphide-bridge. Whether indeed this supposition is correct 
awaits further investigation.
( The authors greatly acknowledge Dr. Alan Thomas (BPRC, Rijswijk) for his gift of genomic DNA of the malaria 
parasite P. reichenowi. )
Fig. 2. Immunofluorescence assay on a 
methanol fixed P. reichenowi blood smear. 
Blood was derived from parasite infected 
chimpanzees. The Prs48/45 antigen was 
visualised with the Pfs48/45-specific 
monoclonal antibody 32F5 (Vermeulen et 
al. 1985) and a fluorescein isothiocyanate 
conjugated rabbit anti-mouse 
immunoglobulin. The arrow points to a very 
strong green fluorescing gametocyte. 
Asexual parasites did not fluoresce while 
lymphocytes gave an aspecific (weak 
yellow) reaction (large cell). Magnification 
600x.
A
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S u m m a r y
A precondition for the development of a transmission-blocking vaccine based on the 
sexual stage-specific surface antigen Pfs48/45 of Plasmodium falciparum is its heterologous 
synthesis in a native state. Here we describe the production of recombinant Pfs48/45 in 
Escherichia coli. Two recombinant proteins, of which one is a glutathione-S-transferase 
fusion protein, were produced. Enzyme-linked immunosorbent assays showed that at least 
a subfraction of the recombinant proteins had a conformation capable of binding 
transmission-blocking monoclonal antibodies. However, despite the fact that both proteins 
were very immunogenic, they did not induce transmission-blocking immunity in mice or 
rabbits. Immunological studies with congenic mouse strains demonstrated that immune 
responses could be boosted with gametocyte extracts and were not restricted to a particular 
class II major histocompatibility complex haplotype.
Keywords: Malaria, Plasmodium falciparum, Pfs48/45, transmission-blocking immunity, 
Escherichia coli
In t r o d u c t io n
Malaria still has an enormous impact on the welfare and health of hundreds of millions 
of people living in the (sub)tropics. Eradication of this disease has been hampered by the 
fact that the mosquito vector and the malaria parasite have become resistant to insecticides 
and drugs, respectively (Butler et al., 1997). This stresses the need for a safe and effective 
malaria vaccine. Besides components which prevent invasion and/or multiplication of the 
parasite in hepatocytes and/or erythrocytes, such a vaccine should preferably also contain a 
component directed against sexual stages of the parasite. These stages are important for 
sexual reproduction and development in the mosquito vector, and hence for parasite 
transmission. The transmission-blocking (TB) vaccine would not only prevent transmission 
and spread of disease, but would also limit the spread of drug resistant parasites, or of 
parasites that have become resistant to vaccine induced immunity. Together with the 
Plasmodium (P.) falciparum gametocyte/gamete antigens Pfs230 (Williamson, Criscio and 
Kaslow, 1993), Pfs25 and Pfs28 (Kaslow et al., 1988; Duffy and Kaslow, 1997), Pfs48/45 is 
a prime candidate for the development of a vaccine capable of inducing long lasting TB 
immunity. First of all, Pfs48/45-specific monoclonal antibodies (mAbs) block transmission of
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the parasite to mosquitoes very effectively (Rener et al., 1983; Vermeulen et al., 1985; 
Carter et al., 1990; Targett et al., 1990). Secondly, Pfs48/45-specific antibodies are present 
in a high percentage of sera of people living in endemic areas (Roeffen et al., 1995a; Riley 
et al., 1990; Ong et al., 1990), which suggests that natural infections are likely to boost a 
vaccine induced immune response. Thirdly, immunological studies performed with sera 
derived from people living in Cameroon have revealed a strong correlation between the 
occurrence of Pfs48/45-specific antibodies and TB immunity (Roeffen et al., 1996). Finally, 
antigenic diversity of Pfs48/45 is very low (Foo et al., 1991; Kocken et al., 1995).
The intronless gene encoding the Pfs48/45 protein has been cloned and characterised 
(Kocken et al., 1993). It codes for a protein that is 448 amino acids long, which contains a 
secretory signal sequence (26 amino acids) at its amino terminal end and a putative signal 
sequence for the addition of a glycosyl phosphatidyl inositol (GPI) anchor (22 amino acids) 
at its carboxy terminal end. Immunological analyses have revealed that Pfs48/45 contains at 
least five unique B-cell epitopes designated I, lla/llc, llb, Ill and V, respectively. The majority 
of these epitopes are constrained by disulphide bonds (Carter et al., 1990; Targett et al., 
1990).
In this paper we describe the production of recombinant Pfs48/45 (rPfs48/45) in 
Escherichia (E.) coli. The recombinant proteins were highly immunogenic in rabbits and in 
mice. The immune responses in mice were independent of the major histocompatibility 
complex (MHC) haplotype and could be boosted with gametocyte extracts. However, they 
did not induce TB immunity despite the presence of conformation dependent epitopes in a 
minor fraction of the recombinant proteins as assessed by enzyme-linked immunosorbent 
assays (ELISAs).
M a t e r ia l s  a n d  M e th o d s
Parasites. Mature gametocytes of P. falciparum (isolate NF54) were produced in an automated large-scale 
culture system as described previously (Ponnudurai et al., 1983). Gametocytes, macrogametes and zygotes 
were purified as described by Vermeulen et al. (1985).
Bacterial strains. The following bacterial strains were used for cloning and heterologous expression: 
JM101(rec A-, supE, th iA  (lac-proAB), [F’ , traD36, proAB , /ad , /acZAM15]); BL21(DE3) (F, ompT, rm, hsdS, 
gal, (lambda lacI, /acUV5-, T7 gene7, An/n5, Sam7+)) (Studier and Moffat, 1986) and DFI5a (supE44, A/acU169, 
(080/acZAM15), hsdR17, recA1, endA1, gyrA96, thi-1, re/A1).
Plasmid constructions. The procedures for the construction of recombinant DNA were essentially as 
described by Sambrook, Fritsch and Maniatis (1989). All enzymes were from Gibco BRL unless stated otherwise.
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Polymerase chain reactions (PCR) were performed with Thermus aquaticus (Taq) DNA polymerase (Eurogentec) 
under standard conditions. Double-stranded DNA sequence analyses were performed following Sequenase 
protocols (United States Biochemicals). Gene pfs48/45 was PCR amplified from genomic DNA (NF54) with the 
5' primer 5'-TAAGGAGGTTGATCCATGATGTTATATATTTCTGCG-3', containing a ribosome binding site and 
overlapping with the pfs48/45 start codon, and the 3' primer 5'-GCTAGCATGAGCTAAATATATAATAATATTGC- 
3', which overlaps with the pfs48/45 stop codon. The product was cloned into the Smal site of the expression 
vector pMA200U, placing the gene under control of the tandem and heat-inducible PRPL promoters. The insert 
was sequenced and designated pMA200U-pfs48/45. Plasmid pMA200U-pfs48/45 was digested with Xmnl and 
^ccl, and the gene fragment encoding amino acid residues 56-401 was blunted with Klenow DNA polymerase. 
Subsequently, the gene fragment was ligated into the Sma1 site of pGEX-3X (Amrad) (Smith and Johnson, 1988) 
to construct pGEX-pfs48/45(56-401) which produces a Schistosoma japonicum glutathione-S-transferase (GST) 
fusion protein under control of the tac promoter. The blunted pfs48/45 gene fragment was also cloned into 
plasmid pT7-4 to construct pT7-pfs48/45 which produces recombinant protein under control of the phage T7 (p 
10 promoter (Tabor and Richardson, 1985). Plasmid pT7-4-gene V, containing gene V of phage Ike, was 
digested with Hpal and EcoRI, and the large (plasmid) fragment was isolated and blunted. The pfs48/45 gene 
fragment was ligated to this plasmid fragment, thereby fusing the gene fragment to the start codon and ribosome 
binding site of gene V.
Production and purification o f recombinant proteins. DH5a and BL21(DE3) colonies containing pGEX 
or pT7-4 derived plasmids were grown to an optical density (OD) at 600 nm (OD600) of 0.3, gene expression was 
induced with 0.1 mM isopropylthiogalactoside (IPTG), and cells were harvested after 3 hours (h) of growth at 
37°C. JM101 colonies containing pMA200U derivatives were grown at 30°C to an OD600 of 0.5, expression was 
induced by a rapid switch to 42°C, and cells were harvested at the times indicated.
For large scale protein production of rGST-Pfs48/45(56-401) and rPfs48/45(56-401), gene expression was 
induced in one litre cultures as described above. Cells were harvested by low speed centrifugation, and the 
rPfs48/45 containing inclusion bodies were isolated as described by Schoner et al. (Schoner, Ellis and Schoner, 
1985). In short, the cell pellet was resuspended in 10 ml 0.1 M Tris-HCl pH 7.3 containing 1 mg/ml lysozyme 
(Sigma) and incubated at 25°C for 15 minutes (min). After sonication twice for 15 seconds and centrifugation (5 
min, 1000 x g, 4°C), the inclusion bodies were isolated from the supernatant by centrifugation (15 min, 5000 x g, 
4°C), washed with 2 ml H2O, and pelleted at 13,000 x g. To obtain a partial purification of the recombinant 
proteins the inclusion bodies were washed with 2 M urea, 0.1 M Tris-HCl, pH 8.5, and pelleted again.
The inclusion bodies were either used directly for immunisation purposes or in ELISAs (/), or the Pfs48/45- 
specific proteins were further purified by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) («).
i) For immunisation purposes the partially purified inclusion bodies were dissolved in 8 M urea, 0.1 M Tris- 
HCl, pH 8.5, and extensively dialysed against 1 M urea, 0.1 M Tris-HCl, pH 8.5. For use in ELISAs the 8 M urea 
protein solution was diluted with phosphate buffered saline (PBS) to a concentration of 4 |j g/ml protein containing 
0.02 M urea.
ii) Recombinant protein was purified from the inclusion bodies via fractionation on SDS-polyacrylamide gels 
(30% acrylamide, 0.3% bisacrylamide), as described by Prussak, Almazan and Tseng (1989). In short, after gel 
electrophoresis the acrylamide gel was incubated for 10 min in 0.25 M potassium chloride (KCl) (0°C) and bands
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containing the recombinant proteins were excised and eluted from the gel slice in 0.01% SDS, 20 mM Tris-HCl 
pH 7.9, 1 mM calcium chloride. Co-eluted unbound SDS was precipitated by the addition of KCl to a final 
concentration of 50 mM, incubation at 0°C for 10 min and centrifugation at 13,000 x g  for 5 min. Recombinant 
protein was stored at -20°C until use.
Animals and immunisation. To generate polyclonal antisera against the recombinant proteins three series 
of immunisations were performed; i) with gel purified rGST-Pfs48/45(118-218) (Kocken et al., 1993) ii) with gel 
purified rGST-Pfs48/45(56-401), iii) with gel purified rPfs48/45(56-401) and V) with urea dissolved inclusion 
bodies containing rPfs48/45(56-401). Each group consisted of two New Zealand Rabbits. The gel purified 
proteins were injected subcutaneously (s.c.) as a homogenate of 500 jg  of recombinant protein emulsified in 
complete Freund’s (CF) adjuvant (Difco). The immune responses were boosted four times at three-week 
intervals with 100 jg  of gel purified recombinant protein in incomplete Freunds (IF) adjuvant. The immunisation 
with urea dissolved inclusion bodies was performed as follows: inclusion bodies were isolated, washed and 
dialysed as described above. Immunisation occurred s.c. with 100 jg  rPfs48/45(56-401) emulsified in CF 
adjuvant (Difco). Boosting occurred s.c. at weeks 2, 8, 23 and 27 with 100 jg  of rPfs48/45(56-401) emulsified in 
IF adjuvant. Sera were collected two weeks after each boost, and stored at -20°C until use.
To test for MHC-restriction, five groups of two mice each of the congenic mouse strains B10A (H-2a), 
B10BR (H-2*), B10S (H-2), B10D (H -2) and C57Bl10 (H-2 ), were immunised with 50 jg  of gel purified rGST- 
Pfs48/45(56-401) emulsified in CF adjuvant. Boosting occurred twice with 25 jg  and 15 jg  of gel purified rGST- 
Pfs48/45(56-401) at two week intervals, followed by one final boost with 12 jg  of gel purified rPfs48/45(56-401) 
after 8.5 months, all in IF adjuvant. Alternatively, B10A, B10S, B10BR and B10D mice were immunised with 50 
jg  rGST-Pfs48/45(56-401) emulsified in CF adjuvant, boosted with 25 jg  rGST-Pfs48/45(56-401) in IF adjuvant 
on day 14, boosted with 1 x 107 gametocytes on day 28, and finally boosted with 15 jg  of rPfs48/45(56-401) in IF 
adjuvant after 8.5 months. Sera were collected on days 0, 28, 48, and 4, 8 and 9 months after the first 
immunisation, respectively.
Monoclonal antibodies. MAbs 32F3 and 32F1 are specific for the epitopes I and llb of Pfs48/45, 
respectively (Vermeulen et al., 1985). MAb IA3B8 is directed against epitope lla of Pfs48/45 (Rener et al., 1983). 
MAbs 42A6 and 82D6, 82C4 and 83D3, and 84A2 are specific for epitopes llc, Ill, and V of Pfs48/45, respectively 
(Targett et al., 1990). MAb 32F61 is specific for the antigen Pfs25 (Vermeulen et al., 1985). MAb 63F2A2 is 
specific for the antigen Pfs230 (Roeffen et al., 1995b). MAb 32F717 reacts with the central domain of the antigen 
Pfs16 (Moelans, 1995).
SDS-PAGE and Western b lot analysis. An equivalent of 1 ml cell suspension with an OD600 of 0.8 was 
precipitated by centrifugation at 13,000 x g, and dissolved in 100 j l  Laemmli sample buffer (LSB) (62.5 mM Tris- 
HCl, pH 6.8, 1% SDS, 10% glycerol, 0.003% bromophenol blue) containing 5% (3-mercaptoethanol, unless stated 
otherwise. Alternatively, gametocytes were dissolved in LSB in the presence or absence of 5% (3- 
mercaptoethanol. After boiling the preparations for 5 min, and centrifugation at 12,000 x g  to remove insoluble 
debris, 20 j l  of the recombinant protein preparation, or 1 x 106 gametocyte equivalents, were size fractionated by 
SDS-PAGE according to standard procedures (Sambrook et al., 1989). Gels were either stained with Coomassie 
Brilliant Blue, or electroblotted onto nitrocellulose according to standard procedures (Harlow and Lane, 1988; 
Sambrook et al., 1989). Western blot analysis was according to Harlow et al. (1988). Primary antibody was used 
in a 400-fold dilution in PBS for polyclonal antisera, or at a concentration of 1 jg /m l immunoglobulin subtype G
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(IgG) for mAbs. To serve as negative control blots were incubated with rabbit pre-immuneserum or mAb 32F61.
Immunofluorescence assays. Immunofluorescence assays (IFAs) were performed on methanol fixed 
sexual stage parasites on multispot slides. The slides were incubated with a 1:200 dilution in PBS of the test 
serum, or with rabbit pre-immune serum as a negative control, in PBS for 30 min, rinsed thrice with PBS, and 
incubated for 30 min with a 1:100 dilution of fluorescein isothiocyanate (FITC) conjugated goat anti rabbit IgG 
(Sigma). After extensive washes with PBS the slides were examined with a fluorescence microscope (Leitz).
Suspension IFAs on live gametes were performed as described by Roeffen et al. (1995b). In short, mature 
P. falciparum gametocytes were allowed to undergo gametogenesis for 30 min by resuspension at a 10% 
haematocrit in fetal calf serum (FCS) at 27°C. Surface immunofluorescence was done on suspensions of live 
female gametes diluted to 108 gametes and 10 j l  packed normal human erythrocytes per ml PBS. 10 Gametes 
(10 j l) were incubated with 20 j  l serum dilutions for 25 min, washed twice with PBS and incubated for a further 
20 min with 50 j l  of 1:100 dilution of FITC conjugated goat anti rabbit or rabbit anti mouse IgG in PBS containing 
0.05% Evans blue. After washing twice with PBS and resuspending in 50 j l  of PBS, the fluorescence of the 
gametes was observed under UV illumination at a magnification of x 400. All incubations were done on ice and 
mAb 32F3 was used as a positive control for the presence of gametes.
Enzyme-linked immunosorbent assays. ELISAs were performed essentially as described by Moelans et 
al. (1991) (/) and Roeffen et al. (1995b) (ii). Unless stated otherwise all reactions were carried out at room 
temperature. Serum dilutions and peroxidase labelled IgG were incubated for 1 h. Peroxidase activity was 
determined by adding 60 j l  TMB (0.25 mM 3,3', 5,5'-tetramethyl-benzidine (Sigma), 0.7 mM hydrogen peroxide, 
0.1 M sodium acetate pH 5.5) substrate followed by an incubation for 20 min. The reaction was stopped by the 
addition of 60 j l  of 2 M sulphuric acid and the OD was determined at 450 nm (OD450) on a Titretek Multiscan 
MCC/340. Titres were expressed as the reciprocal of the highest serum dilution giving an OD450 higher than 0.2.
i) For the determination of antibody titres in sera, microtitre plates were coated with gel purified recombinant 
rPfs48/45 (0.1 jg /m l) in a 50 mM sodium carbonate buffer (pH 9.6) for 2 h at 37°C. Serum and peroxidase 
labelled anti rabbit or anti mouse IgG were diluted in buffer A (PBS supplemented with 0.2 M sodium chloride, 
0.3% Tween-20) which was also used for washes.
ii) For the detection of different Pfs48/45-specific epitopes in recombinant proteins, gel purified rGST- 
Pfs48/45(56-401) (4 jg /m l) or rPfs48/45(56-401) from urea dissolved inclusion bodies (diluted with PBS from an 
8 M urea, 0.1 M Tris-HCl, pH 8.5, stock solution to 4 jg /m l containing 20 mM urea) were used as antigen. 
Microtitreplates were coated with 50 j l  of rPfs48/45 in PBS for 60 min, washed with PBS and free binding sites 
were blocked by incubation with 150 j l  5% FCS in PBS for 30 min. After a washing step the wells were incu­
bated with 50 j l  of mAbs (10 jg /m l) in PBS for 90 min. Following three washes with PBS, the wells were incu­
bated with 50 j l  of horse radish peroxidase (HRP) labelled anti mouse IgG (Zymed; diluted 1:3,000 in PBS 
containing 0.5% FCS). After a washing step the plates were incubated with TMB, the enzyme reaction was stop­
ped and the OD450 was determined.
Transmission-blocking assay. The effect of antisera on the infectivity of P. falciparum for Anopheles 
gambiae mosquitoes was tested in a mosquito membrane feeder assay as described (Vermeulen et al., 1985; 
Ponnudurai et al., 1987, 1989; Roeffen et al., 1995b). In short, sera were diluted three times and fed to the 
mosquitoes in the presence of activated complement, isolated as described by Roeffen et al. (1995b). Twenty 
mosquitoes per feeder were dissected 7 days after feeding, the number of oocysts on the stomach wall counted
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and William’s mean (adjusted geometric mean (GM)) oocyst number calculated (William, 1937). An experiment 
was considered successful if at least 90% of the mosquitoes of the controls carried oocysts. The adjusted GM 
was used to determine the reduction activity R according to the following equation: R = (Tc -Ti)/Tc x 100%, where 
Ti is the geometric mean for the test feeder and T is the geometric mean of 3 controls. Because of assay 
variation only values over 85% were considered to be a positive transmission-blocking result.
R e s u l ts  a n d  d is c u s s io n
Heterologous synthesis o f rPfs48/45. In a first attempt to produce recombinant 
Pfs48/45 in E. coli, the entire coding sequence of pfs48/45 was cloned into vector 
pMA200U. In this plasmid expression is under control of the temperature sensitive repressor 
cI857ts and the strong tandem promoter (PRP ) of phage A. This enables separate cloning 
(at 30 C) and expression (at 42 C) and allows cloning of genes encoding (putative) toxic 
products. Within 10 min after heat induction of gene expression cells were killed, as 
demonstrated by viable colony counting on selective plates. This suggests that Pfs48/45 is 
very toxic. Since it has been shown that highly hydrophobic eukaryotic signal sequences are 
frequently toxic to prokaryotic cells (Kaslow et al., 1992; Goedell, 1990) it was decided to 
make a construct in which the DNA sequences coding for the eukaryotic N-terminal 
secretory signal sequence and the C-terminal GPI anchor signal sequence were deleted. 
Therefore, a gene fragment, encoding amino acid residues 56 through 401, was cloned into 
the plasmids pGEX-3X and pT7-4. In plasmid pGEX the gene fragment is inserted in frame 
with the carboxy terminal end of the gene encoding glutathione-S-transferase (GST) of 
Schistosoma japonicum. This system was chosen because it has previously been used to 
produce disulphide bridge constrained malarial proteins (Ling, Ogun and Holder, 1994; 
Chappel and Holder, 1993; Burghaus and Holder, 1994). However, it does have the 
disadvantage that a fusion protein is produced. Therefore, pfs48/45(56-401) was cloned 
also in a vector derived from plasmid pT7-4-gene V. Both expression systems yielded high 
level expression of recombinant protein. However, the recombinant proteins were only 
found in the insoluble cell fraction, i.e. in inclusion bodies (data not shown). Cells containing 
plasmid pGEX-pfs48/45 produced not only the recombinant fusion protein rGST- 
Pfs48/45(56-401) of the appropriate size of 65 kDa but also a novel recombinant protein of 
approximately 37 kDa (Fig. 1, lane 2). Cells containing construct pT7-pfs48/45 produced 
recombinant protein with the expected molecular weight of 41 kDa (Fig. 2, lane 2). 
Immunological analyses revealed that the 65 kDa and the 37 kDa product, as well as the 41
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Fig. 1. Coomassie Brilliant Blue stained SDS- 
polyacrylamide gel showing production of GST 
(lane 1) and two forms of rGST-Pfs48/45(56- 
401) (lane 2) after induction of gene expression 
in E. colicells containing plasmids pGEX-3X and 
pGEX-pfe48/45(56-401), respectively. The 
positions of migration of the rPfs48/45-specific 
proteins are indicated by arrows.
rGST-Pfs48/45
(56-401)
GST
kDa
Fig. 2. Coomassie Brilliant Blue stained SDS- 
polyacrylamide gel showing total cellular extracts of 
E. coli cells containing plasmid pT7-4-pfs48/45(56- 
401) of which gene expression was either not 
induced (lane 1) or induced (lane 2). The position of 
migration of the rPfs48/45-specific protein is 
indicated with an arrow.
kDa product were Pfs48/45-specific; on Western blots these bands reacted with antiserum 
directed against rGST-Pfs48/45(118-218), and the antiserum affinity purified on the 
truncated protein rGST-Pfs48/45(56-401) of 37 kDa recognised native Pfs48/45 on Western 
blots loaded with gametocyte extracts (data not shown).
To determine whether the recombinant proteins were folded in a disulphide bridge 
constrained conformation, protein preparations were separated by SDS-PAGE under non­
reducing conditions. The relative electrophoretic mobilities of non-reduced recombinant 
proteins were found to be identical to those of the reduced proteins. This indicated that 
neither rPfs48/45(56-401) nor the fusion protein rGST-Pfs48/45(56-401) were folded such 
that their conformation was disulphide bridge constrained. This is in contrast to what has 
been observed previously for the (soluble) GST fusion protein of the 19-kDa fragment of the 
merozoite surface protein-1 (MSP19) (Burghaus et al., 1994) and the GST fusion protein of 
the first epidermal growth factor domain of MSP1 (Chappel et al., 1993). It should be 
stressed, however, that limited disulphide bond formation cannot be excluded solely on the 
basis of the migration patterns.
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The recombinant protein rPfs48/45 is recognised by Pfs48/45-specific mAbs.
Since a component of a subunit vaccine should preferably possess a conformation that is 
identical to that of the native protein, as present on the surface of the malaria parasite, 
Western blot analyses and ELISAs were used to determine whether TB immunity inducing 
epitopes were present in the recombinant products. On Western blot neither of the two 
recombinant proteins reacted with the mAb 32F3 which recognises the conformation 
constrained TB epitope I of Pfs48/45 (data not shown). This indicates that the majority of the 
recombinant proteins is not folded properly. To examine whether a fraction of the 
recombinant protein had a native conformation, two series of ELISAs were performed with 
partially purified proteins. Firstly, full length recombinant rGST-Pfs48/45(56-401) was 
purified by elution from SDS-polyacrylamide gel. Unbound SDS was removed with 50 mM 
KCl. The recombinant protein was coated and, subsequently, indirectly visualised with mAbs 
specific for different epitopes of Pfs48/45 (Table 1). Only epitope I is present in this 
recombinant protein preparation since only the mAb 32F3, specific for this epitope, showed 
a strong reactivity with the recombinant protein. MAbs specific for epitopes IIb, IIc, III and V 
did not react. A weak reactivity was found for epitope III with mAb IIC5B10 whereas the
Epitope mAb rGST-Pfs48/45(56-401) 
purified by SDS-PAGE*
rPfs48/45(56-401) from urea 
dissolved inclusion bodies*
I 32F3 1.65 1.59
IIa IA3B8 nd 0.75
IIb 32F1 0.01 1.45
IIc 42A6 0.05 1.61
82D6 0.01 0.95
III 82C4 0.01 1.45
IIC5B10 0.37 2.01
81D3 0.01 1.70
V 84A2 0.12 1.71
a-Pfs16 32F717 nd 0.04
a-Pfs25 32F61 0.12 0.10
a-Pfs230 63F2A2 nd 0.18
nd: not determined.
* Optical Density values at 450 nm of the mAb minus the OD of the PBS control (mean OD of 0.12)
TABLE 1; Binding of anti-Pfs48/45-specific mAbs (10 jg /m l) to gel purified and urea dissolved recombinant 
proteins (both 4 jg /m l) in an one-site ELISA.
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other mAbs specific for epitope III did not react. The control mAb 32F61, which is specific for 
the P. falciparum antigen Pfs25, was also non-reactive, showing the specificity of the assay. 
Since the recombinant protein was probably still contaminated with small amounts of SDS 
this assay was next repeated with recombinant protein rPfs48/45(56-401) obtained by 
dissolution of inclusion bodies in 8 M urea, 0.1 M Tris-HCl, pH 8.5. Immediately before use 
in the ELISA, this solution was diluted 400 times to allow protein renaturation. Table 1 
shows that in contrast to the results obtained with the gel purified recombinant protein 
rGST-Pfs48/45(56-401), all mAbs tested now reacted specifically with rPfs48/45. From this 
we conclude that at least a fraction of the recombinant proteins possesses a native-like 
structure. The observation that rGST-Pfs48/45(56-401) isolated from SDS-polyacrylamide 
gel did not react with mAbs specific for epitopes IIb, IIc, III and V, in contrast to 
rPfs48/45(56-401) obtained from urea dissolved inclusion bodies, might be explained in two 
different ways. First, the two proteins are not identical, one being a GST fusion protein and 
the other not. However, proteins generally fold stepwise and co-translationally from the 
amino-terminal end to the carboxy-terminal end (Bergman and Kuehl, 1979), and many 
examples are known in which folding of GST fusion proteins is not influenced by the GST 
moiety (Burghaus et a., 1994; Chappel et a., 1993; Kaelin et al., 1991; Johnson et a., 
1989). A second possibility is that the SDS which is unavoidably present in the protein 
isolated from the SDS-polyacrylamide gel, might have influenced the three-dimensional 
structure of rGST-Pfs48/45(56-401) and/or the reconstitution of epitopes IIb, IIc, III, and V 
under the conditions used in the ELISA.
A very remarkable observation was that mAb IA3B8, specific for epitope IIa, reacted in 
the ELISA specifically with rPfs48/45(56-401). This was fully unexpected because 
rPfs48/45(56-401) is encoded by DNA originating from the P. falciparum isolate NF54 which 
is IIa- (Carter et a., 1990). Since eukaryotic cells in contrast to E. coli cells are capable to 
posttranslationally modify proteins, we presume that some kind of modification of native 
Pfs48/45 in isolate NF54 leads to loss of epitope IIa.
Immunisation o f rabbits w ith rPfs48/45 and analysis o f the antisera. To study the 
immunogenicity of the recombinant proteins, rabbits were immunised both with 
rPfs48/45(56-401) and rGST-Pfs48/45(56-401) isolated from gel slices and with 
rPfs48/45(56-401) derived from inclusion bodies solubilised in urea. As shown in Table 2 
both procedures yielded antisera with high rPfs48/45-specific antibody titres. Both under 
reducing and non-reducing conditions all antisera were highly reactive with native Pfs48/45 
on Western blot, and they also reacted with methanol fixed gametocytes and gametes in an
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IFA (Table 2). Both recombinant proteins are, therefore, indeed highly immunogenic.
Since a fraction of the recombinant proteins appeared to have a conformation that was 
similar to that of native proteins, it was also studied whether antibodies were induced that 
are directed against TB epitopes. Therefore, the sera were tested in suspension IFA on live 
gametes. The rabbit antisera did not react with the conformation dependent Pfs48/45- 
specific epitopes that are exposed on the surface of freshly activated gametes (Table 2). 
Hence, the antibodies are primarily directed to epitopes that only become accessible after 
fixation of gametes. Because of this, an effect of the sera on parasite transmission as 
measured with the membrane feeder assay was not expected, and this supposition indeed 
proved to be correct. The reasons for the fact that the recombinant proteins did not induce 
TB immunity must be sought in either the low concentration of properly folded epitopes 
within the protein preparation and/or the immunodominance of conformation independent, 
or conformation dependent but not TB immunity inducing, epitopes. Furthermore, the 
apparent lack of stabilisation by disulphide bonds of the (partially) properly folded protein
Rabbit protein ELISA titres 
against gel puri­
fied rPfs48/451
Western blot 
reactivity with 
Pfs48/452
IFA2 SIFA3 and 
TB4
K56/K57 gel purified 
rGST-Pfs48/45 
(56-401)
1:128,000 + + -
K96/K97 gel purified 
rPfs48/45 (56­
401)
1:256,000 + + -
KD1/KD2 rPfs48/45 (56­
401) from urea 
dissolved inclusi­
on bodies
nd + + -
nd: not determined
1 titres are expressed as the reciprocal of the highest serum dilution giving an OD450 higher tharf 0.2; +: positive and 
Pfs48/45-specific reaction. Rabbit pre-immune seradid not react. 3 on surface of live gametes. -: no fluorescence was 
detected at any dilution of the serum; 4 transmission-blocking immunity. -: no TB effect; transmission reduction activity of 
<30% for all sera.
TABLE 2. Reactivity of antisera obtained by immunising rabbits with rPfs48/45
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structure might well explain the fact that no TB antibodies were induced since Pfs48/45- 
specific TB mAbs lose their capacity to bind upon reduction (Vermeulen et al., 1985; Carter 
et al., 1990; Targett et al., 1990). Stabilisation of recombinant protein by disulphide bonds 
might be achieved by synthesis of the protein in oxidizing environments, i.e. in the 
endoplasmic reticulum of eukaryotes, or by in vitro renaturation of denatured protein under 
oxidizing conditions.
Immunological recognition o f Pfs48/45 in mice is not restricted. Preferentially, a 
vaccine should induce immunity in all individuals. To do so it must contain T-cell epitopes 
that are recognised irrespective of the MHC haplotype of the host. To obtain a first 
indication whether this might hold true for Pfs48/45, the immune responses against 
rPfs48/45 in five different H-2 congenic mouse strains were studied. The mice were 
immunised with gel purified fusion protein rGST-Pfs48/45(56-401) and boosted twice with 
the same antigen. A third boost was given with gel purified rPfs48/45(56-401). Sera were 
collected at several time points and reactivity of the antisera with rPfs48/45(56-401) was 
determined by ELISA. The results are shown in Fig. 3a. All mice responded to the fusion 
protein, although the titres of the sera from C57Bl10 mice were very low (titres <100). After 
the second boost with the fusion protein, titres diminished only slowly, except in B10S mice, 
where after 8 months the titres had dropped to baseline levels. A third boost with (non 
fusion) rPfs48/45(56-401) resulted in a rapid and strong increase in titres indicating that, 
provided that the immunogenic characteristics of rPfs48/45(56-401) were identical to that of 
rGST-Pfs48/45(56-401), a memory against rPfs48/45 sequences was present in all 
congenic mouse strains. In experiments, where after two injections with the fusion protein 
rGST-Pfs48/45(56-401) a second boost with 1 x 107 gametocytes was used, the anti- 
rPfs48/45 response was clearly boosted (Fig. 3b), while primary immunisation with 1 x 107 
gametocytes did not lead to high Pfs48/45-specific antibody titres (unpublished results). 
This implies that Th cell epitopes are present within the Pfs48/45 fragment, and that the 
observed boosting effect is not, for instance, the result of Th cell epitopes provided by co­
processed impurities that might be present in the recombinant protein preparation, or a 
boosted reactivity against the impurities themselves. This observation is of great importance 
since it proves that the immune response elicited by a recombinant Pfs48/45-specific 
vaccine can be boosted by natural infection. None of the mouse antisera reduced 
transmission of parasites, although they did react with native Pfs48/45 on Western blot 
(data not shown). Hence, it remains to be determined whether natural infection also boosts 
reactivity against TB epitopes.
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Fig. 3. Immune responses against recombinant Pfs48/45 in five (A) or four (B) congenic mouse strains. 
Immunisations were performed with (1) rGST-Pfs48/45(56-401), (2) rPfs48/45(56-401) or (3) gametocytes at 
week 0, 2, 4, and after 8.5 months, as indicated with arrows. Sera were collected at days 0 (S0), 28 (S1), 48 
(S2), and at 4 (S3), 8 (S4) and 9 (S5) months after the first immunisation.
The data showing that immune responses are not restricted by MHC haplotype are in 
agreement with the observation that in sera from people living in malaria endemic areas no 
correlation between MHC class-II haplotype and the presence of antibodies reacting with 
Pfs48/45 could be detected (Graves et a/., 1989). Our observations are also in agreement 
with the results of a study reported by Rawlings and Kaslow (1992). They showed that 
following immunisation of congenic mice with gametes emulsified in monophosphoryl lipid A 
and trehalose dimycolate adjuvant all mice produced Pfs48/45 and Pfs40-specific 
antibodies. However, when Freund's adjuvant was used not all mice responded (Rawlings 
and Kaslow, 1992) which was in line with results obtained by Good et al. (1988). The 
mechanisms by which adjuvants can differentially affect antibody specificity remain to be 
elucidated.
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The data presented in this chapter will be published under the title:
"Effect of adjuvants on immunogenicity and antigenicity of recombinant proteins of 
transmission-blocking vaccine candidates Pfs48/45 and Pfs25 of the human malaria 
parasite Plasmodium falciparum in rodents". In preparation
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A b s t r a c t
In chapter 4a the production of two proteins encoded by the gene of the transmission- 
blocking vaccine candidate antigen Pfs48/45 in Escherichia coli has been described. It was 
shown that the conformation of the recombinant proteins at least partly was identical to that 
of the native antigen, though the conformation seemed not stabilised by disulphide-bonds. 
After immunisation of mice and rabbits with the recombinant proteins rGST-Pfs48/45(56- 
401) and rPfs48/45(56-401) emulsified in Freund's adjuvants no transmission-blocking 
immunity could be detected. Here we present an extension of that study in which the effect 
of a number of adjuvants on the quality and efficiency of immunisation with rPfs48/45(56- 
401) obtained by dissolution of inclusion-bodies in urea is investigated. Besides the effects 
of Freund's complete and incomplete adjuvant also those of the adjuvants Quil A, Hunter's 
TiterMax™#R1, and the combination of the block copolymer P1005 with detoxified RaLPS 
and squalene were studied. Using IFA on gametocytes only a positive reaction could be 
demonstrated with sera derived from mice immunised with rPfs48/45 emulsified in Quil A or 
P1005-RaLPS-squalene, and with sera from rabbits immunised with rPfs48/45 emulsified in 
Quil A. None of the immunisation schemes lead to a shift in immunoglobulin subtype and/or 
the induction of transmission-blocking immunity.
Keywords: Malaria, Plasmodium falciparum, Pfs48/45, transmission-blocking immunity, 
adjuvants, Freund's, TiterMax™, Quil A, P1005, squalene, RaLPS.
M a t e r ia l s  a n d  M e th o d s
Parasites. Mature gametocytes of P. falciparum (isolate NF54) were produced in an automated large-scale 
culture system as described previously (Ponnudurai et a/., 1983). Gametocytes were purified by Nycodenz 
(Nijegaard, Oslo, Norway) gradient centrifugation at 37°C as described by Vermeulen et al. (1986). 
Macrogametes and zygotes were purified as described by Vermeulen et al. (1985).
Production o f recombinant Pfs48/45. Recombinant Pfs48/45 was produced as described previously 
(Milek et al., 1998). In short, a gene fragment encoding amino acid residues 56 through 401 was cloned into 
plasmid pT7-4, and expressed in E. coli BL21(DE3) (F-, ompT, r m ,  hsdS, gal, K(lacI, /acUV5- T7 gene 1, Anin5, 
Sam7+)) (Studier et al., 1986). The rPfs48/45 containing inclusion-bodies were isolated as described by Schoner 
et al. (Schoner et al., 1985). The cellpellet was resuspended in 10 ml 0.1 M Tris-HCl (pH 7.3) containing 1 mg ml-
1 lysozyme (Sigma) and incubated for 15 minutes at 25°C. After twice sonication for 15 seconds the cell-debris 
was eliminated by centrifugation for 5 minutes at 1000 x g and 4°C. The inclusion bodies were isolated from the 
supernatant by centrifugation for 15 minutes at 5000 x g and 4°C, washed with 2 ml distilled water, and pelleted
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at 13,000 x g. Next, the inclusion bodies were washed with 2 M urea, 0.1 M Tris-HCl (pH 8.5) and dissolved in 8 
M urea, 0.1 M Tris-HCl, pH 8.5. This solution was extensively dialysed against 1 M urea, 0.1 M Tris-HCl, pH 8.5.
Adjuvants and recombinant protein form ulations for immunisations. The following adjuvants were 
used in immunisations; 1) Freund's complete (Difco), a suspension of Mycobacterium tuberculosis in mineral oil, 
whereby the most active immunostimulator has been identified as muramyl dipeptide, or Freund's incomplete 
(Difco), only containing mineral oil, both emulsified with Arlacel A (mannide monooleate) (Freund, 1951); 2) 
Hunter's TiterMax™#R1 (CytRx Corp.), containing i) the nonionic block polymer CRL89-41 (NBP L141), which is 
a triblock copolymer composed of a hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of 
polyoxyethylene, ii) squalene, a natural unsaturated biodegradable oil that is an intermediate in the biosynthesis 
of cholesterol, and iii) a stabilizer consisting of silica microparticles (Bennet et al., 1987); 3) Quil A, a purified 
saponine containing glycosidic compounds derived from the bark of the tree Quillaja saponaria (Dalsgaard, 
1978); and 4) a combination of i) nonionic block polymer P1005 (NBP L180,5), containing polyoxypropylene of 
larger molecular weight than that used in TiterMax™#R1 (Verheul and Snippe, 1992; Hunter et al., 1991), ii) 
detoxified (deacylated) purified lipopolysaccharides (LPS) from the Escherichia coli Ra mutant strain EH-100 
(RaLPS) (Takayama et al., 1991), and iii) squalene (Sigma). With the exception of P1005-RaLPS-squalene all 
adjuvants were used in water-in-oil (w/o) emulsions. P1005-RaLPS-squalene was used in an oil-in-water (o/w) 
emulsion since P1004-RaLPS-squalene in an o/w emulsion gave in contrast to the w/o emulsion protection 
against P. yoelii parasites (ten Hagen et al., 1993). Freund's complete, Freund's incomplete and TiterMax™#R1 
were used according to the instructions of the manufacturer. Quil A was used in the following formulation; 400 |j l 
rPfs48/45(56-401) (2 mg ml-1 in 1 M urea, 0.1 M Tris-HCl, pH 8.5) was mixed with 800 j l  PBS and 60 jg  Quil A 
and mixed extensively. P1005-RaLPS-squalene was used in the following formulation; 400 jg  of RaLPS was 
extensively mixed with 100 j l  squalene and 100 j l  P1005. Then, 800 j l  of 0.4% Tween-80 was added and 
mixed. Finally, 600 j l  of this mix was combined with 400 j l  of rPfs48/45(56-401) (2 mg ml-1 in 1 M urea, 0.1 M 
T ris-HCl, pH 8.5) and 200 j l  PBS.
Anim als and immunisation. To test the influence of different adjuvants on the quantity and quality of 
immune responses 16 female outbred Balb/c mice and 8 New Zealand rabbits were divided randomly into four 
groups. Then, each group was immunised with one of the four antigen-preparations. Mice and rabbits were, 
respectively, immunised subcutaneously with 50 j l  (35 jg )  and 400 j l  (250 jg )  of rPfs48/45, and boosted with 
an equal amount of antigen at weeks 3, 5, 7, 11, 13, 26, and 30. Sera were collected at weeks 3, 5, 7, 13, 28 and 
32, and stored at -20 C until use.
Immunofluorescence assays (IFAs). IFAs were performed on air dried sexual stage parasites on 
multispot slides. Suspension IFAs on live gametes were performed as described by Roeffen et al. (1995b). In 
short, mature P. falciparum gametocytes were allowed to activate and exflaggelate in FCS for 15 minutes. 
Subsequently, the live macrogametes and zygotes were washed twice with PBS, and incubated at room 
temperature for 20 minutes with the appropriate antiserum. Following low-speed centrifugation the gametes and 
zygotes were washed twice with 100 j l  of PBS prior to incubation for 20 minutes with 10 j l  of goat anti-rabbit or 
rabbit anti-mouse fluorescein isothiocyanate (FITC) conjugated antiserum (Sigma) at a dilution of 1:100 (in 0.05% 
Evans Blue (Merck) in PBS). After three washes with PBS, samples of 10 j l  were applied to slides, covered by 
coverslips and analysed by fluorescence microscopy (Leitz).
One-site, two-site, and isotype-specific enzyme-linked immunosorbent assays (ELISAs). Sera were
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screened for antibodies against recombinant Pfs48/45 in three different ELISA protocols. One-site ELISA was 
used for the determination of serum-titres. Two-site ELISA was used to determine the presence of serum- 
antibodies capable to compete with Pfs48/45-specific mAbs directed against conformation constrained epitopes. 
Isotype-specific ELISA was used to determine the isotypes of the Pfs48/45-specific serum-antibodies.
a) One-site ELISA. Microtitreplates were coated with rPfs48/45(56-401) (1 pg ml-1) in PBS for 60 minutes. 
After three washes with PBS the free binding sites were blocked by incubation with 150 pl 5% FCS in PBS for 30 
minutes. After a PBS washing step the plates were incubated with 50 pl of serial dilution's of the sera in PBS for 
90 minutes. Following three washes with PBS, the wells were incubated with 50 pl of horse-radish peroxidase 
(HRP)-labelled anti-rabbit immunoglobulin subtype G (IgG) (Zymed) or anti-mouse IgG (CLB). After a washing 
step the plates were incubated with 60 pl of 0.25 mM 3, 3', 5, 5'-tetramethyl-benzidine (Sigma), 0.7 mM H2O2, 0.1 
M sodium acetate pH 5.5 substrate solution for 20 minutes. The enzyme reaction was stopped by adding 60 pl of
2 M H2SO4 and the absorbance was determined at 450 nm on a Titertek Multiskan MCC/340 ELISA reader (Flow 
Laboratories). All reactions were carried out at room temperature. Titres were expressed as the reciprocal of the 
highest serum dilution giving an optical density (OD) value >0.2.
b) Two-site competition ELISA. Sera were screened for antibodies directed against different epitopes of 
Pfs48/45 using two-site competition ELISAs as described previously (Roeffen, et al., 1995a and 1995b). Briefly, 
unlabelled mAbs (10 mg ml-1) were coated to plates and Pfs48/45 was captured from an NP40 extract of 
gametocytes. HRP-labelled mAbs 32F3 and 32F1 were used for the competition with antibodies that recognise, 
respectively, epitope I and IIb. The plates were washed, incubated with substrate and the absorbance was read 
at 450 nm as described above. The competition titre was defined as the dilution of the test serum that resulted in 
the same OD value as the mean + 2 standard deviations OD value for 14 non-exposed control sera. Sera with a 
competition titre > 1/20 are considered positive. For the purpose of standardisation, in each ELISA a positive and 
a negative control was included. The OD was read at 450 nm as described.
c) Isotype-specific ELISA. The basic procedure was that of the one-site ELISA using rPfs48/45 (vide 
supra). As conjugate, HRP-labelled rabbit anti-mouse isotype (IgG1, IgG2a, IgG2b and IgG3) was used. All 
incubation steps were carried out at room temperature. The ELISAs were performed in duplicate and the mean 
value of the ODs was used for analysis.
TB assay. The effect of antisera on the infectivity of P. falciparum for Anopheles gambiae mosquitoes was 
tested in the mosquito membrane feeder assay as described (Ponnudurai et al., 1989). Briefly, sera were mixed 
in a 1:9 ratio with in vitro cultured P. falciparum gametocytes (NF54), and the mixtures were fed to A. gambiae 
mosquitoes by membrane feeding. Seven days after engorgement of the blood meal, mosquitoes were dissected 
and the midguts were scored for oocysts.
R e s u l ts  a n d  d is c u s s io n
As described in chapter 4a, recombinant Pfs48/45 can be produced in E. coli in a 
conformation that resembles that of native Pfs48/45. Although the recombinant protein is 
not stabilised by disulphide-bridges it is, nevertheless, recognised in ELISA by mAbs 
specific for discontinuous epitopes. Immunisation with this protein might, therefore,
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putatively lead to the induction of antibodies directed against these discontinuous epitopes. 
This was, however, not observed. Immunisation of rabbits with rPfs48/45(56-401) or rGST- 
Pfs48/45(56-401) emulsified in Freund's complete adjuvants did not result in the induction 
of transmission-blocking (TB) immunity (Milek, et al., 1998). Since this could have been due 
to immunodominance of particular linear epitopes which do not induce TB immunity, or to 
the induction of immunoglobulin subclasses that are not related to TB immunity, it was 
decided to study whether the use of adjuvants other than Freund's complete would result in 
the induction of the desired immunological response. This, because it has frequently been 
observed that the adjuvant might be able to influence the quality and quantity of the immune 
responses (Karagouni et al., 1990; Kenney et al., 1989; Allison et al., 1986). As an 
illustration we note that in vaccination studies with the P. falciparum merozoite surface 
protein-1 (MSP-1) (Chang et a., 1994) and the major merozoite surface protein, gp195 (Hui 
et a., 1991), the efficacy of immunesera to inhibit merozoite invasion in vitro was shown to 
be dependent on the adjuvant used.
To test the effect of different adjuvants on the immunological response against 
rPfs48/45(56-401) rabbits and mice were immunised with this antigen emulsified in four 
adjuvant formulations. Hunter's TiterMax™#R1 was used, because it has shown to induce 
strong B and T cell responses (Hunter et a., 1994; Bennet et a., 1992). The purified 
saponin Quil A was used, because it generally is a very potent adjuvant (Kenney et a., 
1989), and in studies with intact MSP-1 it has shown to give protection against P. yoelii 
(Freeman et a., 1983). Also a combination of immunomodifiers was used (P1005-RaLPS- 
squalene), which (with P1004 instead of P1005) also has shown to stimulate the production 
of protective immunity to P. yoelii (ten Hagen et al., 1993). The use of these adjuvants was 
compared to that of Freund's adjuvants and analysed by ELISA to determine the kinetics of 
the antibody response. After two weeks, the primary antibody response in mice, immunised 
with rPfs48/45 was undetectable or very low in all the sera. After four weeks a secondary 
antibody response was detectable in all sera. Mice that received Quil A and rabbits 
receiving Freund's adjuvants had the highest total IgG levels, which reached a plateau after 
ten weeks, as is depicted in Fig. 1. Animals that received Hunter's TiterMax™#R1 as 
adjuvant had the lowest ELISA IgG titres, but there were no significant differences between 
ELISA results with mice immunised with rPfs48/45 emulsified in either Hunter's 
TiterMax™#R1, Freund's adjuvants or the P1005-LPS-squalene combination.
To characterise qualitative differences between sera obtained by immunisation with the 
four different adjuvant-antigen combinations, sera collected after 32 weeks were further
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analysed by two-site competition ELISA, isotype-specific ELISA (mice sera only), (s)IFAs, 
and TB assay. Isotype-specific ELISA was performed since different adjuvants might induce 
different IgG isotype subsets (Takayama et a/., 1991; Allison et al., 1986); for instance the 
copolymer P1004 plus RaLPS in an o/w emulsion with squalene shifted the antibody 
production against a P. cynomolgi circumsporozoite peptide (NAGG)5 to the IgG2a isotype 
while suppressing IgG1 (Kalish et al., 1991). Such an antibody subtype switch might be 
important for the induction of TB immunity, although no evidence is available yet that TB 
immunity is indeed correlated to specific IgG subclasses. From other reports is known that 
in some cases IgG2a subtypes can be correlated with the level of protection against malaria 
parasites, i.e. after immunisation with P. berghei parasites (Akanmori et a/., 1994) and P. 
yoelii parasites (Hunter et al., 1995; ten Hage et al., 1993), whilst in other cases no 
correlation between IgG subtypes and protection was found, i.e. after immunisation of mice 
with purified MSP-1 (Chang et al., 1994) and with a recombinant fusion protein 
encompassing the carboxy terminal end of MSP-1 of P. yoelii (Daly et al., 1996).
In our studies, no Ig subtype switch could be induced by any of the adjuvants used; 
IgG1 was the predominant isotype of rPfs48/45-specific antibodies in all immunisation 
groups of mice (Table 1). The highest levels of IgG1 were detected in sera from mice 
immunised with rPfs48/45 emulsified in P1005-LPS-squalene, whereas the lowest level was 
for the group that was immunised with rPfs48/45 emulsified in Hunter's TiterMax™#R1. All
week-number week-number
F ig . 1: 0D50 value of sera from rabbits (A) or mice (B) immunised with rPfs48/45(56-401) obtained from 
urea-dissolved inclusion-bodies. Boosts are indicated with an arrow.
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sera showed comparable low levels of IgG2a, IgG2b and IgG3. As assessed in competition 
ELISA none of the sera contained antibodies directed against epitopes I or Ilb. In IFA using 
air dried sexual stage parasites on multispot slides, sera S4 and S5 of mice immunised with 
rPfs48/45 emulsified in either Quil A or P1005-LPS-squalene, and serum S5 of rabbits 
immunised with rPfs48/45 emulsified in Quil A, were positive. None of the sera reacted with 
live gametes in suspension IFA, and none of the sera were able to reduce malaria 
transmission, as assessed in an in vitro membrane feeding assay.
As explained above, a possibility for the fact that the antigen did not induce TB 
immunity might be related to the induction of ineffective sub-types of IgG. For the immunisa­
tions in mice, the host's major histocompatibility complex (MHC) haplotype might also have 
influenced TB immunity. This, because it has been found that the induction of antibodies 
capable of inhibiting the growth of P. falciparum in vitro after immunisation of mice with P. 
falciparum MSP-1 is significantly influenced by adjuvant and by the host MHC haplotype 
(Chang et a., 1994; Hui et a., 1991). The most likely reason for the inability of the antigens 
to induce TB immunity is, however, the fact that the three dimen-sional native-like structure 
of the protein which was used in this study was not stabilised by disulphide bridges.
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Adjuvants HRPO-labelled a-mouse-isotype1
IgG1 IgG2a IgG2b igG3
Quil A 36± 25 16±7 10±5 10±5
P1005-RaLPS-squalene 57±40 22±17 16± 13 12±8
TiterMax™#R1 23±9 8±1 7±2 6±2
Freund's 36±7 18±1 11±2 8±2
1 Reciprocal 0D50 serum titres x 1000 ±SD
TABLE 1: Reciprocal 0D50 values for different immunoglobulin isotypes as asses­
sed by isotype-specific ELISA
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A b s t r a c t
With the aim of developing transmission-blocking vaccines based on the sexual stage 
specific surface antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum, the 
gene encoding Pfs48/45 was incorporated into the genome of a recombinant vaccinia virus. 
In virus-infected mammalian tisssue culture cells, recombinant Pfs48/45 antigen (rPfs48/45) 
is posttranslational modified to produce a highly N-glycosylated polypeptide. The rPfs48/45 
protein was radiolabelled with ethanolamine, consisting of a further posttranslational 
modification in the form of a glycosylphosphatidylinositol anchor at its carboxy-terminal end. 
The rPfs48/45 was not detected on the surface of the infected cells; instead, it remained 
within the secretion pathway of mammalian cells irrespective of the duration of infection or 
culture temperature. Studies with monoclonal antibodies specific for disulphide bond- 
dependent epitopes of Pfs48/45 revealed that rPfs48/45 is not folded in its authentic 
conformation even if /V-glycosylation was chemically inhibited. Infection of mice and rabbits 
with recombinant virus elicited Pfs48/45-specific antibodies; however, the antisera failed to 
block parasite transmission in a standard mosquito membrane-feeding assay.
In t r o d u c t io n
Malaria remains a major problem worldwide. Efforts to control the disease have 
focussed on the mosquito vector and on chemotherapy. These efforts have, however, been 
hampered by the emergence and spread of drug-resistant parasites and insecticide- 
resistant mosquitoes. Vaccines that block parasite invasion and/or replication in either 
hepatocytes or erythrocytes or that target sexual reproduction of parasites within the 
mosquito midgut are important alternatives to limit the spread of the disease. The goal of 
studies in our laboratory is the development of a transmission-blocking (TB) vaccine, i.e. a 
vaccine belonging to the latter category. The best studied examples of TB vaccine 
candidate antigens are surface proteins of sexual-stage parasites. Based on when during 
sexual development they are synthesised, these proteins can be subdivided into two 
groups: one group consists of antigens such as Pfs25 and Pfs28 (Kaslow et a/., 1988; Duffy 
and Kaslow, 1997), which are produced in the mosquito midgut; the other group consists of 
antigens such as Pfs48/45 and Pfs230 (Kocken et al., 1993; Williamson et al., 1993) which 
are synthesised during gametocytogenesis, i.e. within the human host. Because of the latter 
feature it is anticipated that these antigens will maintain/boost TB activity during a natural
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infection in individuals vaccinated with the respective gametocyte antigens or appropriate 
fragments thereof. Strong support for this assumption is provided by the prevalence of 
Pfs48/45 and Pfs230-specific (TB) antibodies in sera of humans living in endemic areas 
(Graves et al., 1988; Graves et al., 1992; Riley et al., 1990; Ong et al., 1990; Roeffen et al., 
1995b; Roeffen et al., 1996).
Pfs48/45-specific monoclonal antibodies (mAbs) are capable of blocking parasite 
transmission to mosquitoes (Rener et al., 1983; Vermeulen et al., 1985; Carter et al., 1990; 
Targett et al., 1990); furthermore, in studies with sera from gametocyte carriers, a strong 
correlation has been observed between the occurrence of Pfs48/45-specific antibodies and 
the ability of these sera to block transmission (Roeffen et al., 1996). Antigenic and genetic 
diversity of Pfs48/45 in parasite strains derived from diverse parts of the world appears to be 
limited (Foo et al., 1991; Kocken et al., 1995).Thus, several lined of evidence indicated that 
Pfs48/45 is a promising TB vaccine candidate.
Molecular biological studies have shown that the polypeptides of the doublet antigen 
Pfs48/45 are encoded by a single gene. The primary translation product is 448 amino acids 
long and contains a putative secretory signal sequence at its N-terminal end for 
translocation across the ER membrane and a putative signal sequence at its C-terminal end 
for the attachment to a GPI anchor. The primary translation product contains seven potential 
V-glycosylation sites (Kocken et al., 1993). Competition studies with mAbs have provided 
unambiguous evidence that the Pfs48/45 antigen contains at least six B-cell epitopes 
designated I, IIa/IIc, IIb, III, IV, and V, respectively. Epitopes I, IIa/IIc, IIb and III are non­
contiguous and, together with epitope V, important for evoking a TB immune response 
(Carter et al., 1990; Targett et al., 1990).
To study some basic features of Pfs48/45, but also to determine whether rPfs48/45 is 
capable of eliciting a humoral and TB immune response in mice and rabbits, pfs48/45 was 
expressed with the aid of a recombinant vaccinia virus (rVV). This vector system was 
chosen because it has proven to be useful for the production of many eukaryotic proteins, 
including proteins encoded by the malaria parasite such as Pfs25 (Kaslow et al., 1991) and 
because it can evoke a strong recombinant antigen-specific immune response in mammals 
(reviewed by Moss, 1996).
M a t e r ia l s  a n d  M e th o d s
Polyclonal antisera and monoclonal antibodies. K57 is a Pfs48/45-specific polyclonal antiserum derived
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from rabbits vaccinated with a fusion protein comprising GST and amino acids 56 through 401 of Pfs48/45, 
synthesised in E. coli. K37 is a Pfs16-specific polyclonal antiserum derived from rabbits vaccinatesd with a fusion 
protein comprising GST and amino acids 39 through 157 of Pfs16, synthesised in E. coli (Moelans et al., 1991). 
32F3 and 32F1 are mouse mAbs specific for the discontinuous epitopes I and IIb of Pfs48/45; 32F61 is a mouse 
mAb specific for the TB epitope I of Pfs25 (Vermeulen et al., 1985).
construction  o f recombinant DNA. The procedures for the construction of recombinant DNA were 
essentially as described by Sambrook et al. (1989). All enzymes used were from Gibco BRL (Gaithersburg, MD) 
unless stated otherwise. The coding region of Pfs48/45 was PCR amplified from genomic DNA (isolate NF54) 
with Taq DNA polymerase, the sense primer 5'-GCTAGCATGATGTTAATATTTCTGCG-3', and the antisense 
primer 5'-GCTAGCATGAGCTAAATATATAATAATATTGC-3'. The 5' and 3' ends of the PCR product were blunt 
ended with T4 DNA polymerase and phosphorylated with T4 polynucleotide kinase. After addition of EcoRI 
linkers to both ends of the DNA fragment, it was inserted into the EcoRI site of pBluescript-KS* (Stratagene, La 
Jolla, CA), which placed the coding region of pfs48/45 under the control of the bacteriophage T7 promoter. The 
nucleotide sequence of the cloned gene was verified by sequence analysis. The recombinant plasmid was used 
for the construction of the vaccinia virus (VV) transfer vector pVV-pfs48/45. For this, plasmid pBS-pfs48/45 was 
restricted with EcoRI. The insert was recovered from agarose gel, made blunt ended with Klenow polymerase, 
and inserted into the SmaI site of pSC11-5212, thus placing gene pfs48/45 under control of the early/late VV 
P7.5 promoter. Plasmid pSC11-5212 is a derivative of pSC11 (Chakrabarti et al., 1985) only differing in the 
multiple cloning site with the sequence 5'-AGATCTGGTACCGCATGCCCCGGG-3' in pSC11-5212.
Construction o f recombinant vaccinia virus, cells and medium. The procedure for the construction and 
isolation of VV recombinants was adapted from Mackett et al. (1984) as described by De Vries et al. (1992). 
Unless stated otherwise, all cells were maintained in DMEM supplemented with 200 IU penicillin ml-1, 200 IU 
streptomycin ml-1 and 10% heat-inactivated FCS. Subconfluent monolayers of HeLa cells in 10-cm2 dishes were 
infected at a low m.o.i. in DMEM without FCS with wild-type VV (Western Reserve strain) and transfected with a 
calcium phosphate precipitate of 5 |jg of the transfer plasmid. Virus recombinants were selected on human 143 
thymidine kinase-negative cells in the presence of 25 jg  ml-1 5-bromodeoxyuridine. The coexpression of lacZ 
further enabled the visual screening of the recombinant viruses in a plaque assay using the chromogenic 
substrate X-gal. After two rounds of plaque purification, a stock of recombinant virus (VV-pfs48/45) was prepared 
in rabbit kidney (RK-13) cells. For late-phase expression HeLa cells were utilised, whereas baby hamster kidney 
(BHK-21) cells were used for early-phase expression. African green monkey kidney (BSC-1) cells were used in 
immunofluorescence assays.
Infection and transfection. Subconfluent monolayer cultures (10 cm2) of either HeLa or BHK-21 cells were 
infected at low m.o.i. with 5x106 p.f.u. of rVV as described (De Vries et al., 1992). Prior to starvation and 
metabolic labelling, infected HeLa-cells were incubated for 14 h, unless stated otherwise, at either 37 °C or 32 °C. 
Alternatively, BHK-21 cells that had been infected with the bacteriophage T7 RNA polymerase encoding rVV 
vTF7.3 (Fuerst et al., 1986), were incubated for 50 min at 37°C prior to transfection with 15 j l  of lipofectin and 
10 jg  of recombinant plasmid. After transfection cells were incubated for 5 h at 32°C.
Metabolic labelling and preparation o f cell extracts. After 30 min of incubation in methionine- and 
cysteine-free DMEM, the VV-pfs48/45-infected or pBS-pfs48/45-transfected/vTF7.3 infected cells were incubated 
for 30 or 60 min in 600 j l  of methionine- and cysteine-free DMEM containing 6 j l  of L-[35S]-/n vitro cell labelling
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mix (60 jC i; > 1000 Ci/mmol; Amersham International, Birmingham, UK). The shortest labelling period was follo­
wed by two rapid washes with chase medium (DMEM supplemented with 10% heat-inactivated FCS, and con­
taining 5 mM methionine). Incubation was then continued in the same medium for time periods ranging from 0 to 
180 min. To determine whether the recombinant protein was GPI-anchored, HeLa cells (10 cm2) were labelled for
5 h starting at 10 h.p.i. with 200 j  Ci of [1-3H]ethan-1-ol-2-amine hydrochloride (5-30 Ci/mmol; Amersham). After 
labelling, cells were washed with ice-cold PBS. Subsequently, they were solubilised in 600 j  l of ice-cold buffer A 
(20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1 % SDS and 1 jg  ml-1 each of aprotinin, leupeptin, and pepstatin A 
[Boehringer Mannheim, Indianapolis, IN]) supplemented with 1% NP40 and 0.5 % DOC. Cell-debris and nuclei 
were removed by centrifugation for 15 min at 10,000 x g and 4°C. Finally EDTA was added to the supernatant to 
a final concentration of 5 mM.
Immunoprecipitation. We diluted 100-200 j l  of the 600 j l  crude protein extracts, derived from 10 cm2 
cells in buffer A supplemented with 0.5% NP-40, 0.1% DOC, and 5 mM EDTA to a final volume of 1 ml. The 
samples were supplemented with either 1 j l  of polyclonal antiserum or 1 jg  of mAb and incubated at 4°C 
overnight. Then 30 j l  of either a 10% suspension of heat-inactivated protein G-bearing group G Streptococcus 
sp. cells (Omnisorb®, Calbiochem, San Diego, CA) or group C Streptococcus sp. cells (Protein G, Sigma 
ImmunoChemicals, St. Louis, MO) was added and the samples were incubated for 2 h at 4°C. The immune 
complexes were collected by centrifugation and washed thrice in 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM 
EDTA, 0.1% NP40 supplemented with 1 j g  ml-1 each of aprotinin, leupeptin, and pepstatin A and once in 20 mM 
Tris-HCl, pH 7.6, 0.1% NP40. Finally, the immune complexes were dissolved in LSB (62.5 mM Tris-HCl, pH 6.8, 
1% SDS, 10% glycerol, 0.003% bromophenol blue) containing 5% 3-mercaptoethanol and heated for 2 min at 
96°C.
Endoglycosidase treatment. Immune complexes were incubated, respectively, with the V-glycan-specific 
enzymes N-glycosidase F or endo H (De Vries et al., 1992), or with a combination of N-glycosidase F and the O- 
glycan-specific enzyme O-glycosidase. In short, for endo H treatment immunoprecipitates were resuspended in 
400 j l  of endo H buffer (50 mM sodium acetate, pH 5.5, containing acetylated BSA (100 jg  ml-1), phenylmethyl- 
sulphonylfluoride (100 jg  ml-1) and 1 jg  mt1 each of aprotinin, leupeptin, and pepstatin A) and split in two equal 
samples. After the addition of 2 mU of endo H to one of the aliquots, the samples were incubated overnight with 
gentle shaking at 30°C. Subsequently, the samples were centrifuged for 2 min at 10,000 x g, and the pellets 
were resuspended in LSB containing 5% 13-mercaptoethanol. To remove both the N- and O-linked glycans 
immunoprecipitates were dissolved in 10 j l  of 0.4% SDS by heating for 5 min at 96°C. Then the solutions were 
adjusted to 20 mM NaPi, pH 7.2, 10 mM sodium-azide, 50 mM EDTA, 0.5% NP40, 0.1% SDS to a final volume of 
40 j l ,  and heated for an additional 2 min at 96°C. After cooling to 37°C 1 mU O-glycosidase and 100 mU N- 
glycosidase F were added, and the samples were incubated overnight at 37 C.
s D s  polyacrylamide gel electrophoresis and fluorography. SDS-PAGE was performed essentially as 
described by Sambrook et al. (1989) and under reducing conditions unless stated otherwise. Where indicated (3- 
mercaptoethanol was omitted from the sample buffer and 5% glycerol was added to the gel-solution. After 
electrophoresis, gels were processed for fluorography as described by Bonner (Bonner et al., 1974).
Indirect immunofluorescence assay (IFA). BSC-1 cells grown on round glass coverslips and infected with 
VV-pfs48/45 (De Vries et al., 1992) were fixed for 30 sec in ethanol/acetone (1:1 v/v), washed thrice with PBS, 
incubated for 30 min with 10 jg  ml-1 mAb or with a 1:200 dilution of the polyclonal antiserum in PBS, washed
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thrice with PBS, and incubated for 30 min with a 1:100 dilution of FITC-conjugated rabbit anti-mouse or goat anti­
rabbit IgG (Sigma ImmunoChemicals) in PBS. After extensive washes with PBS the coverslips were mounted on 
glass slides and examined with either a fluorescence microscope (Leitz) or a confocal laser scanning microscope 
(MCR600 series laser scanning confocal imaging system with a 25mW Argon ion multi line (448nm/512 nm) 
laser; Bio-Rad, Richmond, CA).
Immunisation. Four Balb/c mice (H-2d haplotype, optimally responding to Pfs48/45 after gametocyte 
immunisations [Good et al., 1988]) were challenged thrice by tail-scratch inoculation at three week intervals with 
2x107 p.f.u. VV-pfs48/45 or vAVE25 (Deregt et al., 1994), and bled 3 weeks after the last immunisation. In weeks
0 and 4 two New Zealand rabbits were inoculated intravenously with 2.5x107 p.f.u. VV-pfs48/45, and two other 
rabbits with 5x107 p.f.u. VV-pfs48/45. The rabbit sera were recovered 6 weeks after the final inoculation.
P arasite  cu ltu re  and W estern b lo t ana lysis. Mature P. falciparum gametocytes of isolate NF54 were 
produced in a semi-automated suspension culture system (Ponnudurai et al., 1983). Gametocytes were obtained 
from asynchronous parasite material and purified by Nycodenz (Nijegaard, Oslo, Norway) gradient centrifugation 
at 37°C  as described by Vermeulen et al. (1986). After isolation the gametocytes were heated for 3 min at 96°C  
in LSB. Subsequently, the proteins were size fractionated in SDS 10% polyacrylamide gels, electroblotted and 
analysed according to standard Western blotting procedures (Harlow et al., 1988). As primary antibody, either 
polyclonal serum (diluted 500-fold in PBST, unless stated otherwise) or mAb (1 j g  IgG ml-1) was used. 
Secondary antibodies were alkaline phosphatase conjugated IgGs (Sigma ImmunoChemical).
Enzym e-linked im m u noso rbe n t assay (ELISA), surface  Im m uno fluorescence assay (sIFA), and 
tra n sm iss io n -b lo ck in g  assay. Antibody titres were determined as decribed by Moelans et al. (1991). For this, 
microtitre plates were coated with purified bacterial-derived rPfs48/45 (amino acids 56-401) (0.1 j g  ml-1) in a 
sodium carbonate buffer (pH 9.6) for 2 h at 37°C, essentially as described by Moelans et al. (1991). Baseline 
level of positivity was defined as an OD450 of 0.2. The competitive binding experiments were performed as 
described by Roeffen et al. (1995a). Briefly, microtitre plates were coated with either anti-Pfs48/45 mAb 32F1 or 
32F3 (10 j g  ml-1 in PBS). Subsequently, antigen Pfs48/45 was captured from a gametocyte extract prepared in
0.5% NP40, 25mM Tris-HCl (pH8.0). Competition was tested with either horseradish peroxidase- coupled 32F1 
or 32F3 (2 j g  ml-1 in PBS) and a serial dilution of the polyclonal antiserum derived from animals infected with 
rVV. Competition titres were defined as the dilution of the test serum that resulted in the same OD value as the 
mean + 2 SD of OD values for control sera from 4 non-exposed mice or rabbits. Sera with a competition titre < 
1/20 were considered negative. SIFAs were performed as described by Roeffen et al. (1995b) (or see chapter 
4a). The effect of antisera on the infectivity of P. falciparum for Anopheles gambiae mosquitoes was tested in a 
mosquito membrane feeder assay as described elsewhere (Ponnudurai et al., 1987, 1989; Vermeulen et al., 
1985; chapter 4a).
R e su lts
Synthesis o f recombinant Pfs48/45. To establish whether VV-pfs48/45 would direct 
the synthesis of bona fide protein, HeLa and BSC-1 cells were infected with recombinant 
virus. As a (negative) control cells were also infected with vAVE16, a similarly obtained rVV
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1 2 3 4 5 6 7 8
encompassing the ORF 6 gene of equine arterites virus (Deregt et al., 1994). At 14 h.p.i. the 
infected cells were metabolically labelled with [35S]-methionine/cysteine for 1 h at 37 C and 
then extracted and immunoprecipitated with either polyclonal antisera or mAbs. After 
immunoprecipitation the proteins were analysed under reducing conditions by SDS-PAGE. 
In addition to some proteins of host cell or VV origin that were non-specifically precipitated, 
a protein with a Mr of approximately 75 kDa could be precipitated from cell extracts of VV- 
pfs48/45 infected cells with the polyclonal antiserum K57 (Fig. 1, lane 4), but not with K57 
pre-immune serum (Fig. 1, lane 1) or negative control antiserum K37 (Fig. 1, lane 2).
In contrast to the polyvalent serum K57 the mAbs specific for the conformational and 
reduction-sensitive epitopes I and IIb did not precipitate Pfs48/45-specific product (Fig. 1, 
lanes 6-8) from extracts of VV-pfs48/45 infected cells. Also in immuno-precipitates obtained 
after incubation of cell extracts of vAVE16 infected cells with antiserum K57, the 75 kDa 
protein was absent (Fig. 1, lane 3), although the ORF 6 protein could be precipitated 
specifically (data not shown). Although the 
precipitation is, therefore, Pfs48/45-specific, 
the Mr is larger than that of native Pfs48/45 
(i.e. 58 kDa under reducing conditions).
Furthermore, the 75 kDa band is broad and 
appears to be composed of multiple 
species, which points to heterogeneous 
post-translational modification of the 
primary translation product (vide infra). Of 
interest, the observed heterogeneity largely 
disappeared when glycerol was added to 
the polyacrylamide gels. This may point to 
reduced radial diffusion of the modified 
protein in the presence of glycerol (Hoeffer,
1983).
Post-translational modifications.
Enzymatic deglycosylation of gametocyte 
extracts and studies in which V- 
glycosalation in gametocytes is inhibited 
with tunicamycin (unpublished data) 
indicate that native Pfs48/45 antigen does
kDa 
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33 -
FIG. 1 . Autoradiograph demonstrating precipitation 
of rPfs48/45 with Pfs48/45-specific polyclonal 
antiserum but not with mAbs. HeLa cells were 
infected with VV-pfs-48/45 (lanes 1, 2, 4, 5-8) or 
with the control vAVE16 (lane 3). After labelling 
and preparation of cell extracts 
immunoprecipitations were performed with rabbit 
K57 preimmune serum (lane 1), rabbit control 
antiserum K37 (lane 2), rabbit poly-clonal 
antiserum K57 (lanes 3 and 4), control mAb 32F61 
(lane 5), mAbs 32F1 (lane 6) and 32F3 (lane 7), 
and a combination of mAbs 32F1 and 32F3 (lane 
8).
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not contain V-linked glycans. To determine whether te unexpectedly large Mr and the 
apparent heterogeneity of the recombinant protein might be a result of /V-glycosylation, the 
immunoprecipitated recombinant proteins were treated with endo H or V-glycosidase F. A 
dramatic shift of the Mr from 75 kDa to 55 kDa was observed (Fig. 2, lanes 1 and 2). In 
contrast to rPfs48/45 the native antigen is not sensitive to incubation with V-glycosidase F 
(Fig. 2C, compare lanes 5 and 7 with lanes 4 and 6). Since the glycoprotein fetuin can be 
deglycosylated when added to the gametocyte-extract (Fig. 2C, compare lanes 6 and 7) the 
presence of glycosidase inhibitors in these preparations can be excluded. Hence, native 
Pfs48/45 seems not to be V-glycosylated. Why the native protein and the deglycosylated 
recombi-nant product still do not comigrate is not known; however, because native Pfs48/45 
can be labelled both with radioactive mannose and glucosamine (Vermeulen et al., 1986; 
Kumar and Carter, 1984) residual size differences are most likely caused by differential O- 
glycosylation and/or glypiation (vide infra).
Indirect immunofluorescence data suggested that much of the rPfs48/45 was retained
A  B C
1 2 3 4 5 6 7 
deg lycosyla ted  - + - - + - +
-« - ( g )
- « -  Pfs48/45 
-« - ( d )
F ig . 2. Recombinant, but not native, Pfs48/45 is /V-glycosylated. (A) Autoradiograph of a polyacrylamide gel 
of immunoprecipitated metabolically labelled proteins synthesised in VV-pfs48/45 infected HeLa cells that 
were incubated in the absence (lane 1) or presence of endo H (lane 2). (B) Western blot analysis of 
gametocyte proteins stained with Pfs48/45- specific antiserum K57. (A) and (B) were on the same gel. (C) As 
panel (B), but now proteins were incubated in the absence (lanes 4 and 6) or presence (lanes 5 and 7) of N- 
glycosidase F. To the samples 6 and 7 the glycoprotein fetuin was added as an internal control. The position 
of the glycosylated (g) and deglycosylated (d) fetuin, which was stained with 0.002% Pongeau S, is indicated. 
All proteins were fractionated under reducing conditions by SDS-PAGE containing 5% glycerol.
117 -
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F ig . 3. Indirect immunofluorescence assay of VV-pfs48/45 infected 
BSC-1 cells. After fixation, cells were stained with antiserum K57 in 
combination with FITC-conjugated goat anti rabbit IgG. Cells were 
viewed by confocal laser scanning microscopy (magnification 600x, 
zoom 2.3x). Rabbit preimmuneserum and mAbs did not react (not 
shown). Visible is the round nucleus, a reticular staining pattern, 
intense fluorescing center of the cytoplasm, and low fluorescing bor­
ders. (NB This figure was not presented in the published version)
intracellularly, presumably in the ER or Golgi compartment (Fig. 3). To clarify whether there 
is a complete block in secretory transport, a pulse-chase study was performed to establish 
whether metabolically labelled recombinant protein would remain sensitive to endo H 
(Kornfield et a/., 1985). The N-linked glycans are not detectably modified to more complex 
endo H resistant carbohydrate structures, indicating that transport of the recombinant 
protein out of the ER is indeed completely blocked (Fig. 4). The results further indicate that 
ER retention of the recombinant protein is not accompanied by rapid degradation as 
observed for many other transport-defective proteins (Halban et a/., 1994).
To determine whether the lack of 
recognition of the recombinant 
protein by conformation epitope- 
specific mAbs was caused by 
misfolding and/or shielding of the 
epitopes by N-linked glycosylation, 
the effect of tunicamycin, an inhibitor 
of N-glycosylation (Elbein et a/.,
1987) was studied. After incubation 
for 1 h in the presence and absence 
of tunicamycin, VV-pfs48/45 infected 
cells were metabolically labelled for 
1 h in the absence and presence of 
the same drug. Throughout this 
experiment, cells were incubated at 
32 C rather than at 37 C, because 
misfolding and retention in the VV 
system are often temperature sensi­
chase (m in) -►  0 30 60 180 
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F ig . 4. Pulse-chase analysis demonstrating a prolonged 
sensitivity to endo H and a relative high stability of 
rPfs48/45 expressed from VV-pfs48/45. After infection 
HeLa cells were pulse labelled for 30 min, and chased for 
up to 180 min. Cell extracts were prepared and 
immunoprecipitations were performed with antiserum K57. 
Precipitates were split in equal portions and incubated in 
the presence or absence of endo H, as indicated.
§ § R| É
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tive (Doms et al., 1993; Marquardt et al., 1992). Recombinant proteins were recovered by 
immunopre-cipitation and analysed by SDS-PAGE. Neither lower temperature nor 
tunicamycin treatment affected the recognition of the recombinant protein by conformation 
epitope-specific mAbs (i.e. 32F1 and 32F3) (Figs. 5A and 5B, lanes 4 and 5). 
Concomitantly, some smaller protein species appeared (Fig. 5B, lane 3) of which the 55- 
kDa protein species most likely represents the unglycosylated form of Pfs48/45. The identity 
of the smaller species is unclear, but they probably represent degradation products. 
Increased degradation of proteins due to tunicamycin treatment has been noted before 
(Elbein, 1987).
The observed differences in Mr between native and recombinant deglycosylated 
Pfs48/45 might be due to a host cell-specific difference in the extent of O-glycosylation
and/or to the composition of the 
putative GPI-anchors. Because the IFA 
staining pattern strongly suggests that 
the recombinant protein is retained in 
the ER, O-glycosylation of recombinant 
protein, which is thought to occur in the 
Golgi-complex (Roth, 1987; Dekker et 
al., 1990), is not expected. The results 
of enzymatic treatment of the 
recombinant protein with O- 
glycosidase are in line with this 
hypothesis, i.e. after incubation with 
the enzyme, no change in 
electrophoretic mobility was observed 
(data not shown). That the molecular 
weights of the native versus the 
recombinant GPI-anchors differ is 
possible, because GPI-structures of 
different cells can vary considerably in 
size (McConville et al., 1993). As 
shown in Fig. 6 (lane 4), rPfs48/45 was 
radio-labelled when VV-pfs48/45 
infected HeLa cells were incubated for
A B
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F ig . 5. Autoradiograph showing that tunicamycin- 
treatment does not have any effect on the recognition of 
rPfs48/45 by conformational epitope-specific mAbs. All 
incubations were carried out at 32 C. HeLa cells were 
infected with VV-pfe48/45, metabolically labelled, and 
incubated in the absence (A) or presence (B) of 
tunicamycin (1 |jg  ml-1) for 2 h prior to cell-lysis. Cell 
extracts were prepared, and immunoprecipitations were 
performed with rabbit K57 pre-immune serum (lanes 1), 
rabbit control antiserum K37 (lanes 2), rabbit antiserum 
K57 (lanes 3), mAbs 32F1 (lanes 4) and 32F3 (lanes 5), 
and control mAb 32F61 (lanes 6).
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5 h with the GPI-specific precursor [3H]ethanolamine (Menon et al., 1994). Moreover, all 
recombinant polypeptide chains must contain a GPI modification unless the net effect of 
glypiation to the Mr is zero, because the ethanolamine-labelled product migrates at exactly 
the same position as the [35S]methionine/cysteine labelled protein (Fig. 6, lane 1).
Immunisation o f mice and rabbits w ith VV-pfs48/45. To study whether VV-pfs48/45 
was able to elicit a Pfs48/45-specific and TB immune response, New Zealand rabbits and 
Balb/c mice were infected twice and thrice at 4- or 3-week intervals, respectively. Titres of 
the sera were established by ELISA and Western-blot analyses. The titres of rabbit immune 
sera varied in the ELISAs from 1/1000 to 1/8000, and on Western blots from 1/100 to 
1/1000. The titres obtained in mice were significantly lower, ranging on Western blots from
F ig . 6 . Autoradiograph demonstrating incorporati­
on of [3H]ethanolamine in rPfs48/45. HeLa cells 
were infected with VV-pfs48/45 and metabolically 
labelled with [35S]methionine/cysteine (A), or alter­
na tive ly  with [3H]ethanolamine (B). Cell extracts 
were prepared, and immunoprecipitations were 
performed with either rabbit pre-immuneserum 
(lane 3) or with antiserum K57 (lanes 1 and 4). 
Acrylamide gel contained 5% glycerol. Lane 2 was 
loaded with crude cell extract. Exposure times 
were either 3 days (A) or 10 weeks (B).
1 2 3
kDa
48 -  
45
Fig. 7. Western blot analysis demonstrating speci­
fic reaction of antisera derived from VV-pfs48/45 
infected rabbits with native Pfs48/45. Each lane 
contained 1x106 gametocyte-equivalents fractiona­
ted by SDS-PAGE (10%) under nonreducing condi­
tions. Lane 1 was incubated with antiserum obtai­
ned from rabbits which had been immunised with 
VV-pfs48/45. Lane 2 was incubated with rabbit pre- 
immuneserum. Lane 3 was incubated with mAb 
32F3.
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1/10 to 1/100. By Western blot analysis under reducing (Data not shown) and nonreducing 
conditions (Fig. 7, lanes 1 and 2), rabbit immune sera reacted specifically with native 
Pfs48/45. Similarly, the sera obtained from VV-pfs48/45 infected mice reacted specifically 
with native Pfs48/45, while with the sera obtained from mice vaccinated with the rVV 
vAVE25, a similarly obtained rVV expressing the GL protein of equine arteritis virus (Deregt 
et al., 1994), reaction with Pfs48/45 could not be demonstrated (data not shown). In 
contrast, neither rabbit nor mouse immune sera recognised gametes by surface IFA, nor did 
these sera compete with the conformational epitope-specific mAbs 32F1 and 32F3 by 
ELISA. Neither sera had TB activity by membrane feeder assays (data not shown). Taken 
together, the above results indicated that in neither virus-infected cells nor vaccinated mice 
or rabbits Pfs48/45 is produced in its native conformation.
D is c u s s io n
Considering the characteristics of the recombinant protein produced in the tissue culture 
cells, the failure of VV-pfs48/45 to induce TB immunity was anticipated. That the titres of the 
Pfs48/45-specific antibodies were relatively low might be due to the retention of the 
recombinant protein in the ER, because exposure of a protein at the cell surface has been 
shown to strongly enhance its immunogenicity (Langford et al., 1986). Also, the presence of 
three cryptic early-phase transcription termination signals in gene pfs48/45 might indirectly 
have affected the level of the immune response (Earl et al., 1990). Since production of the 
recombinant protein early after infection (in BHK-21 cells transfected with a plasmid bearing 
pfs48/45 under control of a phage T7 promoter and infected with a rVV coding for T7 RNA 
polymerase [Fuerst et al., 1987]) did not affect its biochemical and biophysical properties it 
is, however, unlikely that removal of these signals would have led to a qualitatively better 
immune response (i.e. to the induction of TB immunity).
The aberrant characteristics in folding and transport of rPfs48/45 protein might have 
been caused by one or more of the following: 1) misrecognition of the N- and/or C-terminal 
signal sequences; 2) presence of (cryptic) ER retention/retrieval signals; 3) the lack of the 
appropriate combination of chaperone proteins; 4) aberrant posttranslational modifications; 
and 5) the lack of co-expression with a protein with which Pfs48/45 forms a hetero-oligomer 
under natural circumstances (Holst et al., 1996; Pelham, 1995; Helenius, 1994; Doms et al., 
1991; Hurtley and Helenius, 1989).
Although inappropriate processing of a primary translation product can lead to retention
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(Rottier et al., 1987; Field et al., 1994), it is unlikely that this is the cause of retention of 
rPfs48/45. First, because the recombinant protein is found to be translocated to the ER and, 
second, because N-terminal signal sequences of a number of P. falciparum antigens 
already have shown to be recognised and processed well in mammalian cells (Theisen et 
al., 1994; Tine et a., 1993; Kaslow et al., 1991; Langford et a., 1986). Third, the 
observation that the recombinant protein can be labelled with ethanolamine suggests that 
also the potential C-terminally located GPI anchor sequence is properly processed. Further 
in line with this conclusion is the finding that deletion of the C-terminal signal sequence did 
not result in secretion of the recombinant protein (data not shown).
One of the most striking characteristics of Plasmodium falciparum is its weakly active 
and highly selective /V-glycosylation system (Dieckmann-Schuppert et a., 1992, 1994; 
Kimura et a., 1996). During its life cycle, few surface antigens are Vglycosylated. Because 
(mis)glycosylation has shown to affect protein folding (Holst et a., 1996; Helenius, 1994; 
Hurtley et a., 1989; Kornfeld et a., 1985), one explanation for the improper folding of 
rPfs48/45 could have been aberrant V-glycosylation. Treatment of VV-pfs48/45 infected 
cells with the V-glycosylation inhibitor tunicamycin, however, did not result in recognition of 
the recombinant protein by mAbs that are specific for discontinuous epitopes.
It is known from numerous studies that oligomer assembly is often essential for 
transport from the ER and the final conformation of the proteins present in the complex 
(Hurtley and Helenius, 1989; Doms et a., 1993). Because Pfs48/45 forms a tight complex 
with the sexual stage-specific antigen Pfs230 (Kumar et a., 1992), it might well be that 
authentic Pfs48/45 and/or Pfs230 can only be produced in heterologous expression systems 
under conditions of coexpression of these antigens. If this hypothesis turns out to be correct, 
the development of TB vaccines based on sexual stage-specific antigens Pfs48/45 and/or 
Pfs230 may require coepression. In this connection it should be noted that a similar 
phenomenon might be responsible for the observation that recombinant CSP was 
demonstrated on the surface of (attenuated) rVV-infected cells only when coexpressed with 
another sporozoite-specific antigen (Tine et a., 1996; Kumar et a., 1988).
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A b s t r a c t
Pfs48/45 is an important transmission-blocking vaccine candidate antigen of the human 
malaria parasite Plasmodium falciparum. This study was aimed at synthesis of recombinant 
Pfs48/45 containing conformation-constrained epitopes of the native antigen in yeast. Since 
in the yeast Saccharomyces cerevisiae induction of gene-expression led to prematurely 
terminated transcripts, an entirely synthetic gene of higher GC content was assembled. 
Replacement of the AT rich natural gene by the synthetic gene relieved the observed 
premature transcription termination. Nevertheless, recombinant protein expression could not 
be detected. In contrast, in the yeast Pichia pastoris low levels of recombinant Pfs48/45 
were produced upon induction of synthetic gene expression. The recombinant protein was 
shown to be disulphide-bridge constrained, but was not recognised by transmission-blocking 
antibodies and did not induce transmission-blocking sera in mice.
Keywords: Plasmodium falciparum Pfs48/45; yeast
In t r o d u c t io n
Malaria is a serious burden in large regions of the world. It causes disease and death of 
millions of people. Control measures for the mosquitoes that transmit the disease and for 
the parasites that cause malaria are becoming more and more ineffective due to increasing 
resistance of both vectors and parasites to insecticides and anti-malarial drugs. A vaccine 
is, therefore, urgently needed. Such a vaccine should not only relieve the clinical symptoms 
of malaria, but preferentially also prevent transmission of the parasite. The sexual stage- 
specific antigen Pfs48/45 of Plasmodium (P.) falciparum is an important candidate for the 
development of a vaccine inducing long lasting transmission-blocking (TB) immunity 
(Vermeulen et al., 1986). The observation that Pfs48/45-specific antibodies can be detected 
in a high percentage of people living in endemic areas (Ong et al., 1990; Riley et al., 1990) 
and the presence of these antibodies correlates to TB immunity (Roeffen et al., 1996) 
additionally stresses the importance of incorporation of Pfs48/45 in a TB vaccine. Such a 
vaccine might be of either protein or DNA content; for instance for the malarial antigen 
Pfs25 both strategies of immunisation were successful in terms of the induction of TB 
antibodies (Kaslow, 1997; Lobo et al., 1999).
The gene pfs48/45 encodes a single antigen that migrates as a doublet protein of 48-
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and 45 kDa under non-reducing conditions, and as one protein of 58 kDa under reducing 
conditions. The genetic diversity of the gene is very low (Kocken et al., 1995), which is 
important since the antigen should preferentially be capable to induce immunity against all 
natural occurring P. falciparum strains. The 448 amino acids long primary translation 
product of Pfs48/45 contains a putative secretion signal sequence of 26 amino acids at its 
amino-terminal end and putatively a C-terminal glycosyl-phosphatidyl-inositol (GPI) anchor 
signal sequence of 13 amino acids at its carboxy terminal end (Kocken et al., 1993). 
Furthermore, it contains 16 cysteine residues and seven putative V-glycosylation signals. 
From immunological data it is known that Pfs48/45 contains at least five different B-cell 
epitopes, i.e. I, IIa/IIc, IIb, III, IV and V. Epitopes I, IIa/IIc, III and V are targets for TB 
monoclonal antibodies (mAbs). A vaccine based on recombinant Pfs48/45 (rPfs48/45), 
should preferentially contain all TB epitopes. Since epitopes I, IIa/IIc, and III are disulphide- 
bridge constrained (Carter et al., 1990; Targett et al., 1990), synthesis of rPfs48/45 in an 
expression system in which disulphide-bonds can be formed is preferred. Formation of 
disulphide-bonds can be accomplished in prokaryotes, as has been described for the 
malarial protein MSP19 (Burghaus and Holder, 1994; Somner et al., 1999), but eukaryotic 
organisms are generally better suited for the synthesis of conformational epitopes.
Here, the production of rPfs48/45 in yeast is described. Yeasts have been shown to be 
capable to introduce disulphide-bonds to proteins that are translocated to the endoplasmic 
reticulum (ER), and are, furthermore, capable to introduce other eukaryotic post- 
translational modifications. Furthermore, yeasts are safe and easy to manipulate, and their 
cultivation is inexpensive and can easily be scaled up; all important characteristics for the 
production of a vaccine to be used in a global vaccination program (Bathurst, 1994). In this 
paper, we describe expression of the natural gene, pfs48/45, and of an artificial gene with 
higher GC content, pfs48/45s, in Saccharomyces cerevisiae and Pichia (P.) pastoris. 
Recombinant Pfs48/45 secreted into the culture medium of a Pfs48/45-specific P. pastoris 
recombinant was purified and used to immunise mice. The derived sera were tested by 
competition ELISA, Western blot analysis and TB membrane feeder assay.
M a t e r ia l s  a n d  m e t h o d s
R ationa le  o f the syn th e tic  gene pfs48/45s design. The design of the synthetic gene pfs48/45s was 
based on the amino acid sequence of Pfs48/45 from Plasmodium falciparum isolate NF54 and had the following 
strategy. First, the amino acid sequence of Pfs48/45 (Kocken et al., 1993) was reverse translated into a
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degenerated DNA sequence. Second, the codon usage in the resulting gene was modified to include those 
triplets that are utilised in highly expressed E. coli, S. cerevisiae and human genes (Nucleic Acids Research, vol.
18 suppl., pages 2401-2403), while retaining the largest possible number of unique restriction enzyme cleavage 
sites. Third, seven putative N-glycosylation sites were eliminated by substituting asparagine codons by glutamine 
codons. The rationale for this substitution were observations in previous studies that indicated that native 
Pfs48/45 does not contain N-linked glycans (Milek et al., 1998b). Fourth, the Kozak sequence CCACC for optimal 
initiation of translation (Kozak, 1989) was placed immediately before the translation initiation codon ATG. Finally, 
5' and 3' sequences were added, in order to enable versatile cloning of the gene in pro- and eukaryotic 
expression vectors. The sequence of the gene pfs48/45s is depicted in figure 2.
C o n s tru c tio n  o f the syn th e tic  gene pfs48/45s. The procedure for the construction of gene pfs48/45s was 
adapted from Majumder et al. (1992). PCR reactions were carried out in a volume of 50 pl, containing 20 mM 
Tris-HCl, pH 8.2, 10 mM KCl, 6 mM (NH4)2SO4, 2 mM MgSQ , 0.1% Triton® X-100, 10 pg ml bovine serum 
albumin (BSA), 50 pM  each of the deoxyribonucleoside triphosphates (dNTPs) (deoxyadenosine-, 
deoxyguanosine-, deoxythymidine-, and deoxycytidine triphosphate), 0.5 pM  sense primer 1, 0.5 pM  antisense 
primer 2, 2.1 units (U) of native Pyrococcus furiosus (Pfu) DNA polymerase (Stratagene), 0.35 U of Thermus 
aquaticus (Taq) DNA polymerase (Eurogentec) and 0.1-250 ng of template DNA. A combination of Pfu and Taq 
polymerases were used to overcome the low processivity while retaining the highest possible fidelity [17]. One 
antisense oligonucleotide with a length of 17 nucleotides (nt), and 24 sense oligonucleotides with lengths of at 
most 80 nt (Fig. 2) and average overlaps of 18 nt and a calculated melting temperature [18] of at least 52°C on 
each site, were synthesised on a Gene Assembler Plus (Pharmacia Biotech, Roosendaal, The Netherlands) and 
were not further purified. Each PCR reaction was started at 94°C (hot start). Each PCR reaction consisted of 10 
cycles; 1 minute (min) at 94°C, 1 min at annealingtemperature [19], and 1.5 min at 72°C. The full-length PCR 
product of each intermediate step was recovered by agarose (NA grade, Pharmacia Biotech) gel electrophoresis 
and subsequent isolation to serve as template in the next reaction. The final PCR products were cloned in Smal 
digested pBluescript-KS+ (Ausubel et al., 1995). Four clones were used to re-assemble an errorfree gene. The 
final construct, pBS-pfs48/45s, was sequenced.
C ons truc tion  o f re com b in an t D N A . The procedures for the construction of recombinant DNA were 
essentially as described by Ausubel et al. (1995). All enzymes were from BRL unless stated otherwise. The 
pfs48/45(s)-genes were obtained from plasmids pBS-pfs48/45 (Milek et al., 1998) and pBS-pfs48/45s (vide 
supra). The S. cerevisiae episomal expression vectors were constructed out of plasmid pUR2730 (Verbakel, 
1991), which contains the 2 pm replication origin for autonomous replication in yeast, the yeast leu2 gene for 
selection of transformants, and the inducible Galactose-7 (Gal7) promoter. The P. pastoris integrative expression 
vectors were constructed from plasmids pHlL-D2 and pPlC9 (lnVitrogen). These plasmids contain sequences of 
the 5' and 3' ends of the alcohol oxidase 1 (AOX1) gene for homologous recombination into the AOX1 locus, a 
his4 gene for selection of transformants, and the very strong AOX1 promoter. pHIL-D2 does not contain a leader- 
sequence. pPlC9 contains the -MAT F leader enabling efficient secretion. Gene-expression is induced by 
growing of cells on medium containing methanol as sole carbon-source.
S. cerevisiae plasmids pUR-pfs48/45 and pUR-pfs48/45s, containing full-length genes encoding amino 
acids 1 through 448 of Pfs48/45, were constructed as follows. pBS-pfs48/45, pBS-pfs48/45s, and pUR2730 
(Verbakel, 1991) were digested with Sacl and Hindlll. The fragments were purified over agarose gel
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electrophoresis, and the vector-fragment was ligated to each gene-fragment with T4 DNA ligase.
P. pastoris plasmids pHIL-D2-pfs48/45s and pHIL-D2-pfs48/45sAA (see Fig. 3) were constructed by 
digesting pBS-pfs48/45s with EcoR1 and Not], or with EcoR1 and BamH1, respectively. pHIL-D2 was digested 
with EcoR1. Protruding ends in all fragments were made blunt-ended with Klenow polymerase. DNA fragments 
were purified via agarose gel electrophoresis, and vector fragment and insert were ligated with T4 DNA ligase.
P. pastoris plasmid pPIC9-pfs48/45s-H (see Fig. 3) was constructed as follows. The corresponding nucleic 
acid sequence of pfs48/45s was PCR amplified from plasmid pBS-pfs48/45s, with a 5:1 mixture of Taq-DNA 
polymerase (Eurogentec) and Pfu-DNA polymerase (Stratagene) and the 5' sense primer 5'- 
GTATCTCTCGAGAAAAGAGAGGGAAACAACGACTTCTGCAAG-3' and the 3' antisense primer 5'- 
GGAATTCGCATGCAAGCTTAATGGTGATGGTGATGGTGGTCAATGGTCACCGTCATATATG-3'. Following 
amplification both the PCR-product and the vector pPIC9 were digested with XhoI and EcoRI, purified by agarose 
gel electrophoresis and ligated with T4 DNA ligase.
The nucleic acid sequences were verified for errors by sequence analysis.
S tra in s  and m edia. The following strains were used: S. cerevisiae SU10 (a , leu2-, ura3-, his4-, cir+) 
(Verbakel, 1991), and the P. pastoris strains GS115 (his4-) and SMD1168 (pep4-, his4-) (InVitrogen; White et al., 
1994). Media used were Minimal Yeast (MY) (Zonneveld, 1986), and the media YPG (1% yeast-extract, 2% 
pepton, 2% galactose), YPD (1% yeast-extract, 2% pepton, 2% dextrose), Minimal Dextrose- or Methanol 
Medium (MD or MM), Buffered Minimal Glycerol- or Methanol-complex Medium (BMGY or BMMY), Minimal 
G lycerol- or Methanol Medium (MGY or MMY), prepared as described in the Pichia expression instruction 
manual of the manufacturer (InVitrogen®).
T rans fo rm a tion  o f yeasts. S. cerevisiae vectors were transformed to the S. cerevisiae SU10 strain by 
electroporation (Ausubel et al., 1995). Transformation was confirmed by Southern blot analyses and by the 
characterisation of plasmids isolated from E. co licells that were transformed with DNA isolated from yeast-cells. 
P. pastoris vectors were transformed to spheroplasts of the GS115 and SMD1168 strains of the methylotrophic 
yeast Pichia pastoris according to the manufacturer's instructions (InVitrogen). Transformation was confirmed by 
PCR on DNA isolated from transformants.
Propagation, induction and metabolic labelling of S. cerevisiae clones. SU10 recombinants were 
grown in MY medium supplemented with L-histidine (20 j g  ml-1) and uracil (20 j g  ml-1) (MY-HU) for 40 hours (h) 
at 30°C. Cells were washed twice with water (MilliQ), resuspended in YPG medium, diluted 10 times, and grown 
in YPG medium for 40 h at 30°C, unless stated otherwise. Alternatively, cells were metabolically labelled with 
(35S)methionine/cysteine as described elsewhere (Harlow et al. 1988).
Culturing and induction of P. pastoris  strains. The recombinant GS115 and SMD1168 strains with 
disrupted AOX1 gene (Muts phenotype) were propagated for 2 days in either 10 ml or 200 ml of BMGY medium. 
Next, cells were pelleted and resuspended in BMMY medium to an Optical Density at 600 nm (OD600) of 10 and 
grown for the times stated in either 50 ml tubes (falcon) or in baffled 500 ml flasks. Alternatively, recombinants 
with non-disrupted AOX1 gene (Mut* phenotype) were grown for 2 days in 10 ml of BMGY medium and 
resuspended in BMMY medium to an OD600 of 0.5. Every 24 h methanol was added to an apparent concentration 
of 0.5%.
N orthe rn  b lo ttin g . Northern blotting was according to standard procedures (Ausubel et al., 1995). Total 
RNA was isolated from yeast cultures as described elsewhere (Schmitt et al., 1990). Northern blots were
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hybridised at 45°C in 50% formamide, 20 mM NaPi, pH 6.8, 1 mM Na4P2O7, 5xSSC (0.75 M NaCl, 0.75 M 
trisodium citrate),1 x Denhardt's (5 mM EDTA, 0.02% each of Ficoll, polyvinylpyrrolidone and bovine serum 
albumin), 0.1 mg ml-1 herring sperm DNA, 0.5% SDS, and washed in 0.1 x SSC, 0.1% SDS at 55°C.
Polyclonal and monoclonal antibodies. K96 and K57 are Pfs48/45-specific polyclonal antisera (Milek et 
al., 1998a). RB2 and RD2 are rat polyclonal antibodies derived from rats immunised with Pfs48/45-specific pools 
of five consecutive peptides (Dr. Jung) that were 20 amino acid residues long and overlapped in sequence with 
five residues, and comprised either amino acids 91 through 185 (RB2) or amino acids 256 through 350 (RD2). 
32F1, 32F3 and 32F61 are monoclonal antibodies (mAbs) specific for the discontinuous epitopes I and IIb of 
Pfs48/45 and I of Pfs25, respectively (Vermeulen et al., 1985). mAbs 32F3 and 32F61 have shown to block the 
transmission of P. falciparum (Vermeulen et al., 1985).
Protein-isolation and immunoprecipitation. For the isolation of cytoplasmic proteins, cells were grown for 
two days, and gene-expression was induced, as described. After 48 h 1.5 ml of a cell-culture was pelleted, 
washed, and resuspended in 200 j l  of ice-cold breaking-buffer (50 mM NaPi, pH 7.4, 1 mM EDTA, 5% glycerol, 
1 mM PMSF). Cells were broken mechanically with an equal volume of acid-washed glass-beads (425-600 jm )  
(Sigma) (Ausubel et al,. 1995). To 100 j l  of the supernatant an equal volume of Laemmli sample buffer (LSB) 
(Milek et al., 1998b) containing 5% 13-mercaptoethanol, was added. The remaining cellpellet was dissolved in 200 
j l  of LSB. Samples were heated for 5 min at 96°C, and 20 j l  of both samples were analysed by sodium- 
dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (Ausubel et al., 1995). For 
immunoprecipitation studies 150 j l  of the supernatant, obtained after centrifugation of glass-bead broken cells, 
was subsequently diluted in immunoprecipitationbuffer (20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM EDTA,
0.5% NP40, 0.1% DOC, 0.1% SDS) containing 1x protease inhibitors (Complete™, Boehringer Mannheim), to a 
final volume of 1 ml. Immunoprecipiations were performed as described elsewhere (Milek et al., 1998b).
P rote in concen tra tion , a ff in ity  pu rifica tion , and im m unisa tion . For rough detection purposes proteins in 
the culture-medium were concentrated by tri-chloro-acetic acid (TCA) precipitation (Mahuran et al., 1983). For the 
detection of recombinant proteins with mAbs, proteins were concentrated by microcentrifugation in a microsep™ 
f i l t r o n  concentrator (cutoff 10k). For immunisation-purposes 1 litre of induced culture-medium was dialysed 
overnight against phosphate buffered saline (PBS), pH 7.4, after which Tween®-20, NaCl and imidazole were 
added to concentrations of 0.5%, 800 mM, and 12 mM, respectively. Also, the pH was increased with NaOH to a 
value of 7.8. Recombinant protein was purified batchwise by the addition of 5 ml of PBS pre-washed Nickel 
chelated Nitrolo-tri-acetic acid (Ni-NTA) Superflow resin (Qiagen) followed by an incubation for 1 h at 4°C. Next, 
the resin was packed into a column and rinsed with one column volume each of a solution of 12 and 25 mM 
imidazole in PBS, 0.5% Tween-20. The recombinant protein was eluted with two column volumes of 100 mM 
imidazole in PBS. Next the protein sample was concentrated by microcentrifugation in a microsep™ FILTRON 
concentrator (cutoff 10k) at 6000 x g  and 10°C. Subsequently, the sample was dialysed extensively overnight 
against PBS at 4°C. For immunisation purposes, Quil A (Dalsgaard et al., 1978) was added to the concentrate to 
a final concentration of 50 j g  ml-1. Two female 6-8 week old Balb/c mice were immunised intraperitoneally (i.p.) 
with 4 j g  of recombinant Pfs48/45 (rPfs48/45), and boosted twice with 2 j g  of rPfs48/45 in three week intervals. 
Sera were recovered three weeks after the last boost.
Gametocytes, Competition ELISA, Surface Immunofluorescence assay and Transmission-blocking 
assay. Gametocytes of P. falciparum were isolated as described by Vermeulen et al. (1986). Competitive binding
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experiments (Roeffen et a l, 1995a), surface immunofluorescence assays (SIFA) (Roeffen et a l, 1995b) and 
transmission-blocking assay (Ponnudurai et al., 1989) were performed as described elsewhere.
R e su lts
Expression of the natural gene pfs48/45 in S. cerevisiae. To obtain recombinant 
Pfs48/45 from the yeast S. cerevisiae, the entire natural gene pfs48/45 was cloned into a 
Gal7 promoter-controlled expression vector which was used previously for high-level 
production of guar -galactosidase (Verbakel, 1991). The plasmid designated pUR- 
pfs48/45 was transformed to S. cerevisiae. At 16, 40 and 70 h after gene-induction total 
RNA was isolated, total protein-extracts were prepared, and culture medium was isolated. It 
was not possible to detect any rPfs48/45 in culture medium or cellular extracts, either by 
Western blot analysis or by immuno-precipitation of metabolically labelled proteins and 
subsequent SDS-PAGE and fluorography analysis (data not shown). In contrast, guar a - 
galactosidase from pUR2730 control transformants was easily detected (data not shown). 
Northern blot analysis of RNA 
isolated from galactose- 
induced yeasts containing 
plasmid pUR-pfs48/45 
revealed the presence of two 
pfs48/45-specific RNAs with 
lengths of about 520 and 850 
nucleotides (nt) (Fig. 1A, lane 
2), instead of an expected 
messenger RNA (mRNA) of 
1400 nt. Further hybridisation 
analyses revealed that the 
two RNAs resulted from 
premature transcription 
termination (data not shown).
Gene synthesis. Since 
gene pfs48/45 is very AT-rich 
(75%) and since transcription 
termination in yeast is
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F ig .1 . Northern blot analysis with a pfs48/45-specific probe, after 
gene-induction of S. cerevisiae SU10 strains containing (A) either 
plasmid pUR2730 (lane 1) or pUR-pfs48/45 (lane 2) or (B) pUR2730 
(lane 1) or pUR-pfs48/45s (lane 2). Each lane was loaded with 10 j g  
total RNA.
B
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1146 1155 1164 1173 1182 1191 1200 1209 1218
CTG GAC TCC CAG ATC AAC ATT GGT GAC ATC GAG TAT TAC GAG GAC GCC GAA GGC GAC GAT AAG ATC AAA TTG TTT GGT ATC 
Leu Asp Ser Gln Ile Asn Ile Gly Asp Ile Glu Tyr Tyr Glu Asp Ala Glu Gly Asp Asp Lys Ile Lys Leu Phe Gly Ile
1227 1236 1245 1254 1263 1272 1281 1290 1299
GTG GGA TCC ATC CCT AAG ACT ACG TCC TTC ACT TGC ATC TGT AAG AAA GAC AAG AAG TCC GCA TAT ATG ACG GTG ACC ATT 
Val Gly Ser Ile Pro Lys Thr Thr Ser Phe Thr Cys Ile Cys Lys Lys Asp Lys Lys Ser Ala Tyr MET Thr Val Thr Ile
1308 1317 1326 1335 1344 1353 1362 1371 1381
GAC TCT GCA TAC TAT GGA TTC CTG GCC AAG ACA TTC ATC TTC CTG ATC GTC GCG ATT CTG CTT TAC ATC TAA GTCGACAAGC 
Asp Ser Ala Tyr Tyr Gly Phe Leu Ala Lys Thr Phe Ile Phe Leu Ile Val Ala Ile Leu Leu Tyr Ile .
1391 1401 1411
TTGCATGCCT CGAGGCGGCC GCTCTAGAGC 
, ccgccgg cgagctatcg
F ig . 2. Nucleotide and amino acid sequence of the synthetic gene pfs48/45s. Dotted and normal lines 
represent the 5' sense oligonucleotides used in the SES-PCR with the 3' antisense primer shown in italics.
cellular cellular 
excreted in soliible insoliible
MuP transformants DNA sequences encoding: msdiiim fraction fradim
AOX-1 leader core of Pfs48/45 GPI signal 
promoter
1 27 426 448
399
pHIL-D2-pfe48/45M ^  I I I
pPIC9- nfrW4.5s-H I I I  +
a-MAT F Hs-tag
-, no expression; +, ++, +++, relative levels of low expression of rPfs48/45. See text for details.
FIG. 3 . Schematic representation of constructs, and results of comparative expression studies with different 
pfs48/45s-specific P. pastoris clones.
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controlled by poorly defined AT-rich sequences (Romanos et al., 1991; 1992), an entirely 
artificial pfs48/45 gene was developed with an optimised codon-bias and high GC-content 
to prevent premature transcription termination. The gene (Fig. 2) was built by stepwise 
elongation of sequence PCR yielding pfs48/45s.
In our hands the error-rate of the Pfu and Taq DNA polymerase combination used to 
synthesise the synthetic gene was with 9-15 errors per clone similar to that of the use of 
Pfu-polymerase alone (9 x 10-3) (data not shown), but much higher than the error-rates 
reported for Pfu-polymerase in literature (i.e. 0.2 x 10-5) (Flaman et al., 1994). This 
discrepancy might be due to the larger number of PCR cycles, the (im)purity of template and 
primers (Hengen, 1995) or the presence of errors in the oligonucleotides themselves 
(Engels, 1989).
Expression o f the gene pfs48/45s in Saccharomyces cerevisiae. The synthetic 
gene pfs48/45s was cloned into the same Gal7 promoter controlled expression vector that 
was used for expression of the natural gene in S. cerevisiae. Analysis of the RNA
synthesised after induction revealed that one RNA 
molecule with a length of approximately 2200 nt (Fig. 
1B, lane 2) was made as opposed to the two short RNA 
species synthesised from the natural gene (Fig. 1A, lane 
2). From these results it can be concluded that by 
redesigning the pfs48/45 gene, premature termination of 
transcription is circumvented. However, rPfs48/45 could 
not be detected in cells or culture-medium by Western 
blot analysis, immunoprecipitation of metabolically 
labelled proteins and subsequent SDS-PAGE and 
fluorography analysis, or SIFA (data not shown).
Expression o f pfs48/45s in Pichia pastoris. 
Because expression of recombinant proteins can be 
highly strain- and species-specific (Romanos et al., 
1992), gene pfs48/45s was also expressed in the 
methylotrophic yeast P. pastoris. Three different 
constructs were prepared (Fig. 3), and stable 
recombinants (30% Muts) were obtained in strains 
GS115 and SMD1168.
First, RNA was isolated from induced and non­
1 2  1 3  4
kB
4.4 -
2.4 -
1.4 -
0.24
FIG. 4.Northern blot analysis 48 h 
after gene-induction of P. pastoris 
pPIC9-VPF121 (lanes 1 and 3) or 
pPIC9-pfs48/45s-H (lanes 2 and 4) 
transformants. Lanes 1 and 2 were 
hybridised with a pfs48/45s-specific 
probe, and lanes 3 and 4 with a 
VPF121-specific probe. Each lane 
was loaded with 10 j g  total RNA.
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induced pPIC9-pfs48/45s-H or control pPIC9-VPF121 (Potgens, 1995) recombinants. 
Northern blot analysis revealed that in pfs48/45-recombinants a pfs48/45s-specific RNA is 
made with a length of about 1.9 kb (Fig. 4, lane 2). The RNA is equally abundant as VPF121 
mRNA (compare Fig. 4 lanes 2 and 3).
Next, culture-medium and cell-extracts of pPIC9-pfs48/45s-H, pHIL-D2-pfs48/45s and 
pHIL-D2-pfs48/45s-AA recombinant yeasts were subjected to Western blot analysis. Low 
level production of recombinant proteins could now be demonstrated in each recombinant 
analysed (Fig. 3). High-level production was observed in control pPIC9-VPF121 
recombinants (data not shown). Figure 5 (part A, lanes 1 to 10) shows the Western blot 
analysis of TCA precipitated proteins from 1 ml culture medium of pPIC9-pfs48/45s-H 
recombinants. rPfs48/45 with a relative molecular weight (Mr) of 58 kDa and comigrating to 
native Pfs48/45 (lane 11) could be detected with the Pfs48/45-specific antisera K96, rB2, 
rD2 (lanes 3, 6, 8) and with the His-tag-specific antiserum K36 (lane 10) but not with their 
pre-immunesera (lanes 2, 5, 7 and 9). The nature of the Pfs48/45-specific band with a Mr of 
approximately 40 kDa, visible in lanes 3 and 8, was not further elucidated. Since in lane 11 
a protein-extract derived from 0.5 x 106 gametocytes containing approximately 70 ng 
Pfs48/45 (Kocken et al., 1993) was loaded, and the bands in lanes 11 and 3 are equal in 
intensity, the amount of recombinant proteins found to be secreted was estimated on 70 jg  
l-1.
Under non-reducing conditions the apparent molecular weight of the recombinant 
protein is significantly different from that measured under reducing conditions (compare Fig. 
5B lane 3 to Fig. 5A, lane 3, 6, 8, 10). Western blot analysis revealed three Pfs48/45- 
specific broad bands of which one, a band of about 40-50 kDa (Fig. 5B, lane 3) comigrated 
to native Pfs48/45 (Fig. 5B, lane 1). This phenomenon might reflect various inter- and 
intramolecular disulphide bonds in rPfs48/45 leading to multiple (conformational) species. 
Recognition of rPfs48/45 with the Pfs48/45-specific and conformation-dependent mAbs 
32F3 and F45.3 could, however, not be demonstrated (data not shown). Thus, the 
conformation of the recombinant protein as produced by P. pastoris seems constrained by 
disulphide bonds but is, at least for the larger part, not identical to that of the native protein 
as present in gametocytes of P. falciparum.
Efforts to increase expression levels of several SMD1168 and GS115 recombinants or 
to find high-expression clonal variants by colony blot analysis (Kocken et al., 1996) were 
unsuccessful (data not shown). It was next examined whether the low expression levels 
could be due to an impaired secretion process; therefore, intracellular proteins were
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F ig . 5 Western blot analysis on proteins present in culture medium of P. pastoris transformants 48 h after 
gene-induction. SDS-PAGE under (A) reducing conditions or (B) non-reducing conditions. Lanes were 
stained with (A) a-Pfs48/45 rabbit immuneserum K96, a-Pfs48/45 rat immuneserum rB2, a-Pfs48/45 rat 
immuneserum rD2 , histidine-specific rabbit immuneserum K36 (a-H is), rabbit pre-immuneserum, and rat 
pre-immuneserum, as indicated in the figure, or with (B) K96. Lanes A11 and B1 contained 0.5 x 106 
gametocyte equivalents.
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subjected to Western blot analysis. The presence of rPfs48/45 could be detected with the 
antiserum K96; it was found to be present both in the water-soluble and water-insoluble 
phase (Fig. 6). Apart from a recombinant protein with an Mr of approximately 58 kDa also a 
protein with a Mr of approximately 70 kDa was detected. Because of its molecular weight 
this protein may be the non-processed form of the pre-protein, containing next to the 
Pfs48/45 sequence the a-MAT F leader of 11 kDa. Since the relative intensity of the protein 
band of 70 kDa compared to the band of 58 kDa is about 20 times lower, the clipping of the 
signal-sequence occurs reasonably efficiently. From the intensities of recombinant protein 
compared to native protein it was estimated that approximately 70 ng recombinant protein is 
present in one lane containing 50-100 pg total protein, hence, implicating an expression 
efficiency of 1%o. These levels of protein expression are extremely low, especially since 
AOX1 expression levels are typically >30% of the total soluble protein in cells grown with 
methanol as the carbon 
source (InVitrogen). Similar 
data were obtained with the 
pHIL-D2-pfs48/45(AA) re­
combinant yeasts, although 
the expression levels in the 
water-insoluble phase 
seemed somewhat higher 
(Fig. 3).
Protein purification 
and immunisation.
Although reaction with 
the TB mAb 32F3 could not 
be demonstrated, possibly 
other TB epitopes, for 
instance the linear epitope 
V (Targett et al., 1990), 
might be present in the 
protein preparation. There­
fore, the recombinant 
protein was tested for its 
ability to induce TB antisera
water- cell-
soluble pellet
I---1 I 1
pPIC9-p/s48/45sH i= >  - +  - +
117 -
kD 80 -
50 “
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Pfs48/45
1 2 3 4 5
F ig . 6 . Western blot analysis on cellular proteins of gene-induced P. 
pastoris transformants of plasmids pPIC9-p/s48/45-H (lanes 2 and 4) 
or pPIC9 (lanes 1 and 3) after SDS-PAGE under reducing conditions. 
Lanes were stained with rabbit immuneserum K96. Lanes 1 and 2 
were loaded with solubilised proteins. Lanes 3 and 4 were loaded with 
proteins remaining in the cell-pellet. Lane 5 was loaded with 0.5 x 106 
gametocyte equivalents.
(NB This figure was not presented in the published version.)
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in mice. rPfs48/45 was purified from culture-medium of pPIC9-pfs48/45s-H recombinants by 
Ni-NTA affinity chromatography. Mice were immunised and boosted twice. The sera 
obtained after the last boost specifically recognised native Pfs48/45 on Western blots, both 
under reducing and under non-reducing conditions. However, the sera did neither recognise 
gametes in a SIFA, nor were able to block transmission as assessed in a membrane feeder 
assay, nor competed with the mAbs 32F1 and 32F3 in a competition ELISA (data not 
shown).
D is c u s s io n
In this study we describe that transcription of the natural gene encoding Pfs48/45 is 
terminated prematurely in the yeast S. cerevisiae. Therefore, a synthetic gene with higher 
GC content was assembled. Upon induction of synthetic gene expression in the yeasts S. 
cerevisiae and P. pastoris full-length messenger RNAs were indeed produced. However, 
rPfs48/45 was detected only in P. pastoris at very low levels. Though secreted recombinant 
product was disulphide-bridge constrained, unfortunately, it was not recognised by mAbs 
specific for conformation-constrained epitopes of Pfs48/45 and did not induce TB sera in 
mice.
It may seem strange that recombinant protein could not be detected in S. cerevisiae 
transformants of plasmid pUR-pfs48/45s. However, S. cerevisiae recombinants generally 
produce 10-100 times less recombinant protein than P. pastoris recombinants when 
examining gene-expression of identical genes (Romanos et al., 1992), and expression- 
levels in P. pastoris were already extremely low. Furthermore, in S. cerevisiae only 
expression of the full-length gene was examined; protein expression levels in P. pastoris 
recombinants containing the full-length gene pfs48/45s were significantly lower than in 
recombinants containing the genes pfs48/45sAA or a-MAT F-pfs48/45s-H. Additionally, the 
strain SU10 might have been suboptimal for the expression of Pfs48/45 (Romanos et al., 
1992).
The low protein-expression levels obtained in P. pastoris may be due to low levels of 
transcription. Northern blots analysis demonstrated, however, that pfs48/45s-specific mRNA 
levels were present in equal abundancy as VPF121 RNA, isolated from a clone producing 
large amounts of VPF121. Poor translation-initiation is also not likely since the mRNA fulfilled 
the requirements for efficient translation-initiation; an A at -3 relative to the initiation site 
(Steven and Sherman, 1988), and 5' nontranslated regions being long enough to support
114
Assembly and expression of a synthetic gene encoding Pfs48/45 in yeast
the annealing of the 40S translation-initiation complex (Francis, 1993), i.e. 32 nt and 198 nt 
for pUR-pfs48/45s and pHIL-D2-pfs48/45s, respectively. A possible reason for low initiation 
efficiencies could be the formation of stable hairpins in the 5' nontranslated region (Oliveira 
et al, 1993). However, the stabilities of putative secondary hairpin structures in the 
synthetic 5' nontranslated region of the pfs48/45s-specific RNAs are much lower than that in 
the a-MAT F 5' nontranslated region which has been used successfully for the production of 
several proteins (Romanos et al., 1992). Furthermore, substantial differences between 
recombinant antigen expression levels were not detected in strains where translation was 
started on the pfs48/45s transcript of pHIL-D2 recombinants or on the a-MAT F-pfs48/45s- 
H transcript of pPIC9 recombinants. The translation efficiency may be influenced by the 
availability of tRNA subsets. S. cerevisiae uses predominantly 25 out of the 61 possible 
codons (Bennetzen and Hall, 1981), and the restricted use of only these preferred codons 
might improve expression-levels. The gene contains also non-preferred codons in order to 
facilitate synthesis in E. coli and higher eukaryotic cells, but all tRNA subsets necessary are 
present in yeast. Theoretically, there might also be a difference in the available tRNA 
subsets in P. pastoris when compared to S. cerevisiae, but specific information on this 
subject is not available.
The most likely explanation for the low levels of rPfs48/45 as demonstrated in the 
medium of P. pastoris recombinants is related to folding and transport. Several observations 
suggest that rPfs48/45 is folded incorrectly: (/) When analysing purified rPfs48/45-H under 
non-reducing conditions smears were observed. (i/) When analysing cellular Pfs48/45- 
specific proteins under non-reducing conditions large protein aggregates were detected. (i/i) 
Recombinant protein was relatively abundant in the water insoluble fraction. (iV) 
Recombinant proteins did not or only very poorly react with mAbs specific for conformational 
epitopes of Pfs48/45. Expression of cysteine-rich foreign proteins in yeasts often results in 
the production of cytoplasmic rather than secreted proteins, and in the formation of 
abnormal - and even intermolecular - disulphide-bonds (Chang, 1994; Weisz et al, 1993). 
Whether expression of truncated genes encoding rPfs48/45-fragments leads to synthesis of 
proteins with intact epitope-domains of the antigen Pfs48/45 awaits further investigation.
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The main aim of the studies described in this thesis was to develop a malaria 
transmission-blocking (TB) vaccine based on the antigen Pfs48/45 of the human malaria 
parasite Plasmodium falciparum. Secondary goals were aimed at a better understanding of 
genetical and biochemical characteristics of the gene pfs48/45 and its encoding antigen.
Malaria belongs to the most severe infectious diseases throughout the tropics. The 
disease is transmitted by mosquitoes and is caused by parasitic protozoa of the genus 
Plasmodium (P.). The disease causes human misery and is a serious burden to the very 
often fragile economies in the tropical regions. Infection with P. falciparum may even be 
lethal. Although some decades ago disease was getting under control, these days the 
problem is worsening again with the spread of mosquitoes and parasites that are resistant 
to the currently available insecticides and (prophylactic) drugs. Therefore, the development 
of vaccines is highly recommended by the World Bank and World Health Organisation 
(Butler et al., 1997). The life cycle of the parasite is complex and involves several 
immunologically distinct developmental stages. During their development some parasites 
differentiate into sex-cells which, when ingested by a feeding mosquito, can fuse, form a 
zygote, and finally, form new parasitic spores that can be injected into a new human victim. 
Targeting of the sexual stages, therefore, offers a unique opportunity to control the spread 
of disease; when development of the parasite in the mosquito can be hampered, 
mosquitoes will not be able to transmit parasites to new human hosts. A TB vaccine would 
target the sexual stages. It would thereby act as a quarantine vaccine by limiting the spread 
of drug-resistant parasites, or of vaccine induced immunity resistant parasites. For several 
reasons one of the most promising vaccine candidate antigens of the sexual stages is the 
gametocyte/gamete antigen Pfs48/45; (1) Pfs48/45-specific monoclonal antibodies (mAbs) 
block transmission of the parasite to mosquitoes very effectively, (2) antibodies directed 
against Pfs48/45 can be found within antisera of people living in malarious areas, which 
implicates that natural infection can boost a vaccine induced immune response, (3) there is 
a positive correlation between presence of Pfs48/45-specific antibodies in sera and TB 
immunity and, (4) antigenic and immunogenic diversity of Pfs48/45 is very low, which is 
important since a vaccine should induce immunity to a variety of strains.
The antigen Pfs48/45 is a protein-doublet with molecular weights of 48- and 45 kDa, 
present on the membranes of gametocytes and gametes. The molecules are thought to play 
a role in the fertilisation process itself, which takes place in the mosquito midgut. Six 
different B-cell epitopes have been characterised, i.e. epitopes I, IIb, IIa/IIc, III, IV and V.
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Epitopes I through IV are constrained by disulphide bonds. Epitopes I, IIa/IIc, III and V react 
with TB mAbs, but epitope I is probably the most important epitope for the induction of TB 
immunity. The primary translation product consists of 448 amino acid residues. The 
hydrophobic N- and C-termini are putative signals for translocation through the endoplasmic 
reticulum (ER) membrane, secretion, and addition of a glycosylphosphatidyl-inositol (GPI) 
moiety. Furthermore, the primary translation product contains seven putative N- 
glycosylation signals.
Chapter 3 is entirely based on the genetic variation of gene pfs48/45. In chapter 3a is 
described how seven in vitro cultivated P. falciparum strains collected from various 
geographic areas were subjected to entire or partial sequence analysis and to single-strand 
conformation polymorphism analysis. It was shown that the antigenic diversity is 
exceedingly low, with only five nucleic acid substitutions in all the genes analysed. Since all 
strains with a lysine residue on position 254 had been shown to have the phenotype IIa+/IIc-, 
and all others (with a asparagine residue) had phenotype IIa-/IIc+ it could be concluded that 
epitope IIa/IIc must be localised around amino acid residue 254. In chapter 3b the analysis 
of the pfs48/45-homologue of the chimpanzee malaria parasite P. reichenowi is described. 
P. reichenowi is the to P. falciparum most closely related Plasmodium species. It was shown 
that also in this case the antigenic diversity is low. Only 28 nucleotides were found to be 
different between genes pfs48/45 (NF54) and prs48/45. In these 28 observed substitutions 
13 were silent and five were conservative. Furthermore, it was shown that the cysteine at 
position 32 of Pfs48/45 is absent in Prs48/45. Since Prs48/45 can still react with a Pfs48/45 
epitope Ia-specific mAb, the cysteine at this position is, therefore, not involved in the folding 
of epitope Ia.
In order to develop a TB vaccine based on a recombinant form of Pfs48/45, it is 
important that the recombinant antigen is folded like the native antigen Pfs48/45, i.e. it must 
contain the epitopes that are involved in inducing TB antibodies. Since, on forehand, it can 
not be predicted in which expression system recombinant antigen with the desired 
characteristics can be produced, gene pfs48/45 was expressed in several systems, 
including Escherichia (E.) col, mammalian and insect cells, and yeasts.
The heterologous synthesis of gene pfs48/45 in the prokaryotic expression system of E. 
coli is described in chapter 4. This system was of first choice out of practical considerations;
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it is extremely cheap, cells grow fast, and are easy to manipulate. It may have the 
disadvantage of producing primarily linear proteins while epitopes I though III of Pfs48/45 
are conformational in character, but mAbs directed against the linear epitope V had also be 
shown to be able to block transmission (Targett et al., 1990). Furthermore, the expression 
system has shown to be able to produce (malarial) conformation constrained proteins, f.i. 
the merozoite surface protein MSP (Ling et al., 1994; Burghaus and Holder, 1994).
It was demonstrated that recombinant proteins could be produced only when the highly 
hydrophobic N- and C-terminal ends of the primary protein were omitted from the 
recombinant product. Several recombinant proteins could be produced successfully. Among 
them were rPfs48/45(56-401) and rGST-Pfs48/45(56-401), both containing amino acid 
residues 56 through 401 of Pfs48/45, and in the latter case in fusion with glutathione-S- 
transferase (GST). Recombinant proteins were found only in the insoluble fraction, i.e. in 
inclusion bodies. Furthermore, from SDS-PAGE analysis it was concluded that they seemed 
not disulphide-bridge constrained. However, when analysed by ELISA it was shown that 
rGST-Pfs48/45(56-401) reacted with two, and rPfs48/45(56-401) with nine different 
Pfs48/45-specific mAbs. Therefore, at least a fraction of the recombinant proteins possess a 
native-like structure. Nevertheless, though the recombinant proteins proved to be 
immunogenic, immunisation of mice and rabbits did not lead to the induction of TB 
immunity. We concluded that stabilisation of the folded structures by disulphide-bonds is 
indeed highly warranted. This might be achieved even by using recombinant proteins from 
the E. coli expression system, i.e. by (1) refolding of non-disulphide bridge constrained 
(denatured) recombinant proteins in oxidizing environments, (2) secretion of recombinant 
proteins to the oxidizing environment of the periplasm of the prokaryote, or (3) synthesis in 
prokaryotes capable to produce to a higher degree intracytoplasmical disulphide-bonds. 
Until now, all these methods have failed; (1) Refolding did not result in stable protein 
preparations (non-published data). (2) Secretion of recombinant truncated forms was 
assessed f.i. by cloning (parts) of the natural or synthetic gene pfs48/45(s) after the omp- 
signal sequence of the periplasmic E. coli protein ompA3 (Ghrayeb et al., 1984). It was 
shown that most of the recombinant antigen remained intracellularly. Reaction of 
periplasmic proteins with mAbs specific for conformation constrained epitopes could not be 
demonstrated (non-published data). (3) Furthermore, it was assessed whether synthesis of 
disulphide-bridge constrained recombinant proteins in E. coli was possible by expressing 
rGST-Pfs48/45(56-401) in a thioredoxin reductase deficient strain. Deficiency of this enzyme 
had shown to lead to formation of disulphide-bonds in several recombinant proteins
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(Derman et al., 1993). Also this strategy was not successful, possibly because rPfs48/45 is 
aggregating into inclusion-bodies (unpublished data).
A more comprehensive vaccination analysis with recombinant E. coli derived products 
revealed interesting views. It was shown that the immunological recognition of Pfs48/45 is 
not restricted in mice and that the immune response can be boosted with gametocyte- 
extracts. This observation is of high importance since it implies that natural infection not only 
leads to non immuneresponsiveness gene restricted responses, but also that boosting of 
vaccine induced immunereactions are achievable by natural infection. Whether boosting of 
reactivity against TB epitopes is also possible remains to be determined. Furthermore, it 
was shown that the adjuvants used for immunisation may be an important factor for the 
reaction that is obtained. rPfs48/45(56-401) emulsified in Freund's complete and incomplete 
adjuvants, Quil A, Hunter's Titermax™#R1, and a combination of block copolymer P1005 
with detoxified lipopolysaccharides in squalene, were used to immunise mice and rabbits. 
Quantitatively, in mice Quil A and in rabbits Freund's adjuvants was most effective in 
producing high antibody titres against rPfs48/45. Qualitatively, no major differences were 
noted between the reactions induced with rPfs48/45(56-401) emulsified in these different 
adjuvants; no immunoglobulin G subclass switch was induced, and none of the schemes 
lead to induction of TB antibodies.
Since the reaction of TB mAbs directed against epitopes I through III of Pfs48/45 is 
dependent on the presence of disulphide-bonds, many efforts were put in the heterologous 
synthesis of recombinant Pfs48/45 (rPfs48/45) in several eukaryotic expression systems 
(chapters 5 and 6). In eukaryotic expression systems, translocation of a protein through the 
membranes of the endoplasmic reticulum (ER) enables oxidation of cysteines and, hence, 
the formation of disulphide-bonds. Furthermore, since P. falciparum is itself a eukaryotic 
organism, and other eukaryotic-specific posttranslational modifications might be essential 
for the formation of epitopes that can react with TB antibodies, expression of rPfs48/45 in 
eukaryotic expression systems is more likely to produce a recombinant protein that is folded 
like the native antigen.
Gene pfs48/45 was expressed in higher eukaryotic cells of several origins with aid of a 
pfs48/45-specific recombinant vaccinia virus (rVV-pfs48/45) (chapter 5), a pfs48/45-specific 
recombinant baculovirus (rBV-pfs48/45) and a pfs48/45(s)-specific DNA vaccine 
(unpublished data).
121
Chapter 7a
The rVV was not only used for the synthesis and study of the characteristics of 
recombinant protein in several cell-lines, but also as a live vaccine for direct immunisations 
of mice and rabbits. In tissue culture dishes, infection of mammalian cells with the rVV- 
pfs48/45 lead to synthesis of rPfs48/45 (chapter 5). It was shown that rPfs48/45 expressed 
from gene pfs48/45 is highly N-glycosylated, and that rPfs48/45 can also be labelled with 
3H-ethanolamine indicating addition of a GPI anchor to the primary translation product. 
However, rPfs48/45 did not react with conformational epitopes I and II-specific mAbs. It was 
shown by confocal laser scanning microscopy and endoglycosidase H treatment of pulse- 
chase labelled proteins that rPfs48/45 is not transported to the outer surface of the cells, but 
is, instead, retained in the ER. Immunisations of mice and rabbits with the rVV expressing 
gene pfs48/45 lead to Pfs48/45-specific immunesera. However, these sera did not contain 
antibodies that are directed against conformational epitopes of Pfs48/45, nor did they block 
transmission of the parasite in an in vitro membrane feeder assay.
With aid of a rBV rPfs48/45 could be produced in insectcells at a very low scale 
(Kocken et al., 1993). Similar to rPfs48/45 produced by the rVV, the synthesised antigen 
was highly N-glycosylated (Kocken and Milek, non-published data). Immunoprecipations 
with mAbs of metabolically labelled proteins were, similar to the rVV-pfs48/45 produced 
recombinant antigens, not possible (Milek et al., unpublished data). To date it is, however, 
unclear whether transport of protein to the outer surface of the cells takes place. Initial 
results obtained by immunofluorescence assays and confocal laser scanning microscopy 
indicated that a subfraction of rPfs48/45 is located on the outer surface of the cells and 
reacted specifically with the epitope I-specific TB mAb 32F5 (Kocken et al., 1993). However, 
later experiments with other batches of mAbs could not confirm these observations (Milek et 
al., non-published data). (For this reason the data obtained with the rBV were not 
incorporated into this thesis). To study the immunogenicity and antigenicity of the rBV- 
produced rPfs48/45, mice were immunised with crude insectcell-extracts containing 
rPfs48/45. Sera obtained did not recognise native Pfs48/45. Possibly, large-scale 
purification of rPfs48/45 from either insectcells grown in bioreactors or from live (infected) 
larvae (O' Reilly et al., 1992) may lead to the induction of Pfs48/45-specific immunesera 
with TB characteristics.
Gene pfs48/45, and a synthetic variant pfs48/45s (vide supra), was also cloned into the 
DNA vector nkCMVint (Sedegah et al., 1994) for direct expression and immunisation of 
eukaryotic cells. IFAs with Pfs48/45-specific antibodies on nkCMVint-pfs48/45s transfected 
cells showed strong and specific fluorescence (data not presented). Direct immunisations
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with 50 pg DNA in both tibialis anterior muscles of Balb/c mice of this nucleic acid vaccine 
and a variant in which the GPI-anchoring sequence of pfs48/45s was omitted did, however, 
not induce Pfs48/45-specific antibodies. Neither pre-treatment of the immunisation-site with 
sucrose (Davis et al., 1993) nor i.p. co-immunisation during five days (from day -1 to +3) 
with 0.1 pg recombinant interleukin 12, a stimulator of humoral responses (Schijns et al., 
1995), did enable induction of Pfs48/45-specific antisera (data not presented).
A very viable alternative for production of rPfs48/45 in mammalian- and insectcells is 
the production of rPfs48/45 in the lower eukaryote yeast. Yeasts are safe, easy to 
manipulate, and their cultivation is inexpensive and can easily be scaled up. All these 
characteristics are important for a vaccine to be used in a global vaccination program 
(Bathurst et al., 1994). Initial experiments in the yeast Saccharomyces cerevisiae showed 
that expression of gene pfs48/45 was not successful due to early transcription termination in 
the very AT-rich gene (chapter 6). Since this AT-richness had also caused problems in 
cloning, and since the codon usage of P. falciparum differs from that in mammalian cells, 
yeasts, and E. coli, it was decided to assemble an entirely synthetic gene with higher GC- 
content and optimised codon-usage. The method of choice was stepwise elongation of 
sequence PCR. This synthetic gene was used for the expression in yeast. It was shown that 
the early transcription termination as observed with the natural gene did not occur during 
expression of this synthetic gene variant. However, recombinant protein expression could 
still not be detected. In contrast, in the yeast Pichia pastoris low levels of rPfs48/45 were 
produced after induction of synthetic gene expression. Most of the recombinant protein 
remained intracellularly, but secreted recombinant protein was shown to be disulphide- 
bridge constrained. However, it was not recognised by TB mAbs and did not induce TB sera 
in mice.
In all expression systems tested, the levels of protein production were very low, 
recombinant proteins did not react with conformation-specific mAbs, and did not induce 
antisera with TB characteristics. Furthermore, in the prokaryotic expression system 
rPfs48/45 was present in the insoluble protein fraction, in the yeast expression system a 
high fraction of rPfs48/45 was present in the insoluble fraction, and also in mammalian cells 
much of the rPfs48/45 seemed to be present in aggregated forms in the cell. It was also 
noticed that soluble protein-preparations of E. coli products were not very stable and tended 
to aggregate during storage. Therefore, it seems valid to propose that the intrinsic
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aggregating characteristics of the Pfs48/45 antigen are the major cause for the poor results 
obtained in all these systems.
One option to circumvent proper folding and transport of recombinant Pfs48/45 is 
heterologous expression in a more homologous setting, i.e. in Plasmodium parasites. It is 
known that there exist subtle differences in the organisation of folding-, secretion, and 
modification pathways in distinct stages of Plasmodium parasites when compared to other 
cells (Banting et al., 1995). Heterologous expression of rPfs48/45 in Plasmodium parasites 
is theoretically possible since transfection techniques have been developed for P. berghei 
(van Dijk et al., 1995) and P. falciparum (Crabb and Cowman, 1996). These transfection- 
techniques offer also the exciting possibility to create Pfs48/45-knock-out mutants in order 
to study the function of this protein.
For reasons explained below, an other way to circumvent the problems encountered in 
folding and transport of rPfs48/45 may be co-expression of Pfs48/45 with (parts of) Pfs230. 
It is known that oligomer assembly of proteins which are present in a complex is often 
essential for solubility and, hence, transport from the ER. It is also known that the final 
conformation of the proteins present in the complex may rely on co-expression (Hurtley and 
Helenius, 1989; Doms et al., 1993). Because in gametocytes Pfs48/45 forms a tight 
complex with Pfs230 (Kumar et al., 1992), and reconstitution of the complex is not possible 
once Pfs48/45 and Pfs230 are divided from each other (Kumar et al., 1985), it might well be 
that authentic Pfs48/45 and/or Pfs230 can only be produced when they are expressed 
together. Especially the VV expression system is suited well for such co-expression since 
the viruses can accommodate very large (foreign) DNA sequences. That characteristic is a 
prerequisite for expression of the entire gene pfs230. An alternative could be immunisation 
with a nucleic acid vaccine expressing both genes.
The outstanding advances in molecular biological techniques and the promising starting 
points for future research validate future funding and research aimed at the development of 
a safe and well-working TB vaccine based on Pfs48/45. The synthetic gene pfs48/45s will 
definitely facilitate this development.
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Hoofdstuk 7b
Deze samenvatting beoogt een algemeen beeld te geven van hetgeen er in dit 
proefschrift is beschreven. Voor een gedetailleerdere wetenschappelijke samenvatting 
wordt verwezen naar hoofdstuk 7a.
Malaria behoort tot de ernstigste infectieziekten van de Tropen. Meer dan de helft van 
de wereldbevolking leeft onder de dreiging van deze ziekte, en ieder jaar opnieuw lopen 
circa 500 miljoen mensen malaria op. Men schat dat alleen al in Afrika ieder jaar tussen de 
1,5 en 3 miljoen personen slachtoffer worden, veelal kinderen. Daarnaast heeft een zo 
grootschalig volksgezondheidsprobleem uiteraard ook gevolgen voor de vaak fragiele 
economieën in de landen rond de evenaar.
De ziekte wordt verspreid door muggen, maar wordt veroorzaakt door een eencellige 
parasiet van het genus Plasmodium (P.). Infectie met P. falciparum, een van de vier voor de 
mens infectieuze Plasmodium-soorten, is het gevaarlijkst. Hoewel de ziekte enige decennia 
geleden onder controle leek, breidt het probleem zich tegenwoordig weer snel uit. Dat komt 
onder andere doordat de muggen resistent werden tegen gebruikte insecticiden, en doordat 
parasieten resistent werden (en worden) tegen de gebruikte geneesmiddelen. De 
Wereldgezondheidsorganisatie (WHO) en de Wereldbank stimuleren daarom sterk de 
ontwikkeling van vaccins.
De levenscyclus van de malariaparasiet is bijzonder ingewikkeld. In een infectieuze 
mug ontwikkelen zich parasietensporen die tijdens een bloedmaal worden geïnjecteerd in 
de bloedbaan van een mens. Deze sporen verdwijnen snel in de lever, waar ze veranderen 
in leverparasieten die zich sterk vermenigvuldigen. Op een gegeven moment komen de 
parasieten weer vrij in de bloedbaan, en ook deze bloedparasieten vermenigvuldigen zich 
sterk. Tenslotte kunnen sommige bloedparasieten zich ontwikkelen tot geslachtscellen. 
Wanneer nu deze geslachtscellen tezamen met bloed worden opgezogen door een mug, 
kan versmelting en geslachtelijke voortplanting plaatsvinden en worden er weer 
parasietensporen gevormd. Al deze verschillende soorten malariaparasieten hebben 
volledig unieke eigenschappen. Om de kansen van effectiviteit van een malariavaccin te 
vergroten zal zo'n vaccin dan ook moeten bestaan uit verschillende componenten en zal 
deze gebaseerd moeten zijn op de verschillende stadia.
Dit proefschrift beschrijft studies die zich richtten op de ontwikkeling van een vaccin 
gebaseerd op een eiwit wat uitsluitend voorkomt op de buitenkant van gametocyten en 
gameten (de geslachtscellen) van de humane malariaparasiet Plasmodium falciparum-, het 
Pfs48/45-antigen. Doel was om (een stukje van) dit antigen via moleculair-biologische
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technieken op zo'n wijze te produceren, dat er na vaccinatie met het recombinante 
(kunstmatige) antigen antilichamen worden opgewekt die de geslachtelijke ontwikkeling en 
voortplanting van de parasiet in de mug kunnen blokkeren. Hierdoor zal de ziekte zich ook 
niet meer kunnen verspreiden en spreekt men dus van een transmissie-blokkerend (TB) 
vaccin. Dat deze benadering een zeer goede kans van slagen heeft, blijkt uit het feit dat 
natuurlijke TB antistoffen, gericht tegen Pfs48/45, circuleren bij mensen met parasieten in 
het bloed. Ook is er een directe relatie tussen de aanwezigheid van deze antilichamen en 
TB immuniteit. Bovendien blijkt de immunologische- en biochemische variatie van het 
antigen laag te zijn. Dat houdt in dat er weinig varianten zijn en een vaccin gebaseerd op 
slechts een van deze varianten zeer waarschijnlijk een goede effectiviteit heeft.
Het antigen Pfs48/45 bevat 6 verschillende B-celepitopen (de stukjes eiwit waartegen 
antilichamen zijn gericht). Epitoop I is waarschijnlijk het belangrijkst als het gaat om de 
inductie van TB immuniteit. Epitopen I, IIa/IIc, IIb, en III zijn voor hun vouwing afhankelijk 
van de vorming van disulfidebruggen (een stabiele versmelting tussen twee verschillende 
aminozuren, de bouwstenen van een eiwit).
Hoofdstuk 3 is geheel gewijd aan de genetische variatie van gen pfs48/45. In hoofdstuk 
3a wordt beschreven hoe weinig zeven verschillende P. falciparum-stammen (afkomstig uit 
Afrika, Azië en Zuid Amerika) van elkaar verschillen; ten opzichte van een referentiestam 
(NF54) werden er slechts vijf verschillende DNA-'mutaties' gevonden. Door deze gegevens 
te vergelijken met bekende immunologische data van deze stammen kon geconcludeerd 
worden dat aminozuurresidu 254 onderdeel moet uitmaken van epitoop IIa/IIb. In hoofdstuk 
3b wordt de analyse beschreven van de homoloog van het pfs48/45-gen van de 
chimpanseeparasiet P. reichenowi. Nu bleken er 28 DNA-veranderingen te zijn ten opzichte 
van de P. falciparum-referentie. Achttien hiervan leidden niet tot een (wezenlijk) andere 
eiwitsequentie. Het cysteïneresidue op positie 32 ontbreekt in Prs48/45. Toch reageren P. 
reichenowi gametocyten nog goed met een epitoop Ia-specifiek antilichaam. Hierdoor lijkt 
het uitgesloten dat cysteïne-32 betrokken is bij de vorming van epitoop Ia.
Voor de productie van een TB vaccin op basis van een recombinante vorm van het 
antigen Pfs48/45 (rPfs48/45) is het belangrijk dat de te maken recombinante vorm precies 
lijkt op het parasitaire eiwit. Alleen dan kan er een immuunrespons worden geïnduceerd die 
ook leidt tot de vorming van TB antilichamen. Aangezien niet van te voren kan worden 
bedacht welk biologisch productiesysteem een goed gelijkend eiwit kan produceren, werd
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het gen pfs48/45 in verschillende productiesystemen tot expressie gebracht.
De productie van recombinant eiwit in de bacterie Escherichia (E.) coli wordt 
beschreven in hoofdstuk 4. Er werd gekozen voor E. coli doordat het een simpel organisme 
is waar veel over bekend is, zodat aanpassingen die men door wil voeren in principe snel 
en gemakkelijk kunnen worden gerealiseerd. Bovendien is de succesvolle synthese van 
disulfidebrug bevattende malaria-antigenen in E. coli in enkele studies beschreven. Het 
bleek bijzonder lastig om grotere hoeveelheden rPfs48/45 te produceren. De hydrofobe 
(vetoplosbare) uiteinden moesten worden verwijderd om enige synthese mogelijk te maken. 
De eiwitten bleken verder onoplosbaar te zijn (ze aggregeerden in de cellen), en geen 
disulfidebruggen te bevatten. Na de eiwitten opgelost te hebben in een ureumvloeistof bleek 
dat deze oplosbare eiwitten wel gedeeltelijk goed gevouwen waren zodat monoklonale TB 
antilichamen er mee konden reageren. Geen van de eiwitten was echter in staat om TB 
antilichamen te induceren in muizen, ratten of konijnen. De geïnduceerde antilichamen 
reageerden echter wel goed met zowel recombinant- als parasitair eiwit, en waren dus 
uitstekend te gebruiken bij verdere analyses en studies. Een belangrijke waarneming was 
tevens dat vijf verschillende muizenstammen allemaal antilichamen konden produceren na 
vaccinatie met de recombinante eiwitten. Dit betekent dat de kans groot is dat de 
immuunrespons tegen Pfs48/45 niet afhankelijk is van de persoon (er treedt blijkbaar geen 
zogenaamde MHC-restrictie op), wat weer belangrijk is aangezien een vaccin moet werken 
bij ieder individu. In hoofdstuk 4b wordt verder beschreven dat in muizen en konijnen de 
keuze van de immunisatiehulpstof (adjuvans) wel bepaalt hoevéél (specifieke) antistoffen er 
worden geïnduceerd, maar niet welke immuunglobulinesubclasse (de soort antilichamen) 
wordt geïnduceerd. Geen van de vijf verschillende immunisatieschema's leidde dan ook tot 
een TB antilichaamrespons.
Aangezien Pfs48/45 een door disulfidebruggen gestabiliseerd eiwit is werd ook veel 
aandacht besteed aan de expressie in hogere eukaryote (celkern bevattende) 
expressiesystemen die veel beter in staat zijn dan E. coli om dit soort eiwitten te 
produceren. Naast productie in zoogdiercellen met behulp van een recombinant 
vacciniavirus (rVV) (hoofdstuk 5) werd ook productie in insectencellen met behulp van 
recombinante baculovirussen (rBV) bestudeerd. Het rVV werd tevens gebruikt als levend 
vaccin op konijnen en muizen. Ook werd directe vaccinatie met een DNA-vaccin bij muizen 
en ratten bestudeerd. Dit laatste bleef zonder succes; er werden geen Pfs48/45-specifieke
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antilichamen geïnduceerd (voor details zie hoofdstuk 7a).
Met behulp van het vacciniavirus- en baculovirus systeem werd aangetoond dat het 
primaire eiwit dat ontstaat in diverse zoogdiercellen en insectencellen na infectie met 
recombinant virus sterk is N-geglycosyleerd (versuikerd). Het parasitaire eiwit Pfs48/45 
bleek niet N-geglycosyleerd te zijn (hoofdstuk 5). De rVV-geproduceerde eiwitten bleken 
verder niet te reageren met Pfs48/45-specifieke monoklonale TB antilichamen, ondanks de 
stabilisatie van de eiwitten door middel van disulfidebruggen. Aangetoond werd dat het 
transport in vacciniavirus geïnfecteerde cellen sterk is verstoord; hoewel Pfs48/45 normaal 
gesproken een (buiten)membraangebonden eiwit is bleek recombinant eiwit zich 
voornamelijk ín de cellen te bevinden (hoofdstuk 5). In het baculovirusexpressiesysteem 
leek (een gedeelte van) het recombinante eiwit zich wel op de buitenmembraan te bevinden 
en zwak te reageren met de TB monoklonaal 32F5 maar immunoprecipitaties met deze 
monoklonaal uit een cellysaat bleken niet mogelijk. Immunisaties met rVV of met eiwitten 
geïsoleerd uit rBV geïnfecteerde cellen leidden niet tot de inductie van TB antilichamen in 
muizen en konijnen.
Een goed alternatief voor de productie van recombinant eiwit in hogere eukaryoten is 
het gist-productiesysteem. Gisten zijn veilig, makkelijk te manipuleren, en hun cultivatie is 
goedkoop en kan gemakkelijk worden opgeschaald, de ideale karakteristieken dus voor de 
productie van een vaccin. In hoofdstuk 6 wordt beschreven hoe initiële experimenten in de 
bakkersgist Saccharomyces cerevisiae aantoonden dat expressie van gen pfs48/45 niet 
mogelijk was; het geïnduceerde Pfs48/45-specifieke RNA (de drager van de informatie die 
moet worden vertaald in een eiwit) bleek niet de volledige lengte te hebben. Met andere 
woorden; de transcriptie (het maken van RNA) bleek voortijdig gestopt te zijn. Terwijl DNA is 
opgebouwd uit vier bouwstenen, die afgekort worden als A, G, C, T, bestaat DNA van P. 
falciparum uit enorm veel A's en T's (in Pfs48/45 circa 75%). De signalen die het afbreken 
van de transcriptie reguleren zijn ook rijk aan A's en T's en de AT rijkdom leek dus de 
oorzaak van de vroegtijdige transcriptieterminatie. Aangezien het kloneren van dit AT-rijke 
gen ook onophoudelijk voor problemen zorgde, en het codon-gebruik (een codon is een 
opeenvolging van drie A's, T's, G's of C's wiens volgorde bepaalt met welk aminozuur een 
eiwit zal worden verlengd) van gist heel anders is dan dat van E. coli en zoogdiercellen, 
werd besloten een nieuw GC-rijk gen te maken met een aangepast codongebruik. Dit 
synthetische gen werd vervolgens gebruikt voor de expressie in bakkersgist en in een 
andere gistsoort, Pichia pastoris. Nu bleken inderdaad volledige lengte RNA's te ontstaan in 
de gisten. Echter, alleen in Pichia pastoris kon ook rPfs48/45 worden aangetoond. Het
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meeste recombinante eiwit bleef ook hier in de cel zitten, maar er werd ook recombinant 
eiwit uitgescheiden. Hoewel het eiwit disulfidebruggestabiliseerd bleek, kon reactie met 
monoklonale TB antilichamen niet worden aangetoond, en ook konden gezuiverde eiwitten 
geen TB antilichaamrespons opwekken in muizen.
Toekomstig onderzoek zal zich moeten richten op een beter begrip van de vouwing van 
Pfs48/45, en het verbeteren van de oplosbaarheid van rPfs48/45 in cellen en in oplossing. 
Wellicht zal de oplossing gezocht moeten worden in expressie in productiesystemen die 
veel meer op P. falciparum lijken. De malariaparasiet lijkt in de organisatie van eiwitvouwing 
en transport namelijk erg veel af te wijken van andere eukaryoten. Nu er sinds enkele jaren 
transfectietechnieken (het kunnen introduceren van vreemd DNA in een cel) bestaan voor 
malariaparasieten biedt wellicht heterologe expressie van gen pfs48/45 in bijvoorbeeld P. 
berghei of in de bloedstadia van P. falciparum een mogelijkheid tot productie van 
recombinant eiwit met de karakteristieken van het Pfs48/45. Mogelijk ook, kan co-expressie 
met het antigen Pfs230 van P. falciparum een doorbraak betekenen, aangezien bekend is 
dat Pfs230 op de parasiet voorkomt tezamen met Pfs48/45, en aangezien ook aangetoond 
is dat het bij sommige eiwitten voor een goede vouwing, oplosbaarheid en transport 
essentieel is dat er zich heteromeren vormen.
De modernste ontwikkelingen in de moleculair-biologische technieken en het bestaan 
van goede aanknopingspunten voor vervolgonderzoek valideren toekomstige inspanningen 
om te komen tot een goed werkend en veilig TB vaccin op basis van Pfs48/45. De 
beschikbaarheid van een synthetisch gen pfs48/45s zal dit vervolgonderzoek sterk 
vergemakkelijken.
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L is t  o f  a b b r e v ia t io n s
a-M AT-F, a-m ating type factor
A, Adenine
AMA, apical membrane antigen 
AOX, Alcohol Oxidase 
BHK-21, Baby Hamster Kidney cells 
BMGY, Buffered Minimal Glycerol Yeast medium 
BMMY, Buffered Miniminal Methanol Yeast 
medium
BPRC, Biomedical Primate Research Centre
BSC-1, African green monkey cells
BV, baculovirus
C, Cytosine
cDNA, copy DNA
CSP, circumsporozoite protein
CTL, cytotoxic T-cell lymfocyte
Cys, cysteine
AA, without anchor sequence
DDT, dichloro-diphenyl-trichloro-ethane ( =
1,1,1,trichloro, 2,2,-bis(p-chlorophenyl)ethane)
DMEM, Dulbecco's modified Eagle's medium
DNA, deoxyribonucleic acid
DOC, sodium deoxycholate
DTT, dithiothreitol
E. coli, Escherichia coli
EBA, erythrocytic binding antigen
EDTA, ethylenediaminetetraacetic acid
EGF, epidermal growth factor
ELAM, endothelial leukocyte adhesion molecule
ELISA, enzyme-linked immunosorbent assay
EMP, erythrocyte membrane protein
endo H, endo-[3-N-acetylglucosamindase H
ER, endoplasmic reticulum
FCS, fetal calf serum
FITC, fluorescein isothiocyanate
G, Guanine
GalNAc, N-acetyl D-galactosamine 
GPI, glycosyl phosphatidyl inositol 
GST, glutathione-S-transferase
h, hours
HEP17, hepatocyte erythrocyte protein 17 
HLA, human leukocyte antigen
h.p.i., hours post infection
HPLC, high performance liquid chromatography
HRPO, horse radish peroxidase
ICAM, intercellular adhesion molecule
IFA, indirect immunofluorescence assay
IFN, interferon
IgG, immunoglobulin type G
IL-12, Interleukin-12
Ile, Isoleucine
i.p., intraperitoneal 
IU, international units 
kB, kilo Bases
kDa, kilo Dalton 
LPS, Lipopolysaccharide 
LSA, liver stage antigen 
LSB, Laemmli sample buffer 
mAb, monoclonal antibody 
MD, Minimal Dextrose medium 
MEF, mosquito exflaggelation factor 
MHC, major histocompatibility complex 
min, minutes
MM, Minimal Methanol medium 
m.o.i., multiplicity of infection 
Mr, relative molecular weight 
mRNA, messenger ribonucleic acid 
MSA, merozoite surface antigen 
MSP, merozoite surface protein 
Mut*, Methanol utilisation positive, strains with 
nondisrupted AOX-1 gene 
Muts, Methanol utilisation sensitive, strains with 
disrupted AOX-1 gene 
MY, Minimal Yeast medium 
Ni-NTA, Nickel chelated Nitrolo-tri-acetic acid 
NP40, Nonidet P-40 
nt, nucleotide
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O-glycosidase, endo-a-N-
acetylgalactosaminidase
OD, optical density
P. pastoris, Pichia pastoris
PBS, phosphate-buffered saline, pH 7.4
PBST, PBS containing 0.1% Tween 20
PCR, polymerase chain reaction
Pf, P. falciparum; Plasmodium falciparum
Pfexp, erythrocytic exported protein
Pfg, P. falciparum gametocyte/gamete
Pfs, P. falciparum sexual stage
pfs48/45s, synthetic gene pfs48/45
p.f.u., plaque forming units
Pfu, Pyrococcus furiosus
PNG, Papua New Guinea
Prs, P. reichenowi
RaLPS, Lipopolysaccharides from Ra mutant 
strain of E. coli 
RAP, rhoptry associated protein 
rBV, recombinant baculovirus 
RESA, ring-infected erythrocyte surface antigen 
RK-13, Rabbit Kidney cells 
RNA, ribonucleic acid
rPfs48/45, recombinant P. falciparum antigen with 
molecular weight of 48/45 kDa 
rVV, recombinant vaccinia virus
S. cerevisiae, Saccharomyces cerevisiae 
SD, standard deviation 
SDS-PAGE, sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis 
sec, seconds 
Ser, Serine
SERA, serine rich antigen
SIFA, surface indirect immunofluorescence assay
Spf66, Synthetic peptide vaccine of Plasmodium
SSCP, single strand conformation polymorphism
SSP, sporozoite surface protein
STARP, sporozoite threonine and asparagine-rich
T, Thymine
Taq, Thermus acquaticus
TB, transmission-blocking 
TBI, transmission-blocking immunity 
TCA, tri-chloro-acetic acid 
TK, thymidine kinase 
TNF, tumor necrosis factor 
TRAP, thromospondin-related adhesive protein 
tRNA, transport ribonucleic acid 
UNDP, United Nations Development Program 
VPF, Vascular Permeability Factor 
VV, vaccinia virus 
WHO, World Health Organisation 
X-gal, 5-bromo-4-chloro-3-indolyl-ß-D- 
galactopyranoside 
YPD, Yeast Pepton Dextrose medium 
YPG, Yeast Pepton Galactose medium
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Da n k w o o r d
Dit dankwoord kreeg al in een vroeg stadium vorm, want groot is het besef dat je zelf 
veel kunt klaarspelen, maar dat hulp van anderen van onschatbare waarde is. En velen 
hebben zich in ingezet om mijn promotie tot een goed einde te brengen. Vooraleerst wil ik 
noemen mijn tweede promotor, wijlen Ruud Konings. Hij was misschien niet de 
gemakkelijkste mens, maar hij was op een bijna 'vaderlijke' wijze zeer begaan met mijn 
onderzoek en toekomst. Helaas is hij vroegtijdig komen te overlijden na een tragisch auto- 
ongeluk in de Beierse Alpen. Ook dank aan mijn eerste promotor, wijlen John 
Schoenmakers, die al in het eerste jaar van mijn onderzoek na een kort maar hevig ziekbed 
kwam te overlijden. Uiteraard gaat mijn dank uit naar de praktische en morele steun van 
mijn labgenoten en paranimfen; Josephine Jansen, Anita Kaan en Brenda Pisa, bedankt 
voor de vele blots, de kweekjes, de foto's, en de gezelligheid. Anita, ook het carpoolen 
tussen Wageningen, Rhenen en Nijmegen was een succes. Gerd Brunekreef, Marleen 
Visker, en Paul van de Ven, ook dankzij jullie bijdrage (zelfs een keertje koffie onderweg) 
waren al die kilometers zeer genoeglijk! Clemens Kocken ben ik uiteraard heel veel dank 
verschuldigd. Clemens, de samenwerking gedurende de eerste jaren van mijn promotiewerk 
vond ik niet alleen leuk, maar ook bijzonder leerzaam! Anneke Braks, Monique Slijper, Huub 
Dodemont, Karin Merck en Manja Boerman, ook jullie bedankt voor de 'inhoudelijke' 
ondersteuning en discussies. Koen Dechering, Gerd Brunekreef, Erik Jan Klok, Harm 
Nijveen, Ron Dirks, William Leenders, Harry Kraft, Siebe van Genesen, Andy Pötgens, 
Robin Kroone, Inge Moelans, Sandra Laban en Petra de Wilde, mede dankzij jullie was het 
(meestal) erg gezellig op het lab. Datzelfde geldt ook voor de mensen van de afdelingen 
Celbiologie en Toegepaste Biologie. William ook nog bedankt voor de Pichia-kloons, Harry 
voor de ondersteuning bij de DNA-vaccinproefjes en Siebe voor allerlei hand-en- 
spandiensten. Lettie, ook jouw zorg wil ik bijzonder roemen. Vooral ook tijdens de tijdelijke 
afwezigheid van Ruud na diens hartaanval liet je je van je beste zijde zien! Tevens bedankt 
voor je correctiewerk. Joan Beck, thank you for your time in reading and correcting the 
introduction. Ook Marianne ten Voorde bedankt voor het corrigeren van de Nederlandstalige 
stukken. Adriaan Vermunt, dank voor de computersearch. Uiteraard bedank ik ook de 
mensen 'aan de overkant'. Will Roeffen, jij was gezien je sterke (praktische) betrokkenheid 
vaak aanspreekpunt. Dank voor je luisterend oor als ik weer eens met een ELISA aankwam. 
Wijnand Eling, je heldere uiteenzettingen tijdens werkbesprekingen hebben altijd zeer veel 
indruk gemaakt! Karina Teelen, bedankt voor het uitvoeren van vele ELISA's. Pieter
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Beckers, Annette Beetsma, Rob Harmsen, Ton Lensen, Marga Bolmer, Arianne Huisman 
en Geertjan van Gemert, dank voor inbreng bij werkbesprekingen, en voor zover van 
toepassing, plezier in Liverpool en uitvoering van transmissieblokkadetesten. Ook veel dank 
ben ik verschuldigd aan Peter Rottier en Twan de Vries (Universiteit Utrecht); Ik vond het 
altijd heerlijk om in jullie lab te vertoeven! Virgil Schijns; de samenwerking (en gift van rIL- 
12) was kort maar prettig. Daarnaast bedank ik Paul van de Heusden en Ide Steensma 
(Universiteit Leiden), die mij de eerste vaardigheden in het werken met gist bijbrachten. 
Veel plezier heb ik beleefd aan de samenwerking met de vele studenten die ik heb mogen 
begeleiden: Ruud van de Steen, Peter van de Veen, Sally Hill, Kerstin Hölscher, Jeroen van 
de Bovenkamp, Hans Visser, Ralf Triepels en Annemieke Jansens. En ook de 
werkzaamheden van Ralf Smeets, Mark Daalderop, Henk Meijers en José van Tiel moeten 
vermeld worden. Ik wens jullie een goede toekomst! Tenslotte wil ik mijn ouders heel 
hartelijk bedanken voor de mogelijkheid en stimulans die zij mij hebben gegeven om te 
gaan studeren, te gaan promoveren en vol te houden.
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